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Proton therapy has been shown to offer clinical advantages over standard photon 
based external beam modalities. Additionally, there is evidence from small animal 
experiments showing that the recovery of healthy tissue is improved with the use 
of spatially modulated beams, referred to as microbeams or minibeams which 
consist of an array of parallel narrow beamlets. Using Monte Carlo modelling, this 
thesis explores the potentially powerful combination of minibeams and proton 
therapy by characterising the physical and biological dose when generating proton 
minibeam by means of a collimator. 
 
It is known that patient motion has the potential to spread dose to regions between 
the minibeams thereby, reducing or removing the spatial modulation. A thorough 
characterisation of the impact of such motion on lateral spread of dose was 
performed for a wide range of motion amplitudes, relevant for small animal 
irradiation (60 µm to 10 mm). Clinical beams appropriate for human therapy were 
also investigated to determine the impact motion has on proton minibeams. 
Motion was shown to detrimentally impact all proton minibeam dose distributions. 
However, simulations for irradiating a brain undergoing pulsations of up to 300 
µm an array of a 0.3 mm wide beamlets, (centre to centre (CTC) spacing of 1 mm), 
showed that the dose between the beamlets, known as the valley region, only 
increased by a maximum of 2% for both mouse and human treatments. It was 
further found that increasing the CTC spacings up to 10.77 mm reduced the impact 
of motion on the valley region, for motions up to as high as 1.1 mm. Increasing the 
width of the beamlet reduced the effect of motion on dose delivered within the 
 
 
beamlet tracks, however it increased dose in the valley regions, and therefore it is 
not recommended. 
 
Having established motion does not negate the usefulness of proton minibeam 
therapy, a comprehensive Monte Carlo framework was developed in Tool for 
particle simulation (TOPAS) to simulate the University of Washington’s preclinical 
proton radiation platform, which is currently the only existing preclinical proton 
minibeam beamline. A detailed and novel analysis of the impact each beamline 
component has on the resulting dose distribution was performed. Unknowns in the 
physical dimensions of beamline components were identified and estimated by 
adjusting physical dimensions in the simulated beam transport system. The final 
beamline model was experimentally verified against measurements with an ion 
chamber and diamond detector to have a Bragg peak depth consistent with an 
energy of 44.95 MeV (a depth of 18.1 mm). The decrease in energy from the 
nominal 50.5 MeV (depth of 22.3 mm) was shown to be due to proton interactions 
with the graphite degrader, Kapton exit window, and the monitoring ion chamber. 
It was further shown that these components reduced the Bragg peak depth by 2.0 
mm, 0.3 mm, and 2.0 mm, respectively. Other components were also investigated 
and found to have minimal impact on the beam energy. 
 
At the University of Washington proton minibeams are currently produced by 
means of a physical collimator designed and manufactured during this thesis. A 
comprehensive analysis and characterisation of collimator material and physical 
dimensions was carried out with the aim of defining the ideal proton minibeam 
collimator designed for this beamline, i.e. one that maximises spatial modulation 
and limits scattered dose. Results indicated that there exists an optimum 
iv 
collimator thickness and a 20 – 25 mm thick collimator was found to be ideal. 
Increasing the thickness of the collimator beyond this was undesirable, as the 
collimator would then reduce the number of primary protons whilst maintaining 
the same number of scattered protons. It was shown of the 50.5 MeV proton beam 
with a nickel collimator that the first 15 mm of the collimator was responsible for 
producing the most neutrons, electrons, and photons. The ideal width of the 
collimator slot width for the UW proton beam was found to be between 0.3 – 0.4 
mm as it produced beamlets with a high spatial modulation, commonly 
characterised as the peak to valley dose ratio (PVDR), whilst only reducing dose at 
the Bragg peak by approximately 60% of an open (non-collimated) beam. It was 
also shown that although a high-density collimator should be used to maximise the 
PVDR, care needs to be taken to reduce neutron production. Of the 78 materials 
investigated, Group 4 transition metals, particularly nickel, provided the highest 
PVDR. Nickel was also found to result in the lowest neutron yield, 2.7 times less 
than that of tungsten, making it an ideal material for minibeam collimators. 
 
To fully understand the therapeutic benefit of collimated proton beamlets requires 
knowledge of the Relative Biological Effectiveness (RBE) and the resulting RBE 
weighted dose (RWD), of all primary and scattered particles emanating from the 
proton minibeam collimator. These were investigated for four previously identified 
materials. While at 50.5 MeV the neutron dose from the different materials varied 
by a factor of 3.2, overall, it was an insignificant component of the total RWD. The 
RBE of protons was shown to increase by up to a value of three on the distal edge 
of the Bragg peak, shifting the Bragg peak depth deeper by 0.1 mm. The RBE in the 
valleys was found to be up to a value of 1.5 at the surface. This has the consequence 
of reducing the effective normal superficial tissue sparing from proton minibeams. 
 
 
Summarising the main results from this thesis, it has been shown that proton 
minibeams for small animal irradiation are feasible even when the target is 
undergoing internal motion. Having accurately simulated the preclinical proton 
radiation platform (PPRP) beamline at the University of Washington it was 
identified that the most suitable design for a physical collimator for 50.5 MeV 
protons is to construct from either nickel, stainless steel, copper, and brass. The 
thickness of the collimator should be 25 mm to sufficiently block protons without 
introducing any additional scatter. This thesis also provides evidence for 
supporting an increase in the commonly used value for proton RBE as a function 
of depth in tissue. This result is imperative for planning treatment and therefore 
should be implemented when considering dose effects for any animal and 
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Chapter 1      
 Introduction 
1.1. Background 
Radiation therapy kills or slows the growth of cancerous tissue by delivering a 
lethal dose of radiation, whilst simultaneously delivering a minimal dose to normal 
tissue [1, 2]. Various clinical treatment techniques aim to improve normal tissue 
sparing, and thus reduce treatment complications. Some techniques achieve this 
by delivering a large number of small radiation fields from multiple beam 
directions to precisely sculpt the dose to the tumour. Examples of this are intensity-
modulated radiation therapy (IMRT) and volumetric modulated arc therapy 
(VMAT). Both of these techniques have been shown to reduce toxicity compared to 
more traditional and less conformal techniques [2-4]. Stereotactic body radiation 
therapy (SBRT) is a hypo-fractionated treatment regime showing further 
improvements for some cancers [2, 5]. Both IMRT and VMAT are delivered with 
photons and are utilised clinically around the world. Proton therapy is less 
common and more costly than photon therapy with benefits in terms of how the 
radiation is deposited. This can lead to further reduction of toxicity in normal 
tissue, which is beneficial especially for paediatric patients [6, 7]. Currently there 
are 93 proton therapy treatment centres worldwide, compared to several thousand 
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linear accelerators used for photon treatments, with a growing interest in this 
treatment modality [8, 9]. 
 
Reduction of toxicity in normal tissue when using protons is due to an intrinsic 
dosimetric advantage they have over photons. Protons deliver dose to the 
surrounding medium proportional to the ionisation per millimetre of path, with 
the maximum dose delivered at the end of the proton’s range, referred to as the 
Bragg peak [10]. The depth of this Bragg peak depends on the initial energy of the 
proton; thus, manipulation of the initial energy allows the Bragg peak to coincide 
with the tumour at depth. The tumour will consequently receive a large dose, whilst 
normal tissue near the surface receives a low dose, and there is virtually no dose 
beyond the Bragg peak. 
 
Preclinical research with spatially fractionated beams referred to as microbeams, 
has indicated that they may be advantageous compared to uniform beams, due to 
the considerably reduced normal tissue toxicity that has been observed in cell and 
small animal experiments [11-13]. This normal tissue sparing effect was first 
discovered in the 1950’s by Curtis et al. using synchrotron generated radiation, 
whilst studying the effects of cosmic radiation on mice [12]. The radiation 
resistance of the mouse brain tissue was discovered to be inversely related to the 
width of the beam. The use of small beams on the micro scale was later established 
by Slatkin et al. at the European Synchrotron Radiation Facility [13]. This research 
used microscopically narrow, synchrotron generated photon beams for treatments 
on the central nervous system of vertebrates and was the first implementation of 
microbeam radiation therapy (MRT). Further research by the National 
Synchrotron Light Source, Brookhaven National Laboratory and European 
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Synchrotron Radiation in the 1990s demonstrated that use of MRT on rat 
physiology exhibited the same tissue sparing effect [14]. This reduction of toxicity 
could be of notable benefit to children with brain tumours as it will reduce damage 
to their developing nervous system [15]. If this sparing effect is demonstrated to 
be applicable for treatment of human oncology patients, then normal tissue 
complications could be reduced whilst simultaneously maintaining or increasing 
local tumour control. 
 
The unique dose distribution of protons combined with spatial fractionation has 
the potential to improve upon traditional synchrotron generated photon 
microbeams. By designing appropriate spatial modulation of proton beams, it is 
possible to produce a beam which can deliver a nearly uniform dose to the 
cancerous tissue whilst maintaining spatial modulation of dose near the surface 
and normal tissues. A typical proton MRT dose distribution is displayed in Figure 
1.1.  
 
Methods of producing this type of dose distribution require either; a physical 
collimator, which blocks portions of a uniform beam, or a temporarily varying 
collimator, such as a scanning pencil beam, which moves a small beam over a 
region in a pattern designed to result in a spatially modulated dose [16]. The degree 
of dose modulation may be described by the ratio between the peak and the valley 
dose and is referred to as the peak to valley dose radio (PVDR) [16]. This is used to 
describe the beam modulation relative to a uniform beam. The widths of these 
spatially modulated beams can either be in the order of micrometres or millimetres 
and are referred to as microbeams and minibeams, respectively. The combination 
of proton therapy and minibeams, which is known as proton minibeam radiation 
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therapy (proton MRT), could drastically reduce normal tissue toxicity, whilst 




Figure 1.1: Simulation of a 50.5 MeV proton minibeam dose distribution in water phantom. Beam 
is obtained from below. The minibeam peak regions are the high dose regions at the entrance surface 
shown in red. The valley regions are in between the peak regions and are regions of low dose shown 




This work was in collaboration with the University of Washington and focused on 
small animal irradiation for use in preclinical research into proton minibeams. 
While the work presented is generalised for a range of proton energies, there is a 
focus on the 50.5 MeV PPRP at the (UW) in Seattle, USA [17, 18]. 
 
The thesis has the following primary aims: 
1. Investigate the effects of motion on proton MRT dose distributions. 
2. Produce and experimentally verify a TOPAS model of the 50.5 MeV PPRP 
beamline and use this model to produce an understanding of how beamline 
components reduce the energy spectrum of the proton beam. 
3. Consider various materials for use in proton minibeam collimators to 
reduce secondary radiation production and maintain sharp beam profiles. 
And to optimise the geometry of proton minibeam collimators to maximise 
the PVDR and reduce the minibeam valley dose. 
4. Model the RBE effects of proton MRT caused by different collimator 
materials. 
 
The first aim of investigating the effect of motion is to address a key limitation of 
proton MRT. This limitation arises as spatially modulated dose distributions are 
vulnerable to motion, which blurs their sharply defined peak and valley profiles, 
resulting in unwanted dose in the valley regions. Spatially modulated proton 
minibeams generated by the PPRP have a comparatively low dose rate, in the order 
of 8.4 Gy/min relative to the traditional synchrotron generated X-ray microbeams 
with dose rates of several thousand Gy/s [18, 19]. This results in longer treatment 
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times on the PPRP. Consequently, the proton minibeam dose distributions may be 
more susceptible to organ motion. Work by Manchado de Sola et al. demonstrated 
that even very high dose rate synchrotron generated microbeams can be impacted 
by small brain pulsations [19]. This highlights the need for research to be applied 
to proton minibeams as motion has the potential to fully destroy any spatial 
modulation of the dose distribution removing any potential benefit of proton MRT 
over uniform proton treatments. Characterising the effects of motion on the 
spatially modulated proton dose distributions and determining if there are 
methods to limit the impact of motion is therefore the first aim of this thesis. 
 
The second aim of this thesis is to produce and experimentally verify a working 
model of the 50.5 MeV PPRP in TOPAS and use this to produce an understanding 
of how the beamline components reduce the energy spectrum of the proton beam. 
Production of the model requires modelling all components that the beam will 
come into contact with before delivering dose to a target. Verifying this model 
requires the simulated dose from the model to match physical measurements taken 
from the PPRP at the University of Washington. An in-depth investigation to 
explain how the energy and particle spectrum of the beam is modified by beamline 
components will be performed with this model. This information on the PPRP can 
then be directly applied to further research throughout this work and for future 
biological experiments. 
 
The third aim is to investigate how the dose distribution of proton minibeams is 
affected by different design components of physical collimators. Proton MRT dose 
distributions can be produced with either pencil beam scanning or a physical 
collimator, each of which have their advantages and disadvantages for clinical 
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applications. This thesis focuses on physical collimators for the following reasons. 
This work is in collaboration with UW’s PPRP, which does not have pencil beam 
scanning capability currently. Also, the majority of current pencil beam scanning 
systems have spot sizes that are a magnitude too large to produce minibeam dose 
distributions [20]. There are two areas of research into the design of physical 
collimators that will be focused on in this thesis. The unwanted secondary radiation 
produced due to interactions between the incoming proton beam and the physical 
collimator. This scatted radiation is unwanted and increases the surface dose, as 
well as blurring the sharp beam profiles, reducing the PVDR thereby reducing the 
effectiveness of the treatment. Collimator material has been shown to have a 
considerable impact on the secondary dose produced from the collimator and the 
neutron production is of particular concern [21, 22]. Therefore, the first area of 
research in collimator design aims to determine an optimal collimator material for 
use in proton minibeams which reduces the secondary dose, particularly dose from 
neutrons, whilst maximising the PVDR throughout the dose distribution. The 
secondary area of research is the optimisation of the geometry, as this directly 
controls the shape of the resultant dose distribution. Minimising the dose delivered 
to the valley regions whilst increasing the PVDR will increase the sparing effect 
thus reducing biological damage to normal tissue. This work builds on previous 
research by Lee et al. and aims to provide an in-depth analysis on how the 
collimator geometry controls the final dose distribution [23]. 
 
The fourth aim of this thesis is to investigate how collimator material can impact 
the RBE of the proton minibeams. The RBE is the ratio of biological damage 
between two different types of radiation for the same physical dose. For this 
research, the RBE for photons, electrons, neutrons, and protons generated by 
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minibeam collimator is considered. The RBE of protons varies with energy and 
depth in the target. Protons that interact with a collimator will lose energy and thus 
their dose and RBE is affected. Collimator material influences the variation caused 
by this and therefore how these two factors interact is an important area of this 
research. The RBE of neutrons produced by the collimator is another important 
factor. Although the number of neutrons exiting the collimator is a small 
component of the total number of particles, they can have a remarkably high RBE 




This thesis is comprised of seven chapters. Chapter 2 contains an overview of 
background material in radiation therapy, proton therapy, microbeams and Monte 
Carlo modelling relevant to this thesis. Chapter 3 investigates the effects that 
motion has on proton MRT dose distributions for 50 MeV – 250 MeV proton beams 
using Monte Carlo modelling. Chapter 4 introduces the design of a Monte Carlo 
model of the proton beamline at the University of Washington Medical Centre. This 
model was generated to match the actual preclinical beamline and was used to 
investigate how components of the beamline interact and impact the beam energy 
and the final dose distribution. The accuracy of the model was verified 
experimentally to match the Monte Carlo model. Chapter 5 discusses collimator 
design parameters and limitations. An in-depth analysis of how geometric designs 
and materials impact the resulting dose distributions and output from the 
collimator was carried out. Chapter 6 covers RBE modelling of proton and neutrons 
exiting various proton MRT collimators. The origin and impact of these particles 
have on the dose distribution is investigated. Chapter 7 contains concluding 




Chapter 2      
 Background Material 
This section starts with a brief overview of radiation therapy covering the need and 
the objectives that radiation therapy aims to achieve when treating cancer. Proton 
therapy is then discussed and the difference to traditional photon treatments 
highlighted. The physics behind proton therapy is covered to provide the reader 
with a background in these concepts which will be discussed later in the thesis. 
Background on how beams are shaped is included as this is important background 
information when dealing with collimators to produce proton MRT beams. The 
differences between proton beams and photon beams can in some part be 
explained by the differences in linear energy transfer (LET) and RBE, so a brief 
background is provided to introduce the reader to these topics. An introduction to 
spatially fractionated treatments is provided covering their history and current use. 
This is expanded upon in a section on proton microbeams, which are a subset of 
spatially fractionated treatments that use protons rather than synchrotron 
generated photons. Proton minibeams are a main component of this thesis and the 
background and history of this treatment modality is introduced. The last section 
in is on Monte Carlo modelling providing important background on the methods 
used for investigating proton MRT beams throughout this thesis. 
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2.1. Radiation Therapy 
Cancer was responsible for 9.6 million deaths worldwide in 2018, with new cases 
estimated to rise by around 70% over the next 20 years [24]. Current treatment of 
cancer is achieved with one or a combination of: radiotherapy, chemotherapy, or 
surgery. Radiotherapy has been shown to be beneficial to at least half of cancer 
patients [1]. 
 
Radiation therapy aims to use ionising radiation to deliver sufficient dose to kill all 
tumour cells whilst sparing normal cells. Ionising radiation is defined as radiation 
with sufficient energy to free an electron when interacting with an atom, resulting 
in the atom becoming ionised. There are two main types of ionising radiation; 
directly ionising, which consists of charged particles such as protons, electrons, 
positrons, and heavier ions, and indirectly ionising radiation which has no charge 
such as high energy photons and neutrons. Charged particles can directly ionise 
atoms through the Coulomb force, where non-charged particles do not interact 
strongly with matter and therefore ionise atoms through secondary interactions, 
such as the photoelectric effect. Ionisation occurs along the path of ionising 
radiation, ionising both normal and cancerous tissues indiscriminately, leading to 
cell death of both. 
 
Ionising radiation kills cells by damaging the DNA molecule in a cell, causing the 
cell to die. DNA is made up from base nucleotides that form a sugar phosphate 
backbone forming a single polynucleotide strand, which is bonded with another 
complementary stand using hydrogen bonds. Damage to the DNA occurs either 
directly in the DNA when an atom in the molecule is ionised by radiation, or 
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indirectly when a free radical interacts with a DNA atom. Free radicals are often a 
result of the ionisation of water in the cell, in close proximity to the DNA molecule 
[25]. The various types of DNA lesions that can occur from ionising radiation is 
shown in Figure 2.1 [26]. Base damage occurs when part of a single nucleotide is 
ionised. Single strand breaks occur when an ionisation occurs in the sugar 
phosphate backbone resulting in a break. If two of these breaks occur on opposite 
sides of two strands in proximity this can fully break the DNA molecule in a double-
strand break. Of these DNA lesions, the most damaging type is the double-strand 
break, which has a high correlation of cell death [25]. 
  
Figure 2.1: Various types of damage that can occur from interactions between radiation and 
DNA. Showing the differences between base damage, single strand breaks and double strand 




2.2. Proton Therapy 
The use of protons in radiation therapy was first proposed by Wilson in 1946 [10]. 
The advancement of new accelerators enabled production of protons with energy 
higher than 125 MeV. These protons have a penetration depth of around 11 cm 
enabling use in human treatments [10]. Wilson proposed the use of protons over 
the traditional photons due to their unique dose distributions. The first human 
treatments were carried out at the Berkeley Radiation Laboratory in 1954 and in 
Uppsala, Sweden in 1957 [27, 28]. 
 
Protons are charged particles, when they travel though matter, they will primarily 
interact with the matter through Coulomb interactions. They also interact 
infrequently with an atom’s nuclei via nuclear reactions resulting in various nuclear 
decays to occur, or, with electric fields to produce photons known as 
Bremsstrahlung. The most common of these interactions are illustrated in Figure 
2.2 [29]. Inelastic Coulomb interactions with electrons are the most common 
interactions where the positively charged proton interacts with a negatively 
charged electron, resulting in kinetic energy being transferred from the proton to 
the electron. This collision will have little impact on the momentum of the proton 
as it has a rest mass of nearly 2000 times that of an electron, resulting in the 
protons path being roughly linear throughout the interaction. Most of the energy 
from the proton beam is lost in this manner, thus, the resultant path of a proton 
beam is roughly linear, with a slight increase in the spread with depth. 
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When a proton interacts with a nucleus repulsive Coulomb interaction occur. 
However, this this type of interaction occurs infrequently, as the relative size of the 
nucleus is significantly smaller than that of the electron orbitals. The kinetic energy 
is transferred from the proton to the nucleus in this interaction. As the proton has 
less mass than the nucleus, there is a large change in momentum for the proton, 
deflecting it from its original path. This effect causes a small amount of spread in 
the proton beam, which increases with depth, thus decreasing the penumbral 
sharpness. 
 
Figure 2.2: Diagram of proton interactions (a) Inelastic Coulomb interactions with electrons, 
(b) Repulsive Coulomb interactions with nucleuses, and (c) non-elastic nuclear interactions. 




Non-elastic nuclear interactions occur when a proton directly collides with a 
nucleus, which results in the nucleus emitting secondary particles either: a proton, 
a neutron, a gamma ray, or a heavier ion. If the secondary particle is a proton or 
heavier ion, then they will have a short range and deposit dose nearby. However, 
the gamma ray and neutrons can deliver secondary dose over a large range. As the 
cross-sectional area of a nucleus is quite small, nuclear interactions occur 
infrequently. Nuclear interactions are the primary reason for the decrease in beam 
fluence, and unwanted secondary radiation. 
 
The energy lost in matter from these interactions was described by Bethe in 1932, 



















𝐼 ∙ (1 − 𝛽2)
) − 𝛽2] 
 
[1] 
The energy lost per distance travelled (dE/dx) is inversely proportional to the 
electron number density (n) in the medium, z the particle charge in multiples of 
the electron charge, the mean excitation potential I, the relativistic velocity β=v/c, 
and mr the rest mass. Where ε0 is the permittivity of free space and c is the speed 
of light in a vacuum. This results in the energy lost being approximately inversely 
proportional to the velocity of the particle squared, particularly for protons with 
β<<1. This relationship results in a unique dose distribution for protons. The depth 
that a proton will travel in matter is dependent on the initial energy of the proton 
[10]. Energy lost per distance travelled increases with depth, resulting in protons 
depositing the majority of their dose near the distal end of the path. This high dose 
Background Material 16 
 
region at the end of a proton path is known as the Bragg peak (BP) [10]. The Bragg 
peak as a percentage of depth dose is illustrated in Figure 2.3 in red as the pristine 
peak, showing the low surface dose, which increases to a maximum at the Bragg 
peak with a small trailing dose. 
 
The depth of the Bragg peak, or range of a proton beam is defined as the depth 
when half of the protons have come to a rest state [29]. The depth is dependent on 
the initial energy of the proton beam. This means that the beam can be 
manipulated to coincide with a tumour at any depth. Figure 2.3 shows a 
comparison between the proton beam and two x-ray (photons) beams, highlighting 
the large difference in the depth of the peak. This gives protons a dosimetric 
Figure 2.3: Depth dose curve for various particles types highlighting their differences. 150 MeV 
Protons shown in red displaying a Bragg peak at depth. 20 MeV and 4 MeV X-ray (Photon) beams 
shown in green and blue, respectively. Demonstrating that higher energy photons have their peak 
at a greater depth. 4 MeV electrons shown in purple, showing that electrons are not very 
penetrating. Adapted from wikicommons by Cepheiden 
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advantage over photon treatments when using a single fixed beam. However, 
modern photon treatments use multiple beams from different angles, which all 
converge on the tumour to overcome this problem. This leads to some debate on 
the overall advantages of proton therapy for many applications, however, there has 
been some evidence that it is superior for paediatric central nervous system 
malignancies [7, 31]. 
2.2.1. Linear Energy Transfer 
LET is defined as the amount of energy deposited by ionising radiation per unit 
length into local medium. LET is dependent on radiation type, energy, and local 
medium. Protons deliver a large amount of energy over shorter distances because 
they are charged particles and readily interact with matter. Protons are therefore 
classified as having a high LET, with an LET greater than 100 MeV/mm at the 
Bragg peak [32]. There is a relationship between the LET and the biological 
response of the radiated tissue [33]. This allows LET to provide some insight into 
why different types of radiation cause disproportionate biological responses with 
the same amount of absorbed dose. The relationship between LET and biological 
response can be modelled dependant on several factors, such as the alpha and beta 
ratios for specific tissues, and are often built on empirical models [34, 35]. 
 
When protons travel through a medium they lose energy and their rate of dose 
deposition increases thus the LET increases with depth until it peaks on the distal 
edge of the Bragg peak [36]. The high LET on the distal edge of the Bragg peak 
comes with a corresponding high biological response. Quantifying the magnitude 
of this effect is an important area of research as the distal edge of the Bragg peak 
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can be placed near heathy tissue and an increase in biological damage in this region 
is a concern. 
 
2.2.2. Relative Biological Effectiveness 
The damage to biological tissue which results from two equal doses of radiation 
may differ if the two sources are of different radiation type. This is known as the 
RBE and is dependent on cell type and biological response to radiation, making it 
difficult to simulate and measure. Low LET radiation such as 60Co is used as 
reference radiation and therefore has an RBE of one. An RBE of 1.1 has been used 
clinically in the past for proton beam therapy [37-40]. This average RBE of 1.1 for 
clinical proton was confirmed to be a reasonable estimate of the average RBE in 
the spread out Bragg peak, with a range between 0.9 and 2.1 observed by Paganetti 
et al [37]. However, further results for a large range of proton beams from 
preclinical energy to clinical energy beams was summarised in 2014 by Paganetti 
et al demonstrating that the RBE varies between 1.1 for the entrance region and 
1.7 for the distal edge clearly showing that using an averaged RBE may be 
inadequate [9]. Results from these studies showed that the RBE of protons varied 
based on energy, biological endpoint and LET [9]. The RBE of protons also 
increases on the distal edge of the Bragg peak, and therefore increases the 
biological response at this point [36]. The high biological response at the distal 
edge of the Bragg peak is of great concern as this is often placed near critical 
structures and normal tissue and increasing the biological damage may lead to 
unwanted complications. 
Neutrons have a higher RBE than that of photons, with an RBE of up to 20 for 
neutrons with one MeV of energy [41]. This is significantly higher than that of 
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protons, resulting in increased biological damage from neutrons for the same 
amount of energy deposited. Production of proton microbeams by means of a metal 
collimator has the side effect of producing a small number of unwanted neutrons. 
Neutrons are not charged particles and will not readily interact with matter. This 
results in the energy, which is deposited being spread throughout the patient, 
potentially causing increased biological damage to normal tissue. While the energy 
deposited from neutrons is typically a small component of the total energy 
deposited from the proton MRT beam, the higher RBE is a concern as it 
disproportionately increases the biological damage caused by neutrons. 
 
2.3. Spatially Fractionated Treatments 
Initial work on spatially fractionated treatments was performed by Kohler in 1909, 
where a mesh of wire was used to block sections of the incoming kilovoltage x-ray 
beam, this was known as grid therapy [42]. The idea behind this was to reduce dose 
to the skin and allow higher doses to treat difficult large, bulky tumours. Further 
work by Liberson in 1933 used lead to shield regions on the skin enabling these 
regions to act as areas of regrowth healing areas of skin around them damaged by 
treatment fields [43]. The development of megavoltage x-ray treatments which 
have increased depth dose and skin sparing properties led to the decline in use of 
grid therapy. This difference is illustrated in Figure 2.3. Recently there has been 
research into using megavoltage beams for grid therapy, using multi-leaf 
collimators or fixed collimators to produce dose grids. Recent studies have 
demonstrated some benefit for bulky tumours [16, 44-46]. This improvement over 
uniform beams is often attributed to the bystander effect [47]. The bystander effect 
occurs when an unirradiated cell behaves as if it has been irradiated as a result of 
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signals from nearby irradiated cells [48]. Some initial work implementing grid 
therapy for clinical use with proton therapy was done by Geo et al. for use in a 
single fraction treatment of large tumours to improve the treatment of these 
difficult to treat tumours, this is illustrated in Figure 2.4 [49]. 
  
Figure 2.4: Geo’s proton grid treatment plan. Showing the array of parallel beams that are used 
to treat a target centred at 6 cm depth (a, b) or 14 cm depth (c, d). Target is outlined by the orange 




Microbeams are a subset of spatially fractionated treatments modulated on the 
scale of microns. Initial work on microbeams was first done by Zeman and Curtis 
at the Brookhaven National Laboratory in an experiment with a deuteron 
microbeam [11, 12]. This experiment simulated the biological effect of heavy 
cosmic-ray particles to determine the impact on manned spaceflight. Their 
research investigated the effect of a 25, 100 and 1000 µm deuteron beam on mice 
brains. Results indicated that to produce a histological lesion, a dose of 250, 750 
and 10,000 Gy was required for each of the beams, respectively. This initial 
research demonstrated that microbeams had extraordinary normal tissue sparing 
properties, with resistance of the mouse brain tissue to the radiation being 
inversely proportional to the beam size [12]. 
 
Slakin proposed the idea of MRT for use in treatment of brain lesions in rats in 
1992, with initial work at Brookhaven National Laboratory and further work at the 
European Synchrotron Radiation Facility [13, 50-54]. Slakin proposed the use of 
synchrotron generated x-rays with a sub-beam width ranging between 7- 75 µm 
and a CTC separation between sub-beams of 50-400 µm for treatment [14]. These 
beams produce regions of low dose and regions of high dose that remain parallel 
and constant with depth. A diagram of a minibeam dose distribution is shown in 
Figure 2.5, highlighting differences in the peaks and valley doses at the surface and 
illustrating the naming convention used throughout this thesis, note this figure 
shows the illustration with minibeams rather than microbeams for clarity. 
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Microbeams allow tissue sparing beyond just the skin surface, maintaining sparing 
throughout the beam’s depth. This offers an improvement over that of grid therapy. 
The sparing effect was demonstrated to reduce damage to the developing nervous 
systems of young rats [50]. Thus, this particular treatment method is ideally suited 
for paediatric brain tumours due to the decreased normal tissue damage and 
decreased risk for developing nervous systems [53]. MRT also demonstrated 
palliative and curative effects on rat cerebral tumours whilst maintaining tissue 
sparing effects [51, 55, 56]. 
 
Spatially fractionated treatments with large sub-beam widths of up to 0.67 mm and 
CTC separation of up to 1.2 mm have been shown to preserve this extraordinary 
normal tissue sparing, these larger beams are known a minibeams [57]. 
 
Figure 2.5: Surface dose profile of a 50.5 MeV proton minibeam dose distribution, displaying: 
The minibeam peak dose which occurs at the maximum dose in the minibeam path and the valley 
dose which occurs at the minimum dose between two peaks. Also displayed is a single minibeam 
that is part of the dose distribution, the centre to centre spacing between the minibeams, and the 









2.4.1.  Proton Minibeams 
As discussed in Section 2.2, protons offer intrinsic dosimetric advantages over 
photons. These advantages have the potential to be improved on when the proton 
beams are spatially fractionated on either a micrometre scale (microbeams) or a 
millimetre scale (minibeams). Initial Monte Carlo modelling by Prezado et al. 
demonstrated the proof of this concept [16]. As discussed previously protons lose 
energy inversely proportional to the square of the velocity. This results in most of 
the dose being delivered at the Bragg peak. The dose at the Bragg peak will have a 
greater spread in all directions than the surface due to Coulomb interactions. This 
results in proton micro/minibeams having a spatially modulated dose region at the 
surface with well-defined regions of high and low dose. These region’s definition 
blurs with depth, resulting in a semi-uniform high dose region at the Bragg peak. 
Figure 2.6 shows a 50.5 MeV proton minibeam dose distribution, demonstrating 
the modulated dose at the surface and the uniform dose at the Bragg peak. This 
figure also shows the relatively high maximum dose delivered at the surface and 
the dose delivered at the Bragg peak. The lateral spread of the proton beam is a 
function of initial energy. The uniformity of the dose distribution at the Bragg peak 
is therefore controlled by the initial energy and the spacing between 
micro/minibeams. While it is possible to produce a uniform dose distribution with 
photon synchrotron generated microbeams, there is a requirement for at least two 
interlaced beams. This results in a more error prone complex setup [58]. 
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The quality of a spatially fractionated dose distribution is often measured by the 
ratio, between the peak dose and the valley dose. The peak dose, not to be confused 
with the Bragg peak, is the maximum dose across the width of the microbeam and 
the valley dose is the minimum dose located between the spatially fractionated 
beams. This is shown in Figure 2.5, displaying the profile for a 50.5 MeV proton 
minibeam at the surface. The PVDR is roughly consistent for synchrotron 
generated beams throughout their depth. Spatially fractionated proton beams 
diverge with depth, resulting in PVDR decreasing with depth. 
 
Spatially fractionated proton beams can either be generated with a physical 
collimator blocking a designated portion of a uniform beam or they can be 
produced temporarily with a scanning pencil beam. Pencil beams have the 
Figure 2.6: Dose distribution for a 50.5 MeV proton minibeam. Showing the spatially modulated 
dose profile at the surface (black line) and the semi uniform dose profile at the Bragg peak depth 
(black dashed line). Displaying the minibeam peak dose PDD (red) and the minibeam valley PDD 
(blue). Dose results have been scaled to the Bragg peak dose. 
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advantage of producing no secondary particles which can affects the dose 
distribution. However, scanning pencil beams has the disadvantage of a lower dose 
rate, requiring a typically longer treatment time. A second major limitation of 
pencil beam scanning is current treatment spot sizes generated on clinical beams 
are considerably larger than the required sub-millimetre size [20, 59, 60]. A 
physical collimator overcomes these two limitations and is significantly less 
complex and expensive to implement. 
 
The use of a physical collimator has the drawback of introducing secondary scatter 
into the dose distribution. These scattered particles primarily consist of lower 
energy proton, neutron, electrons, and photons. Scattered particles increase the 
surface dose, the valley dose, and the dose post Bragg peak. Scatter also blurs the 
peaks and the valleys of the minibeams. The physical collimator also reduces the 
dose rate that can be delivered to the Bragg peak as it blocks a portion of the beam. 
 
Proton therapy is typically delivered at a dose rate of around 20 Gy/min compared 
to that of synchrotron generated photon beams at 10,000 Gy/s. This results in 
proton micro/minibeam therapy having a non-instant delivery and thus the dose 
distribution is susceptible to motion artefacts that might compromise the skin 
sparing effects. Work on the impact that motion has on proton minibeams is 
discussed in Chapter 3. 
 
The PVDR is impacted by secondary radiation generated from the collimator. The 
position of the collimator has been shown to have a strong effect. Research from 
Meyer et al, showed that moving a minibeam collimator from being adjacent to a 
water phantom to a distance of 2 cm resulted in a PVDR decrease by a factor of ten 
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from 37 to 3.7 [18]. This decrease in the PVDR is a result of scatter from the 
collimator. Scattered particles generated by the minibeam collimator have a 
greater divergence than protons that pass through the collimator without 
interacting with it This scatter consists of mostly protons that have undergone 
Coulomb interactions and some particles that have been generated through 
interactions between protons and the collimator. These scattered particles will 
have a higher angular divergence than the proton beam due to deflection and 
transference of momentum. This effect increases the minibeam peak dose at the 
surface when the collimator is placed close to the water phantom. Placing the 
collimator further away will spread the scattered dose into regions of low dose 
decreasing the peak dose and increasing the valley dose. As the proton’s energy 
determines its path length when depositing dose, these secondary protons 
contribute significantly to the surface dose and their impact decreases with depth. 
This is the inverse of an ideal treatment, as the skin is at the surface with a tumour 
located at the Bragg peaks depth. Therefore, increasing the primary dose and 
decreasing the secondary dose is important to maintain the Bragg peak ratio. This 
effect is outlined in research by Hong et al. with work on pencil beams [61].  
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2.5. Monte Carlo Modelling 
The Monte Carlo method is a well-known mathematical algorithm which uses 
repeated random measurements to estimate results [62]. The idea behind this is 
that computing the exact interactions of all particles involved in an experiment 
would be unfeasible, therefore an approximation is required. 
 
The Monte Carlo method estimates an unknown quantity using inferential 
statistics [62]. Inferential statistics assumes that a random sample of the 
population has the same properties as the whole population. An estimation of the 
true properties of the population can therefore be determined with repeated 
random sampling. The variation in the mean of each random sample gives an 
underlying uncertainty in the overall mean value of the population. Increasing the 
number of samples will cause the sampled mean to trend towards the population 
mean. 
 
Monte Carlo modelling in physics uses physical cross sections of atoms to compute 
probability. Each type of interaction has its own probability for a range of energy 
and a range of atoms. For example, a photon interacting with an electron can 
undergo: the photoelectric effect, Compton scattering or pair production. 
Therefore, each of these processes have an independent likelihood of occurrence. 
Cross sections for an interaction occurring per length of matter for a particle 
passing through, is determined by the density of atoms in the material, the 
probability each atom has to interact, and the probability of each type of 
interaction. 
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Monte Carlo modelling models transport of a single particle at a time, usually 
known as a history. Variations between each history are randomised based on the 
initial design of the simulations. The particle is tracked until it exits the simulation 
boundary or loses all its energy through interactions. Secondary particles can be 
produced through some interactions and these particles are also tracked. 
Researches are usually only interested in measuring a single quantity in a single 
part of the beam, such as the dose in a water phantom. Only this information would 
be recorded and carried over between each history. Multiple measurements can be 
performed at the same time if necessary, although this can impact the time it takes 




Chapter 3          
 Effect of  Motion on Proton 
Minibeam Dose Distributions 
A primary concern of proton minibeams is the comparatively low dose rate, in the 
order of 20 Gy/min, compared to that of synchrotron generated x-ray beams, with 
dose rates of 1000 Gy/s or higher [63]. As a result, treatment times for proton 
minibeams are, depending on the dose to be delivered, in the order of minutes, 
rather than sub-second for synchrotron generated x-ray beams. Consequently, 
spatially modulated proton minibeam dose distribution is more susceptible to 
motion artefacts that occur over this longer time period. Motion blurs the sharply 
defined spatial modulation of the dose distribution. If there is sufficient motion, 
then the spatial modulation can be entirely removed leaving only a uniform dose 
distribution. Work by Manchado de Sola et al. investigated the impact of cardio-
synchronous brain pulsations on microbeams for synchrotron radiation [19]. This 
work demonstrated that even with the extremely high dose rates generated by 
synchrotrons, spatially modulated dose distributions were still blurred by motion. 
This indicates the need for research into this area as proton microbeams will be 
impacted to a greater degree by motion due to their greater amount of time to 
deliver the same dose. 
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Motion in patients can originate from internal organs, or from skeletal muscle 
movements. Skeletal muscle movements, which are commonly up to 10 mm or 
larger, can be reduced or removed fully through utilising immobilisation devices 
and/or anaesthesia [64-66]. Internal organ motion, for example lung tumour 
movement as a result of breathing, was reported by Seppenwoolde et al. in one 
study to have an average amplitude of 12 ± 2 mm [67]. The impact breathing 
motion has on the dose distribution to a lung tumour can be reduced through the 
use of gating and breath hold techniques. However these techniques do not fully 
remove the effect of this motion, and is a current area of research [66, 68]. 
Breathing motion is likely to negatively impact the spatially modulated dose 
distribution from proton minibeam if used to treat lung tumours. A second 
example of organ motion is small brain movements caused by cardiovascular 
pulsations, these can be up to 0.3 mm [69]. The amplitude of these movements is 
small and is typically inconsequential for typical radiotherapy treatment 
modalities, yet is potentially still problematic for proton MRT, as these motions are 
similar in size to the small beams used and can potentially blur the modulated dose 
distribution. These movements are complex and non-rigid and exist throughout 
the body. In addition, various sections of the body experience different amplitudes 
of motion over brief time periods [67, 69]. 
 
Research in this thesis is particularly interested in motions that occur in small 
animals, which can impact treatments on the PPRP at UW. The magnitudes of 
these movements in small animals are smaller than in humans, for example rats 
have a maximum displacement of 60 µm in sections of their brain, compared to 
300 µm for humans [69, 70]. While the maximum displacement of these 
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movements is small, they still potentially reduce the modulation of the dose 
distribution and thus reduce the sparing effect. 
 
When motion is applied to a dose distribution, the sharp peaks are smoothed into 
the valleys. Figure 3.1 displays and illustrates a profile of a simplified 300 µm wide 
proton minibeam distribution at the surface of a water phantom and what occurs 
to this dose distribution after different amplitudes of motion are applied. Motion 
is applied in single direction with linear motion having a constant velocity and 
Gaussian motion having in a variable velocity. This shows that when motion is 
applied, the profile broadens, and the penumbra sharpness decreases. Further 
broadening as a result of 400 µm of motion also decreases the height of the peak, 
this occurs after the amplitude of the motion is greater than the width of the 
minibeam. 
 
Figure 3.1: Illustration of surface dose from proton beam illustrated with a simple step function with 
motion modelled in MATLAB. (a) displaying no motion 300 µm minibeam width. (b) 120 µm of 
gaussian motion simulated. (c) 400 µm of gaussian motion simulated. (d) no motion. (e) 120 µm of 
linear motion simulated in MATLAB. (f) 400 µm of linear motion simulated in MATLAB.  
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The difference between linear and Gaussian movement is also displayed, 
highlighting the maximum width of the minibeam is increased by the same amount 
for each type of movement, and the shape of the profile varies with the different 
types of movement. Increasing the width of the micro/minibeam has been shown 
to decrease the sparing effect for photons [12]. While this relationship has not been 
fully verified for protons it is assumed to behave similarly. The increase in the width 
of the micro/minibeam from motion thus reduces the normal tissue sparing, 
negatively impacting the treatment. Figure 3.1 implies that the valley dose between 
the minibeam peaks is zero, in a realistic micro/minibeam dose distribution the 
valley dose is low but non-zero. It can be hypothesised that low valley dose is the 
determining factor for normal tissue tolerance [71, 72]. Internal organ motion is 
able to increase this valley dose by spreading dose from the micro/minibeam peaks 
in the valleys. These two factors are the primary way that motion negatively 
impacts a micro/minibeam dose distribution and reduce the normal tissue 
tolerance. 
 
A diagram of a proton beam with a collimator and a water phantom is shown in 
Figure 3.2, illustrating the naming conventions and orientations used for this work. 
In this design arrangement, proton minibeams are most susceptible to motion in 
width direction as a result of the dose modulation being in this direction. Motion 
which is less than 10 mm in the height (y) or z (direction) do not directly impact 
the spatial modulation of the beam, as the beam in these directions behaves similar 




This work is primarily concerned with the overall impact motion will have on a 
dose distribution. The treatment time of a proton minibeam treatment is on the 
order of minutes, which is significantly longer than the timescale of most motions 
particular brain pulsations [69]. We therefore aim to model motion as the sum of 
a large number of combined single movements that impact the total dose delivered 
to a target. 
 
Synchrotron generated kV photon micro/minibeam widths remain roughly 
constant when penetrating a water phantom. Proton micro/minibeams on the 
other hand have an intrinsic divergence with depth, due to increased lateral scatter 
with slowing down. It is this property of protons that can be used to generate the 
uniform profile at the Bragg peak. This contrasts with the photon minibeams 
discussed by Manchado de Sola et al. where motion had a similar impact on all 
depths of a photon micro/minibeam dose distribution [19]. Investigating how 
Depth (z) 
 
Width (x direction of motion) 
Height (y) 
 
Figure 3.2: Diagram of simulation setup and directions. Showing the proton beam in green, the 
minibeam collimator with vertical slits (fewer are shown for clarity) in grey and the water 
phantom in blue 
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motion effects proton minibeam dose distribution as depth increases is an area of 
research that is currently lacking. 
 
The work presented in this chapter aims to model and characterise the effects of 
motion, from smaller respiratory and cardiovascular pulsations (60-300 µm) to 
larger motions with amplitudes of up to 10 mm, on proton minibeam dose 
distributions. 
 
This chapter investigates two areas regarding motion and the impact it has on dose 
distribution from proton MRT beams generated from a physical collimator. The 
first area of investigation is how the spacing of the minibeams can be used to 
minimise the impact of motion, particularly on the valley regions. The spacing 
between the minibeams is dependent on the spread of the protons at the Bragg 
peak and the desired uniformity. The magnitude of the spread of the protons at the 
Bragg peak is a function of energy, therefore we decided to investigate a range of 
proton energies. The second are that was investigated was how the width of the 







3.1. Methods to Model Motion Effects 
Modelling the effects of motion on a proton minibeam dose distribution was 
divided into two steps. The first step was to simulate high resolution proton 
minibeam dose distribution in TOPAS. The second step, motion was simulated in 
MATLAB. Modelling the motion in MATLAB allowed greater flexibility and a wider 
range of parameters to be investigated, and this greater volume of data to be 
produced. This methodology is similar to that used by Manchado de Sola et al [19]. 
 
The TOPAS simulation was designed to produce a realistic proton minibeam dose 
distribution from a physical collimator. The particles exiting the collimator enter 
at a water phantom in which particle interactions will result in the deposition of 
dose. The interaction of the proton beam with the collimator generates secondary 
particles that impact the dose distribution. Water was used as it has similar 
properties to human tissue, which allows findings to be applied to a wide range of 
tissues. 
 
Motion was simulated in MATLAB by making copies of the original dose 
distribution and shifting each copy in the width direction by an incremental 
amount of 1 µm. Each copy is then weighted based on a motion function and then 
combined to form a dose distribution that has undergone motion. For linear based 
motion, each step would be weighted evenly. Further details can be found in the 
MATLAB modelling section (Section 3.1.4). The high resolution of both the TOPAS 
simulation and the small steps of the MATLAB modelling enables exceedingly 
small motions on the micron scale to be analysed. This work assumes that all 
motion is non-deforming translational motion for two reasons. First, that this 
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translational motion in the width direction has the greatest negative impact on the 
dose distribution. Secondly, the type of translation is dependent on the location in 
the body and tissue type. This requires specific motion types to be modelled for 
individual organs and is therefore more complex to model and less applicable to a 
range of situations. Motion was modelled primarily in the direction that minibeam 
dose distribution is most vulnerable, shown previously in Figure 3.2. Motion which 
is in the depth or height directions will not have a substantial impact on the dose 
distribution. 
 
3.1.1. Monte Carlo Modelling of Proton Minibeams 
Monte Carlo simulations were performed using TOPAS version 3.0.1, TOPAS is a 
wrapper for Geometry and Tracking (GEANT) 4, a well-known Monte Carlo 
particle simulation toolkit [73-75]. These simulations used the default physics 
parameters built into TOPAS, which are optimised for proton therapy, and have 
been experimentally validated for a range of proton facilities [76-80]. The 
simulations modelled a pristine beam with no beamline. This keeps the results 
general so they can be applied to wide range of proton beamlines. As discussed in 
previous sections, the generation of a proton minibeam dose distribution currently 
requires a physical collimator, and it was decided to model the collimator so as to 
include the scatter generated from it in the dose distribution. 
 
The simulation modelled a vacuum world with a water phantom located at its 
centre, a brass minibeam collimator was placed adjacent to the water phantom. 
Brass was chosen for the collimator material as it is frequently used for collimating 
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proton beams [22, 81]. A detailed analysis of different collimator materials can be 
found in Chapter 5. The proton beam was modelled as a rectangular source with a 
fixed height of 25 mm and a variable width to ensure it covered the required 
minibeam spacing, this is given later in Table 3.1. The proton beam was simulated 
with a Gaussian energy spread of 1.15% and a Gaussian angular distribution with 
a standard deviation of 0.15 degrees. This angular and energy spread is to produce 
a more realistic result and is based off previous work [23]. The beam simulated 100 
million histories for each energy to reduce statistical variation of individual 
histories and results in a maximum uncertainty of 0.5% in the peak and valley 
regions for final results. The proton beam traverses 100 mm in the vacuum world 
and then is collimated into minibeams when passing through the collimator. A 
diagram of the setup was shown previously in Figure 3.2. Full details on the 
collimator variables are provided in Section 3.1.2 and 3.1.3. 
 
The simulations were split into two sets of collimator variables. The first simulation 
modelled different minibeam CTC spacing between each sub-beam, collimator 
variables are shown in Figure 3.3. The amount of lateral spread of a proton beam 
CTC spacing Slot width 
Slot height 
Figure 3.3: Beams eye view of the collimator. Showing the collimator slots and variables used in 
TOPAS simulations. Note size and number of slots has been changed for clarity. 
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is energy dependent, therefore the amount of spacing between minibeams to 
produce the same level of uniformity at the Bragg peak is also energy dependant. 
While it is possible to use a fixed energy proton beam and change the spacing of 
the minibeam to highlight the impact the spacing has on how minibeams can affect 
motion, this method will not produce a uniform dose at the Bragg peak as the 
protons only have a set amount of lateral spread. 
This results in the minibeam peaks combining at a shallower depth or not 
combining at all. The merging of the minibeams with depth is a key component of 
proton minibeams as discussed previously, and, if not utilised then protons are not 
being used to their full potential. To illustrate this, Figure 3.4 shows how the width 
of a 300 µm wide minibeam increases with depth for various proton minibeam 
energies used in this thesis. It can be observed that at a certain depth the 
minibeams merge and produce a uniform dose distribution, at this point the width 
of the minibeam is shown as a constant width, which is equal to the CTC spacing. 
Four different energies, 50, 100,150 and 200 MeV were modelled. This range was 
selected to be appropriate for application to a range of applications, from 





The second set of simulations varied the width of the minibeams from 100 to 700 
µm. The aim of this simulation was to determine if modifying the width of the 
minibeam can be used reduce the effects of motion on the dose distribution. The 
range between 100 and 700 µm was simulated as this covers the full range of 
minibeams, up to the point where the spatially modulated sparing effect has been 
observed. This simulation used only a single proton beam energy of 50 MeV,  so 
the energy of the beam would not be a factor of the comparison. 
 
  
Figure 3.4: Diagram displaying how the width of the minibeam increases with depth until it 
becomes uniform near the depth of the Bragg peak for various proton minibeam energies. Width 
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3.1.2. CTC Spacing and Motion 
As discusses previously, having the ideal CTC spacing between the minibeams 
allows for a spatially modulated dose at the surface and uniform dose at the Bragg 
peak. Each of the proton beam energies has a different lateral spread and depth of 
Bragg peak. Using this lateral spread of the protons the CTC spacing was set to 
produce uniform dose where the minimum dose was 85% of the maximum dose at 
the Bragg peak. This level of uniformity was chosen based on previous research by 
Lee et al. Decreasing the CTC spacing would increase the level of uniformity at the 
Bragg peak if this was desired [23]. The required spacing was calculated by 
maintaining a constant ratio between the lateral spread of the beam and the CTC 
spacing. The lateral spread of the proton beam was obtained from the stopping and 
range of ions in matter (SRIM) 2013 [82]. The calculated CTC for each energy is 
show in Table 3.1 along with all parameters for the collimator. 
 
Each proton beam energy has a different range in brass and water, therefore the 
thickness of the collimator and water phantom required adjustment to ensure all 
particles were fully absorbed in the respective media. As the CTC spacing increased 
to maintain the same number of slots in the collimator, the incoming uniform 
beams width was increased as well as the total width of the collimator and water 






Dose was measured in the water phantom, which was divided into 25000 voxels in 
the direction of motion (x) and 250 voxels in the height (y) and direction of the 
beam (z) directions. The higher number of voxels in the direction of motion 
increases the resolution in this direction and allows the simulation of small 
motions to be observed and maintains overall voxel limitations and trade-offs. 
  
Table 3.1:Proton minibeam collimator and water phantom parameters used in Monte Carlo model 
Incoming uniform proton beam initial energy (MeV) 50 100 150 200 
Incoming uniform beam width (x) (mm) 25 75 145 230 
Total collimator width (x) (mm) 50 100 200 300 
Total collimator thickness (z) (mm) 25 80 160 260 
Water phantom width (x) (mm) 25 75 150 250 
Water phantom thickness (z) (mm) 25 80 160 260 
Bragg peak depth in water (z) (mm) 21.9 76.0 155.6 256.2 
Distance between collimator and water phantom (mm) 0 0 0 0 
CTC spacing (x) (mm) 1.00 3.35 6.69 10.77 
Slot width (x) (mm) 0.3 0.3 0.3 0.3 
Slot height (y) (mm) 10 10 10 10 
Slot depth (z) (mm) 25 80 160 260 
Septa between slots (mm) 0.7 3.05 6.39 10.47 
Effect of Motion on Proton Minibeam Dose Distributions 42 
 
3.1.3. Minibeam Width and Motion 
To model how the width of the minibeam is affected by motion, a simulation was 
developed for a 50 MeV proton beam, defined using the same parameters as per 
the minibeam CTC spacing simulation in section 3.1.2 for the 50 MeV beam. The 
primary modification was varying the width of the slots in the collimator, to 
produce minibeams of various widths. The width of the collimator slots was varied 
between 0.1 – 0.7 mm, the CTC spacing remained constant at 1000 µm. This 
resulted in the material between the slots varying between 0.9 – 0.3 mm, 
respectively. This allows the width of the minibeam to be decoupled from most 
other variables and its effect to be investigated independently. 
 
3.1.4. Motion Simulations 
As discussed previously, there are several advantages to the approach taken in this 
thesis with regards to the simulation of phantom motion. The Monte Carlo 
simulations produce a dose distribution without applying motion to the phantom; 
instead, this motion is simulated further down the processing chain using 
MATLAB. For this section we modelled motion as a Gaussian motion to represent 
the true motion of any part of the body which is based off the motion of brain from 
MRI studies [69]. The difference in how linear motion and Gaussian motion impact 
minibeams was displayed previously in Figure 3.1. The MATLAB motion 
simulation was achieved by making copies of the original dose distribution and 
shifting each copy in the width direction by an incremental amount of 1 µm. Each 
copy is then weighted based on a motion function, in this case a Gaussian, and then 
combined to form a dose distribution that has undergone motion. 
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 This, in effect, weights each position by the percentage of time the dose 
distribution is located at that position. This is shown for 60 µm of motion in Figure 
3.5 for Gaussian, sinusoidal and linear motion. It can be observed that as the dose 
distributions are only moved in 1 µm voxel steps, and that this results in discrete 
steps rather than a continuous distribution. This should not pose any problem 
especially for larger motions. A range of different magnitudes of motion was 
simulated from 60 to 9500 µm, in steps of 60 µm. This large range covers from 
small motions from animals, 60 µm, and human brains, 300 µm, up to larger cardio 
induced and breathing motions [69].  
Figure 3.5: Position of dose distributions used to build a final dose that has undergone 60 µm of 
motion. 
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3.2. Results 
This section contains the results from the previously discussed simulations and 
first starts with an introduction to the dose distribution from a static proton 
minibeam with no motion, which will be used as a standard to compare all other 
results. 
 
The 50 MeV proton minibeam simulation has eleven 0.3 mm wide minibeams 
which deposits dose in the water phantom. The dose distribution from the 50 MeV 
simulation before any motion is applied in MATLAB is shown in Figure 3.6 as a 
reference. This shows the spatially modulated dose distribution at depth = 0 mm. 
The minibeams then broaden with depth to produce a near uniform dose 
distribution at the Bragg peak at depth of 21.9 mm. In the valley regions at the 
surface there is a dose of approximately 10-3 Gy, this small dose is a originates from 
scatter which is discussed further in Chapter 4. 
 
Figure 3.6: 50MeV Proton minibeam dose distribution in water phantom with no motion 
applied. Normalised to the entrance dose. 
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A percentage depth dose (PDD) of the peak and valley regions for all proton 
energies used in this section is displayed in Figure 3.7. The depth scale of this 
graphic was modified to illustrate difference between different energies. The PDD 
was also normalised to the entrance dose. It can be observed that the ratio between 
the surface dose and the Bragg peak dose increases with energy between 50 MeV 
and 200 MeV. This was caused by the separation of the minibeams and the width 
of the minibeam resulting in a lack of in-scatter with depth [83]. Proton beams 
diverge with depth, as discussed in Chapter 2. As the beams are spaced further 
apart energy from the beam is spread over a larger volume resulting in lower dose 
at the Bragg peak. The large surface dose is produced by scatter from the 
collimator, which is investigated further in Chapter 4. The scatter consists of mostly 
lower energy protons that have interacted with the collimator and lost energy 
thought Coulomb interactions. These low energy protons deposit their energy at a 
shallow depth in the water phantom. 
Figure 3.7:PDD for peak and valley for various proton minibeam energies. Dose is scaled to the 
entrance dose. Depth is normalised to the Bragg peak. 
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While this high surface dose is a concern with a uniform dose distribution, due to 
increased damage delivered to normal tissue. This is likely to not have a negative 
effect on proton minibeam dose distributions as normal tissue tolerance is believed 
to correspond to the valley dose. The rest of the results section is split into how the 
minibeam CTC spacing and width are impacted by motion. 
 
3.2.1. CTC Spacing 
A minibeam dose distribution was generated for each motion range from 0 – 10000 
µm and was analysed using the method described below. For clarity, only a small 
number of the motion simulations are shown, The range chosen was 0, 60, 90, 150, 
240, 400, 660, 1100, 1800, 3000, 4900, 8100 µm, these are on an exponential curve 
so the range could be covered evenly. 
 
A depth dose curve was generated for each dose distribution for the peak region 
and the valley region. Rather than generate the depth dose curve from a single voxel 
at each depth a small width and height, 100 µm, was averaged, this reduced noise 
in the data. The peak curve is generated from the central voxels of the beamlet 100 
µm in the width and height directions. Of the eleven beamlets, the two edge were 
ignored for this section of work, as they had lower dose at the Bragg peak, due to 
less dose being spread from one adjacent, instead of two adjacent beamlets. The 
remaining nine beamlets were averaged together to reduce fluctuations from 
individual histories, thus reducing noise. The valley curve is generated from the 
100 µm wide central voxels that are evenly spaced between the peaks. The valley 
curve is processed with the same method to how the peak curve is generated. With 
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the peak and valley curves generated the PVDR can be calculated as the ratio 
between the two. This is often used as a metric in spatially modulated dose 
distributions, as discussed in Chapter 2. The width of the minibeam is measured 
from the 50% of the maximum dose of the peak of the minibeam profile for all 
depths, for values when the minimum dose is greater than 50% of the maximum 
dose the beam width is then equal to the CTC spacing, or the dose is uniform. This 
threshold of 50% of the maximum dose was selected as a usual standard of full 
width half maximum is used to measure with width of Gaussians and provides an 
adequate estimate of the area which the minibeam covers. 
 
The four metrics described above, peak dose, valley dose, PVDR and beam width 
were calculated for each motion magnitude and are used to produce Figure 3.8 – 
3.11 for the 50 MeV to 200 MeV proton minibeam distributions, respectively. The 
peak and valley dose have been normalised to the Bragg peak of the zero-motion 
result. Results only display motions which were less than the CTC spacing for each 
energy, as in motions larger than this the dose distribution becomes uniform. 
 
The peak dose shown in Figure 3.8 – 3.11 demonstrates that all energies follow a 
similar trend, where motion has a large impact at the surface and this impact 
decreases with depth. Increasing the energy of the minibeams does not appear to 
change the relationship between motion and the peak dose. Which implies that 
increasing the CTC spacing does not have an influence on this as beam energy is 
linked to CTC spacing for this setup. It can be observed that the peak dose at the 
Bragg peak will sometimes exceed a dose of one Gy as large motions cause some 
overlap in the minibeam peaks resulting in increased dose. A discontinuity in the 
peak dose data can be observed in the Figures 3.8 – 3.11, between the 240 and 400 
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µm motions, where the peak dose only decreases by 10 – 15% before the 
discontinuity, and after by 37 – 44%. Occurring when the motion exceeds the width 
of the minibeam in this case 300 µm, this is investigated further in the next section 
of results. For the 60 µm motion scenario the peak dose at the surface only has a 






Figure 3.8:Impact of motion on the peak, valley PVDR and beam width for a 50 MeV proton 




Figure 3.9:Impact of motion on the peak, valley PVDR and beam width for a 100 MeV proton minibeam 
dose distribution 
Figure 3.10:Impact of motion on the peak, valley PVDR and beam width for a 150 MeV proton minibeam 
dose distribution 
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The valley dose shows similar trends in Figures 3.8 – 3.11, where motion has a 
minimal impact at both the surface and the Bragg peak, but affecting a region part 
way between them. For the valley dose to be increased, dose from the minibeam 
peak regions needs to be spread into the valleys. This occurs when the minibeams 
are broadened to a width nearing the CTC spacing. Minibeams have been shown to 
broaden with depth, however, motion also broadens the minibeams causing a 
compounding effect, which results in an increase in the valley dose. This 
demonstrates that the ratio between motion and the CTC spacing is important in 
maintaining a low dose in the central valley regions. For the 60 µm motion scenario 
the valley dose at the surface only has a 2% increase, demonstrating a minimal 
impact for small mouse motions. As motion increases the depth where the valley 
Figure 3.11:Impact of motion on the peak, valley PVDR and beam width for a 200 MeV proton 
minibeam dose distribution 
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dose is impacted decreases, this is further shown in the beam width results in 
Figures 3.8 – 3.11. 
 
The PVDR results follow similar trends for all energies, being greatest at the surface 
and decreases with depth. The impact of motion is greatest at the surface, 
decreasing the PVDR by the largest amount. The impact motion has on the PVDR 
depends more on the large decrease in the peak dose rather than the small increase 
in the valley dose, due to the high spatial modulation at the surface. 
 
Results from the beam width demonstrate that the full width half maximum 
(FWHM) of the beam increases with depth until it becomes uniform slightly before 
the Bragg peak. Motion increases the width of the minibeam at all depths. It is 
typically expected that the width of the minibeam plus the motion would equal the 
measured FWHM at the surface, this does not occur as the FWHM measures the 
width at the halfway point so the overall width at the base of the minibeam has 
increased but the width halfway up might not have change by the same factor. This 
can also lead to some artefacts where motion appears to reduce the width of the 
minibeam. Motion has a secondary effect where it reduces the depth where the 
minibeams merge into a uniform beam, this occurs rapidly before the Bragg peak 
and appears as a sharp increase in the width of the minibeam. Increasing the 
spacing between the minibeams allows a reduction in the amount of dose that can 
be spread into the centre of the valleys. 
 
Overall, it can be observed that motion has the greatest impact on the peak dose, 
decreasing by a similar magnitude for all energies at the surface. The decrease in 
the peak dose is dependent on the width of the minibeam. This is explored further 
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in the next section. When the width of the beam increases with depth, motion is 
able to spreads dose from the peak regions into the centre of the valley. This makes 
the central valley region vulnerable to motion at a depth between 25 – 75% of the 
depth of the Bragg peak. 
 
3.2.2. Minibeam Width. 
This section of results investigates how the dose for different slot widths is 
impacted by motion. The peak dose, valley dose, PVDR and beam width were all 
produced with the same method as the previous section. A motion range of 0 – 660 
mm was chosen to cover a wide range up to where the minibeams start to merge 
into a uniform dose distribution. In the following, only four representative sets of 
data are shown for clarity, displaying minibeams with widths of 100, 300, 500 and 
700 µm. Each setup has a CTC spacing of 1 mm between the minibeams. The 
results are shown in Figure 3.12 – 3.15, respectively. Results have been normalised 
to the Bragg peak for the zero-motion result. Some results have a higher Bragg peak 
than one due to motion merging the minibeams at the Bragg peak. 
 
Results of the peak dose in Figures 3.12 – 3.15, demonstrate that the peak dose is 
only reduced by up to 15% for motions less than the width of the minibeam 
beamlet. It would be expected that the peak dose would not decrease for motions 
less than the width of minibeam beamlet. However, the minibeams are not flat so 
a small decrease is observed in the peak. For motion larger than the width of the 







Figure 3.12: Impact of motion on the peak, valley PVDR and beam width for a 100 µm wide 50 
MeV proton minibeam dose distribution 
Figure 3.13: Impact of motion on the peak, valley PVDR and beam width for a 300 µm wide 50 
MeV proton minibeam dose distribution 





Figure 3.14: Impact of motion on the peak, valley PVDR and beam width for a 500 µm wide 50 
MeV proton minibeam dose distribution 
 
Figure 3.15:Impact of motion on the peak, valley PVDR and beam width for a 700 µm wide 50 
MeV proton minibeam dose distribution 
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The valley results show that increasing the width of the minibeams, whilst 
maintaining a constant CTC spacing, results in more dose spread into the valleys. 
This makes the valleys more susceptible to motion. The valley results show that 
there is a depth where they are most susceptible to motion, this depth is located 
partway between the surface and the Bragg peak and depends on the magnitude of 
motion applied and the width of the minibeam. 
 
The PVDR results agree with the previous results showing that the reduction in the 
PVDR primarily depends upon the reduction in the peak dose. Therefore, as the 
width of the minibeams is increased, and the peak dose is less susceptible to 
motion, the PVDR is also less susceptible to motion. This does have the drawback 
that the overall PVDR is less with wider minibeams. 
 
The increased width of the beam results in a decrease in the depth where the beam 
becomes uniform. Overall, the width of the minibeams show similar effects of 
motion with the primary difference being the initial starting width of the minibeam 
and the depth where the minibeams merge into a uniform dose distribution. The 
results from this section clearly show that increasing the width of the minibeams is 
beneficial at reducing the impact motion has on the peak dose but it does increase 
the dose delivered to the valley, reduce the PVDR and decrease the depth where 
the minibeams merge into a uniform beam. 
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3.3. Discussion 
This discussion is divided into three parts. Firstly, the results of the impact motion 
have on the minibeam peak dose distribution. This region delivers high dose tracks 
through normal tissue and maintaining high peaks means that less dose is spread 
into the valley regions. Secondly, the impact on the valley dose distribution. The 
valley region is a key region in proton minibeams, as normal tissue damage in this 
region is believed to be correlated to the valley dose. Maintaining a low valley dose 
reduces normal damage to this tissue. The last section discusses the overall impact 
motion has on proton minibeams and combines the results from the previous 
discussions. 
 
3.3.1. Impact of Motion on Peak Dose 
When motion is applied it has been shown to widen the minibeam and spread dose 
from the peaks into the valley regions, which reduces the PVDR. The high surface 
dose in the peak regions may been seen as a concern, however, previous research 
has indicated that these regions are likely to be repaired by the surrounding normal 
tissue [53, 72, 84]. It is therefore vital to maintain the height of these peaks, so 
dose is not spread into the valleys and any reduction in the peak dose is 
subsequently added to dose in the valley regions. 
 
The results from the CTC spacing simulations demonstrate that increasing the 
spacing between the minibeams does not an impact on the peak dose or limit the 
impact motion has on it. Differences observed in the results can be attributed to 
the different energies used in the simulations, which produce various magnitudes 
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and types of scatter with a range of energies. The peak dose is less impacted by 
motions that are less than the beamlet width. Larger motions will rapidly decrease 
the peak dose. This creates a plateau effect for motions smaller than the width of 
the beamlet. Which occurs as a product of the geometric design of the collimator 
and minibeams. For a beamlet with a flat profile it is expected that there should be 
no decrease in maximum dose when the amplitude of the motion is less than width 
of the minibeam. However, some differences are observed this indicates the profile 
of the minibeam is not flat. 
 
3.3.2. Impact of Motion on Valley Dose 
 It is critical to maintain a low valley dose to minimise biological damage to surface 
and normal tissue [53, 72, 84]. Results from the CTC spacing simulations (see 
Figures 3.8 – 3.11) demonstrate that there is a relationship that increasing the 
spacing between the minibeams reduces the effects motion on the dose 
distribution. This occurs as increasing the spacing decreases the amount of dose 
that can be delivered to the central region of the valleys. If the spacing between the 
minibeams is greater than the width of the minibeam plus motion, then minimal 
dose from the peak can reach the centre of the valleys. This allows higher energy 
beams to less impacted by motions with larger amplitudes, this is beneficial for 
scaling from small animals to human size motions as human treatments will use a 
higher energy with increased CTC spacing. 
 
Increasing the width of the minibeam has been shown to reduce the threshold for 
motion to spread dose from the peak regions into the valley regions. Increasing the 
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CTC spacing is shown to counteract this problem by increasing the width of the 
valleys between the minibeams. 
 
The broadening of minibeams with both depth and motion has been shown to have 
a threshold at a depth between the surface and the Bragg peak where the valley 
dose is rapidly increased. This occurs when the motion plus the width of the 
minibeam at depth approaches the CTC spacing between the minibeams, thus 
spreading dose into the low dose regions. Any motion will impact the valley dose 
at some depth as the spacing between the minibeams trends towards zero when 
they merge at the Bragg peak. Therefore, motion decreases the depth where the 
peaks merge into a uniform dose. This problem is limited by modulation of the dose 







3.3.3. Impacts of Motion on Proton Minibeams 
The combined results of the PVDR showed a strong relationship between the 
decrease in the peak dose caused by motion and the decrease in the PVDR at the 
surface of the water phantom. The PVDR is often used in the literature to gauge the 
spatially fractionation of a modulated dose distribution, and therefore is used to 
gauge the quality [63, 71]. Results showed that increasing the width of the beamlet 
did help to limit the impact of motion, however this did reduce the PVDR and the 
width of the beamlet has been shown in photons to be inversely related to the 
normal tissue sparing [11-13]. The microbeam sparing effect has also been 
observed in x-ray synchrotron generated beam with widths of up to 0.68 mm [57]. 
Assuming this minibeam width is applicable to proton minibeam, this creates an 
upper bound for the beam width. This is an important consideration as proton 
beams broaden with depth. Avoiding this potential limit will help maintain normal 
tissue sparing. Therefore, it is not recommended to increase the width of the 
beamlet whilst trying to reduce the impact of motion. Further investigation into 
the width of the minibeam is investigated in Chapter 5. 
 
Healthy tissue sparing is also believed to depend on the valley dose [63]. The key 
method investigated, which helped in reducing the valley dose in the presence of 
motion was increasing the CTC spacing between the minibeams. The ability to 
increase the CTC spacing is limited without increasing the energy of the proton 
beam without reducing uniformity in the dose distribution at the Bragg peak. 
Human brain motion has a been observed to have a maximum motion of 300 µm, 
therefore using a minibeam of equal width will have reduce the impact from this 
motion [69]. For small animal studies a maximum motion of 60 µm was observed 
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in a rat brain [85]. Based on the simulations in this chapter, this small motion 
should have very minimal effect on the overall dose distribution and allows the use 
of small minibeams in treatment without compromising the minibeam maximum 
dose. The results from this research indicate that motion less than 300 µm only has 
a minimal impact on the valley dose. Therefore, the effect of motion on normal 
tissue should be minimal. The impact of motion on the valley dose primarily 
depends on the minibeam CTC distances. Therefore, if the distances are 
significantly greater than any applied motion then the effect of motion will remain 
minimal. 
 
Motion has been shown to decrease the depth where the Bragg peak dose becomes 
uniform. This could potentially be used to improve the uniformity at the Bragg 
peak. If the motion is regular and repetitive narrower beams with greater CTC 
spacings could be used to produce a dose distribution that is still uniform at the 
Bragg peak. For example, for the simplified scenario modelled here, if the mean 
amplitude of motion in a particular human brain is 120 µm then the CTC spacing 
could be increased by this same magnitude and the minibeam width could be 
decreased by the same amount. Care should be taken with this as most motions will 
not be fully predictable and repetitive and the profile of the dose distribution will 
be less sharp than an equivalent distribution with no movement. 
 
It should be noted that this work does look at a worst-case model for motion in 
terms of motions being perpendicular to the slots. This leads to the results 
potentially over exaggerating the impact of motion for a given motion value. To 
correct for this a smaller amount of motion would be used if the direction of motion 
were at an angle to the direction of motion modelled. The overall motion could be 
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reduced to just the component that matches the direction modelled. Another 
limitation of this work is this model uses a monoenergetic beam that produces little 
scatter, future work should verify these results on a more realistic beam that can 
generate a spread out Bragg peak.  
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3.4. Conclusion 
This chapter investigated and characterised the effects of motion on the dose 
distribution for various proton minibeam collimator designs, providing insight into 
a critical area of research that currently is currently unexplored. This work is novel 
and covers a wide range of motion relevant for small animal irradiation, but also 
extends to clinical beams and as such is easily translatable to a range of proton 
minibeam geometries. 
 
It was demonstrated that whilst motion can be problematic for proton minibeam 
dose distributions, by spreading dose from the peak regions into the valley regions, 
there are solutions to mitigate this effect. These include maximising the CTC 
spacing to reduce the ability of motion to reach the centre of the valleys and 
minimising the widths of the minibeams in order to reduce collateral damage from 
them. This work also demonstrates that for an expected motion of 60 µm in mice 
brains, the impact minimal for all minibeam width investigated, with a drop of less 
than 1% in the peak dose and an increase of 2% for the valley dose. For proton 
energies and geometries relevant for human patients, the results show that a 
greater CTC spacing allows the valley dose to be unaffected with motions smaller 
than 1000 µm. 
 
The effect of motion has been shown to have minor impact on the peak minibeam 
dose for motions less than the beam width of the minibeam. The decrease in peak 
minibeam dose caused by motion is greatest at the surface and decreases with 
depth, this effect is primarily dependant on depth and not energy/spacing. It was 
determined that the area between the surface and the Bragg peak is the most affect 
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by motion due to the diverging beamlets. Human scale motions on the order of 300 
µm have minimal to no effect on the valley dose for 100 MeV proton beams and 
above. This is a result of the valley dose being dependant on the CTC spacing 
between each of the minibeams. Control of the CTC spacing is determined by the 
beam’s initial energy, to produce a uniform dose distribution a collimator with a 
specific CTC measurement is required. The effect of motion on the valley dose is 
therefore dependant on beam energy, with higher beam energies being less 
impacted by motion due to the larger CTC spacing. 
 
This work primary investigated monoenergetic beams. However, the results should 
be easily translatable to a wide range of multi-energy proton beams as the primary 
difference would be the depth where the beamlets merge into a uniform 
distribution. An assumption made during this research was that the treatment time 
would be much longer than the motion that would occur, so the effect of motion 
would be the sum of all small motions that occurred during a treatment. If the 
patient was shifted during treatment or the treatment time was shorter than a 
period of motion, then some of these results might not fully apply to that situation. 
It was also assumed that motion would not deform the shape or the density of the 
target, this would modify the resulting dose distribution in ways that are not fully 
modelled with this setup. However, these results should provide a baseline and 
provide a good initial approximation for most cases. 
 
A critical area of future work is determining the full extent of the relationship 
between the width of minibeams, and their sparing effect. This is of importance for 
proton minibeams that diverge and increase their width with depth. This would 
require biological experiments and is beyond the scope of this thesis. This 
Effect of Motion on Proton Minibeam Dose Distributions 64 
 
biological experimental information is also key to complete the motion work and 
give a complete guide to how minibeams can be designed to reduce the impacts of 
motion. While high dose proton beams are possible in the future there will still 
always be some degree of motion present that reduces the spatial modulation by 






Chapter 4              
Monte Carlo Modelling of  the 
Preclinical Proton Beam 
This chapter introduces modelling of the Precision Proton Radiotherapy Platform 
proton beamline at the University of Washington. A detailed Monte Carlo model 
was developed, including all beamline components, which was used in later 
chapters of the thesis. The model output was compared and verified against 
measurements from the real output of the proton beam. A novel in-depth analysis 
was then performed on the impact of each of the beamline components, to 
determine the scatter contribution from each component and the impact they have 




The University of Washington Clinical Cyclotron was installed in 1983 and 
primarily used to treat patients with fast neutrons produced by bombarding a 
beryllium target with protons [86]. Currently a second neutron treatment room is 
setup as a proton research facility, referred to as the Precision Proton Radiotherapy 
Platform (PPRP). The PPRP outputs a proton beam of up to 50.5 MeV and is shown 
in Figure 4.1. The relatively low proton beam energy, compared to clinical proton 
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beams with a maximum energy of typically around 230 MeV, is ideal for biological 
studies on small animals, such as mice due to the shallow depth of the Bragg peak 
of approximately 20 mm in water. It is possible to conduct biological studies on a 
clinical proton beam, however, in order to do so the beam energy would need to be 
degraded. This requires the use of a degrader or range modulator, which absorbs 
energy from the protons. Which has the side effect of introducing scattered 
radiation, thus reducing the quality of the beam from near monoenergetic with a 
pristine Bragg peak to a poly-energetic beam with a lower dose rate, and a flattened 
Bragg peak. The aim of this chapter was to develop a full and accurate model of the 
proton beamline in TOPAS, with the intention to use it for current and future 
biological proton beam experiments. 
  
Figure 4.1: Image of PPRP beamline with minibeam collimator and water phantom. Note the ion 
chamber is currently not in place in the picture. 
Beamline and direction Collimator Water phantom 
Ion chamber holder (ion chamber 
not currently installed 
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The cyclotron beamline has been in operation for over 35 years, and whilst for most 
parts of the beamline detailed documentation was available, it was found that some 
changes to the original beamline have not been recorded or detailed records could 
not be found. It is currently impractical to disassemble the entire beamline to 
catalogue all components. Therefore, there was some uncertainty in the materials 
and intricate details of the design of some components. 
 
The goal was to model known components accurately and estimate unknown 
details to the best available knowledge before refining and analysing the model 
through physical measurements of the current beam. Interactions between the 
beam and each component in the beamline as simulated in the model was 
examined to identify where energy or particles are lost and determine any impact 
the secondary radiation produced had on the final dose delivered. Future proton 
minibeams radiobiological experiments will make use of the model and forms a 
real-world grounding for much of this work. 
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4.2. Methods 
TOPAS 3.0.1 was used for modelling with the default physics lists, remaining 
consistent with the previous chapter in this thesis. The output from the model was 
then processed in MATLAB version R2016a. The following method used in the 
chapter is divided into four sections. The first discusses the initial design of the 
model produced in TOPAS and the various components modelled. The following 
section explains methods used in measuring the physical dose delivered to a water 
phantom from the 50.5 MeV beam at the University of Washington. These physical 
measurements are used to verify the TOPAS model of the beamline. The third 
section covers the modelling of scatter from beamline components, and how each 
component degrades the energy of the proton beam. The final section explains the 
methods used to model how each component of the proton beamline affects the 
final dose distribution delivered to the water phantom. 
 
4.2.1. Producing a Model of the PPRP Beamline in TOPAS 
A TOPAS model was produced which contains of all components of the 50.5 MeV 
proton beamline at the University of Washington that are downstream from the 
cyclotron. The cyclotron was excluded from the model as the output from it is a 
monoenergetic 50.5 MeV proton beam, and majority of the degradation of the 
beam occurs downstream, this assumption is based off previous work [23]. 
 
TOPAS simulations start with what is defined as the ‘world’ box which contains all 
other components. For the simulations used throughout this chapter the world is 
defined to be composed of air to simulate realistic degradation of the beam in 
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getting to the target. All other components are then added to the world. It should 
be noted that whilst the world is air-filled, some components can still contain 
vacuum inside them to match the physical beamline, as necessary. Figure 4.2 is a 
diagram displaying the various components of the beam, which are modelled in the 
simulation. This next section will work through each of the components in the 
beamline in the order in which the beam traverses them.  
 
First the near monoenergetic proton beam from the cyclotron encounters a beam 
degrader. This is located upstream to the left of the diagram and is not shown for 
clarity due to the long length of the large beampipe. The degrader consists of a 1.23 
mm sheet of graphite that is the entire width of the beampipe.  
 
Large beampipe 







Figure 4.2: Diagram of the components in the TOPAS model of the PPRP. The proton beam enters 
the large beampipe from the left. The beam degrader is not shown for clarity. 
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The degrader has two functions, first to spread out the narrow pencil beam coming 
from the cyclotron in to produce a wider beam on the beam exit side. The second 
is to decrease the ultra-high dose rate of the beam to dose rates comparable to that 
of clinical photon and proton beams. As a consequence, the peak energy of the 
beam is reduced, and scattered radiation is produced as the protons pass through 
it. This is explored later in this chapter. 
 
The beam then travels down a large stainless steel beam pipe, 4.158 m long with 
an internal radius of 30 mm and a thickness of 1.75 mm. Vacuum is maintained in 
the large beam pipe, stray beam connector and small beampipe, ensuring that the 
beam does not interact with any particles on its path which would degrade it as it 
travels. The large beampipe then connects with a 26 mm long graphite and 
stainless steel stray beam connector which is used to reduce the diameter of the 
beam and connect it to a smaller stainless steel beam pipe. The radius of the beam 
is reduced from 30 mm to 16 mm when passing through the stray beam connector. 
 
The beam then travels down the small beam pipe with an internal radius of 19 mm 
and an outer thickness of 1.5 mm and a length of 255 mm. Upon exiting the small 
beam pipe, the beam passes through a 0.15 mm long Kapton window into an air-
filled room. The Kapton window maintains a vacuum inside the beampipes and is 
designed to reduce the energy of the beam by a minimal amount. The beam passes 
through an air-filled pipe, no interactions between the beam and the pipe occur 
due to its larger internal diameter. Once in the air-filled room, the beam passes 
through a pancake ion chamber, used for monitoring the amount of dose delivered. 
For minibeam experiments the beam is passed through a 25 mm long stainless 
steel collimator, reshaping the uniform beam into spatially modulated minibeams. 
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The collimator was designed as part of this thesis and was based using results 
obtained in Chapter 5. The collimator contains 31 individual 0.3 x 30 mm air-filled 
slots cut out of it, each slot is spaced 1 mm CTC, creating a 30 x 30 mm minibeam 
field. During some simulations and setups, the minibeam collimator is omitted to 
allow a uniform beam to deposit dose in the water phantom. After exiting the 
collimator, the beam travels 23 mm before depositing dose into a water phantom. 
A cube with sides of 4 cm, which is surrounded by 1 mm of Lexan. The simulated 
water phantom is smaller on the distal side than the physical water phantom. As 
the beam only deposits dose to a small volume of the phantom and simulating the 
remainder of the phantom would have only increased computational complexity 
with no additional benefit. This covers all components of the beamline that were 
simulated in this chapter. The next sections of the methods will cover any changes 
to this model and any other methods used. 
 
4.2.2. Verification of PPRP Model 
For this section, simulated dose delivered to the water phantom is verified against 
physical measurements on the PPRP at the University of Washington. The 
minibeam collimator was removed from both the TOPAS model and the real 
beamline, enabling an open field comparison to be performed, with the goal of 
matching the PDD from TOPAS to the measured PDD on the beamline. 
 
The TOPAS model used in this section is based on the model described in Section 
4.2.1, with a few small modifications. First the minibeam collimator is removed 
from the model as explained previously. Then the exterior of the water box was 
removed, enabling an easier comparison between the measurements and modelled 
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values. This was done because the water equivalent depth of the material on the 
surface of the water box was included in the measured values. The modelled water 
phantom was divided into 100 µm voxels in the depth direction, no divisions were 
made in the other directions. Ensuring high resolution for producing depth dose 
curves to compare to the measured results and reduces statistical variation from 
individual histories in the Monte Carlo simulation. The simulation calculated 100 
million histories for this section. 
 
The physical dose measurements were performed with an Exradin Spokas A11 
parallel plate ion chamber with a collecting volume of 0.62 cc (Standard Imaging, 
Middleton, WI, USA) and a micro-Diamond detector (Type 60019, PTW-Freiburg, 
Germany) with a nominally sensitive volume of 0.004 mm3. The detectors were 
able to be precisely positioned in the water phantom with a motion stage with the 
ion chamber positioned in 1 mm steps in the build-up region of the Bragg peak and 
100 µm steps close to the Bragg peak. Higher spatial resolution was used around 
the Bragg peak as this region has a much higher dose gradient. The micro-Diamond 
detector was moved in steps of 500 µm. 
 
4.2.3. Modelling Beamline Components Scatter in TOPAS 
This section aims to gain and understanding of how each component interacts with 
the beam and how the beam was degraded from the initial 50.5 MeV beam. The 
entire beamline is simulated including the minibeam collimator. The large beam 
pipe’s radius was modified from 30 to 45 mm as per results explored later in 
Section 4.3.1. This was to be done to better match the TOPAS model to measured 
values. This change will be used throughout the remainder of the thesis. How each 
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component alters these particles as they pass through is of particular interest. As 
the beam predominately interacts via Coulomb interactions with the components 
along the path of the beam the particles will lose energy and produce secondary 
particles. To collect particle information phase space filters were placed on the 
front and rear surface of each component orthogonal to the beam. The filter 
counted every particle passing through it and measured their position, direction, 
angular cosine, energy, and particle type. This naturally generates a large amount 
of data and analysis of this data provides an in-depth picture and valuable insight 
of where particles are produced and absorbed throughout the beamline. 
 
Ten million histories were simulated for this investigation. The number of histories 
is smaller than the other simulations performed throughout this thesis. Recording 
all the details to all particles is very diskspace dependent and total useable RAM 
puts constraints on the maximum number of histories. As this method collects 
particles over the entire surface of each component the number of histories 
required to reduce statistical variation in the mean is lower. 
4.2.4. Quantifying Contributions Beamline Components 
Have on the Dose Distribution 
This section explores how the proton beam interacts with each component along 
the beamline and resulting impaction of the final dose distribution. The primarily 
interest of this work is any secondary radiation from interactions between the 
proton beam and components of the beamline. The simulation was designed based 
on the TOPAS model discussed previously in Section 4.2.1. A simulation with all 
components was first performed to establish a baseline of dose delivered to the 
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water phantom. Components were then removed one at a time, firstly from the 
exterior of the beam in the following order: Lexan exterior of the water box, 
minibeam collimator, ion monitoring chamber, small air-filled pipe and the 
Kapton exit window on the end of the small beam pipe. The air in the world was 
then removed and changed to vacuum, to determine the impact of the beam 
travelling through a short distance of air. Changing the world to vacuum is also 
useful are components upstream from this point are vacuum filled. Each 
component of the beamline was then removed in the following order: small beam 
pipe, stay beam connector, large beam pipe and the graphite beam degrader. The 
final simulation was just the pure beam from the cyclotron and the water phantom, 
with no exterior box, collecting dose. The order used here allows the beam exiting 
each component to be compared and the cumulative effects of the components to 
be investigated. 
 
In each of the simulations the water phantom was divided into 40 x 40 x 400 voxels 
in the x, y, z directions, resulting in voxel sizes of 1 mm x 1 mm x 0.01 mm, 
respectively. The arrangement of voxels was chosen to increase resolution in the 
depth direction and decrease the resolution in the other directions, since we are 
primarily interested in PDDs rather than lateral profiles in this section. Simulation 
time was reduced and the average number of histories per voxel was increased by 
reducing the number of voxels in the x and y directions. Results from these 
simulations were processed in MATLAB. The following section contains results 





The results from the models are split into four sections. The first section considers 
the dose modelling and experimental verification of the model by comparing the 
physical measured results to the TOPAS model. The second section explores 
particle energy results from the scatter modelling, displaying the various particles 
passing through each component of the beam and their energy. The third section 
containing the beam positional distribution and angular deviation distribution 
results from the scatter modelling, showing the divergence, and spreading of the 
beam as it passes through various components. The final section displays results 
from how the beamline components impact the dose distribution. 
 
4.3.1. Verification of the PPRP 
When comparing the results from the dose modelling a comparison of the PDD is 
used to match the results from TOPAS to the measured results obtained from the 
ion chamber and the diamond detector. The PDD was selected from the central 
voxels (along central axis) in the x and y directions and every voxel in the depth 
direction. PDDs presented within are scaled to have a dose of one at a depth of 5 
mm in the water phantom. Results from the ion chamber and diamond detector 
were obtained in collaboration with the University of Washington. The ion 
chamber and diamond detector were cross calibrated with a clinical ion chamber 
from the Seattle Proton Therapy Centre, which is traceable to a primary standard. 
These results also include a depth calibration to consider the water equivalent 
thickness of the water tank and the material the beam passes through. The two 
water tanks used for these measurements were made from Perspex and had a 
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physical thickness of 1 mm for the ion chamber set up and 1.5 mm for diamond 
detector set up. The water equivalent thickness of 1 cm of the Perspex is 1.158 cm 
for a 50 MeV beam [87]. Therefore 1.2 mm and 1.7 mm have been added to all 
measurement results. These depth measurement results have a 0.5 mm positional 
zero uncertainty attached to them. The ion chamber and diamond detector have 
had an additional 0.3 mm added to their depth measurement to allow the depth of 
their Bragg peak to agree with the Bragg peak depth from the TOPAS model. This 
offset of 0.3 mm between these results is likely a minor setup error and is within 
the positional uncertainty.  
 
Figure 4.3 shows the initial results, illustrating that that the ion chamber and 
diamond detector are both in agreement, but there is some disagreement between 
the TOPAS model and the physical measurements.  
  
Figure 4.3: Comparison of PDD measured with TOPAS, ion chamber and diamond detector. Dose 
normalised at a depth of 5 mm. 
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The Bragg peak is sharper in the TOPAS model than in the experimental results, 
possibly an artefact of the physical detectors having lower resolution, resulting in 
volume averaging, than that of the TOPAS simulation. The physical results have 
also been shifted by a depth of 0.3 mm for the Bragg peak to align, to allow the 
shape of the PDD curves to be compared. A secondary peak can be observed at a 
depth of 15.6 mm with a considerable dip before the Bragg peak in the TOPAS 
model. The profile of the PDD from both the ion chamber and diamond detector 
agree, indicating that any difference between the TOPAS model and physical 
measurements is unlikely to be due to measurement error. Testing of the various 
components modelled in TOPAS revealed that this secondary peak was caused by 
the beam interacting with the sides of the large beam pipe and introducing 
secondary scatter into the beam. 
 
The amount of secondary scatter is not present in the real measurements from 
either the ion chamber or the diamond detector. This disagreement between the 
model and the measurement is most likely not an issue in TOPAS physics or the 
measurements, but an inaccuracy in the geometry and inputted components put 
into TOPAS not matching the real components. As the beamline was built in 1983 
and has undergone some undocumented changes throughout its history, current 
drawings and technical diagrams may be out of date. While external dimensions 
can be measured it was not feasible to disassemble the entire beamline to catalogue 
the internal geometry and materials of all components, leaving some inaccuracy in 
the components modelled. To address this problem, the model was modified so the 
scatter contribution was removed from the large beam pipe, by modifying the 
radius of the large beam pipe. As the proton beam travels down the beam pipe the 
beam broadens with depth, if the radius of the large beam pipe is large enough then 
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the beam will not interact with the large beam pipe due to the fixed length of the 
beam pipe. The model was simulated with the same components as the previous 
simulation except the large beam pipe’s internal radius was changed to 30, 45 and 
60 mm to determine which of these would best match the measurements. The 
thickness, length and material remained unchanged. These results are shown in 
Figure 4.4. 
 
The results obtained with the beam pipe with a radius of 45 mm closely matches 
the measurement values. The secondary peak was removed, and the surface value 
closely match. The 60 mm simulation is approximately equal to the 45 mm 
simulation. 
It can also be observed that the relative peak dose at the Bragg peak has increased, 
this is likely caused by volume averaging affects and is the expected outcome. The 
modification to the beam pipe will be used throughout the remainder of the thesis. 
Figure 4.4: Results from multiple TOPAS simulations compared to physical measurements, 




4.3.2. Scattered Particles Energy Distributions 
Histograms of the energy distribution results from modelling scattered particles in 
the beam are shown in this section. They are split into following the types of 
particles: protons, electrons, photons, and neutrons, and are displayed in order. 
Starting at the cyclotron and progressing down the beamline through each 
component that has an impact on the spectrum of the beam, some components do 
not have a noticeable impact, these results will not be shown for clarity. 
 
The beam first exits the cyclotron as a near monoenergetic pencil beam with a 
radius of 1.5 mm. It then impinges on a graphite degrader which is placed in the 
beam to reduce the dose rate and broaden the beam. Figure 4.5 displays spectra for 
particles on the entrance side of the graphite degrader. It can be observed that the 
beam consists of primarily 50.5 MeV protons. A small number of low energy 
electrons, photons and neutrons are also shown to exist in the beam, these are a 
result from backscatter from the graphite beam degrader and are all travelling in 
the opposing direction to the beam. 
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As the beam passes through the 1.23 mm thick sheet of graphite it interacts via 
Coulomb interactions and loses energy. The result of these interactions on the 
beam energy spectrum is shown in Figure 4.6, showing the particles on the exit side 
of the graphite degrader. The beam now primarily consists of protons which have 
lost energy to the degrader. The mean energy of exiting protons has decreased by 
2.51 MeV, to 47.99 MeV. The standard deviation of energy of the protons in the 
beam increased to 1.22 MeV.  





The number of electrons present in the beam has increased by a factor of 17 
representing 2.4% of the total number of particles in the beam. The mean energy 
of these electrons is 67.75 KeV with a standard deviation of 116.83 KeV. A small 
number of photons and neutrons are produced as a result of the interactions of the 
beam with the graphite degrader. These particles are less than 0.1% of the total 
number of particles in the beam. 
Figure 4.6: Spectrum of particles on the exit surface of the graphite degrader after passing through 
the degrader 
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The beam exits the graphite degrader and enters the vacuum of the large beam 
pipe. The front surface of the beam pipe is adjacent to the rear surface of the 
graphite degrader, so the particle distributions are unchanged. The beam then 
travels down the large beam pipe a total distance of 4.158 metres. As it does so it 
broadens. Broadening of the beam enables the edge of the beam to interact with 
the wall of the beam pipe. The spectrum for particles exiting the large beam pipe is 
displayed in Figure 4.7.  
  




The majority of protons in the beam remain unchanged as they have travelled 
through vacuum, with a small number of them having impacted the side of the 
beam pipe, consequently losing energy, shown as a small peak at approximately 45 
MeV. An analysis of these scattered protons is shown in Figure 4.8. The number of 
electrons in the beam has been reduced as a result of the high angular divergence 
they have when exiting the graphite degrader causing them to collide with the large 
beam pipe walls which absorbs them. Low energy photons can be observed in the 
energy spectrum of the beam as it exits the large beam pipe, these photons are 
produced when the beam interacted with the large beam pipe and, make up 1.5% 
of the total number of particles in the beam. They have peaks at 0.02, 017, 0.55, 
0.71, 1.01, 1.98, 3.15 and 4.47 MeV. Both neutrons and electrons are a minor 
component of the beam representing less than 0.1% of the total number of particles 
in the beam. 
 
Figure 4.8: Spectrum of protons on exit surface of the large beam pipe, shown with a log scale 
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Protons that have interacted with the side of the large beam pipe can be observed 
as a small number of lower energy peaks, this is shown Figure 4.8 with a log scale 
to highlight the differences, but it should be noted that it will exaggerate the size of 
the small peaks. These lower energy peaks have a mean energy in decreasing 
amplitude of 44.8, 41.9, 39.2, 36.7, 34.0 and, 31.8 MeV. The largest secondary peak 
is 44.8 MeV and each further peak decreases by approximately a factor of two. Each 
peak is a result of a higher order scatter off the walls of the collimator. The first 
order scatter at 44.8 MeV has a high number of particles as particles that contribute 
to it. They originate from the original 47.99 MeV peak, whereas the second order 
scatter peak only originates from the first order particles and so on. Scattered 
protons represent 25% of the total number of protons that exit the large beampipe 
and thus are a significant proportion of the beam. Ten million protons enter the 
large beam pipe and only 6.83 million protons exit, resulting in a 31.7% drop in the 
total number of protons in the beam. 
 
The beam’s radius is then reduced from 45 to 16 mm when passing from the large 
beam pipe to the small beam pipe, with the use of a stray beam connector. How the 
reduction of the radius impacts on the beam spectra is shown in Figure 4.9. The 
figure illustrates, the spectra of particles on the front surface of the stray beam 
connector, demonstrating that the reduction of radius does not impact the proton 
energy spectrum apart from reducing the total number of protons by 85% (6.83 
million down to 1.07 million) in the beam. It can also be observed that secondary 
photons and neutrons are removed from the beam, most of these particles are on 
the edge of the beam and have a high angular divergence, this is further 




Passing through the vacuum filled stray beam connector, the radius increases from 
16 mm to 20.5 mm at the midpoint. This has no impact on the beam as the total 
length of the stray beam connector is 2.4 cm which is not long enough for the 
divergence of the beam to impact the sides of the beam connector. Results for the 
beam exiting the stray beam connector are not shown, as no major changes to the 
beam occurs. 
 
Figure 4.9: Spectrum of particles on the front surface of the stray beam connector 
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The beam then enters the small beam pipe which has a radius of 17.5 mm, the beam 
travels a total distance of 250 mm through the pipe. The beam broadens to a radius 
of 17 mm over the length of the pipe, which will be discussed in the next section. 
The increased radius is not sufficient enough for the beam to impact with the side 
of the beam pipe, resulting in no change to the proton spectrum, shown in Figure 
4.10. It can also be observed that the number of photons and neutrons in the beam 
has been drastically reduced resulting in the beam consisting primary of protons. 
The reduction is a result of two factors, the beam not producing any scattered 
particles and the scattered particles already present in the beam having a high 
angular deviation and being absorbed by the small beam pipe. 




The beam then exits the beam pipe and the internal vacuum into air through a 0.15 
mm thick Kapton window. Figure 4.11 displays the spectrum of the beam exiting 
the Kapton window. Low energy electrons are produced when passing through the 
exit window. These electrons have two peaks at 1.5 KeV and 67 KeV and represent 
3.6% of the total number of particles. The energy of the proton peak also has a slight 
reduction of 0.20 MeV which is observed for all proton’s peaks in the beam as a 
result of Coulomb interactions between the beam and the Kapton material. 
  
Figure 4.11: Spectrum of particles on the exit surface of the Kapton exit window 
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After the Kapton exit window, the beam travels through a 30 mm long air-filled 
beam pipe with a radius of 19.75 mm, increasing to 20.5 mm for the final 12 mm 
of length. The beam does not interact with the air beam pipe due to its larger radius. 
Upon exiting the air beam pipe, the beam travels another 4.85 mm in air before 
impacting on an ion chamber. Figure 4.12 displays this spectrum, highlighting the 
effect air has on the beam. The mean energy of the protons in the primary peak has 
been slightly reduced from 47.79 to 47.74 MeV. The number of electrons has 
increased to 6.7% of the particles in the beam and has a peak at 2.1 KeV. 




Some of these electrons were produced by the Kapton window but the majority of 
these have been produced due to backscatter from the ion chamber and are 
travelling in the opposite direction to the beam. Low energy neutrons are only 0.3% 
of the beam with a peak at 0.5 MeV, they are produced due to proton interactions 
with air. 
 
The beam then passes through the ion chamber which consists of three acrylic 
layers, three graphite layers in-between the acrylic layers, and an air-filled layer. 
The total thickness of these layers is 1.7, 0.08 and of 2 mm, respectively. Figure 
4.13 displays the spectrum of the particles in the beam exiting the ion chamber 
after they have passed through it. The primary proton peak has reduced in energy 
by 2.79 MeV. Secondary peaks that resulted from interactions between the large 
beam pipe and the beam are still present in the proton distribution with peaks at 
41.60, 38.50, 35.50 and 32.8 MeV. Electrons are now 3.9% of the total number of 
particles in the beam and with a peak at 2 and 60 KeV. The number of neutrons 
increases to 0.4% of the particles in the beam as a result of interactions with the 
ion chamber. 
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The beam then travels 100 mm through air before being collimated by the 
minibeam collimator. Figure 4.14 displays the spectrum of particles exiting the 
minibeam collimator, displaying the impact the collimator has on the beam. The 
energy of the primary peak decreases to 44.85 MeV. The majority of the protons 
pass through the collimator without interacting with the stainless steel, thus only 
loose energy to the air they pass through.  
  




The secondary proton peaks are observed to be increased as a result from both 
impacts of protons with the collimator and the secondary peaks from the large 
beam pipe with a sizeable peak at 41.8 MeV and a smaller peak at 39.0 MeV. The 
spectrum is the final output of the beam before hitting a target, in this case a water 
phantom. 
  
Figure 4.14:Spectrum of particles on the exit surface of the minibeam collimator 
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The final beam largest energy peak primarily consists of protons with a peak energy 
of 44.85 MeV. This peak energy has a standard deviation of 0.21 MeV and consists 
of 62% of all protons in the beam. The number of neutrons in the beam has 
increased to 3% of particles in the beam and peaks at 0.6 MeV as a result of 
interactions with the collimator. A more detailed analysis of the impact of these 
neutrons is covered in chapters five and six. A peak of photons is visible at 0.5 MeV, 
the total number of photons is 9.9% of the total number of particles. 
 
4.3.3. Beam Positional and Angular Distribution 
This section displays the positional distribution and angular distribution results 
from the scatter modelling of the particles in the beam. A diagram of the geometry 
and orientations of this setup is shown in Figure 4.15. Angular deviation is shown 
in width (X) and height (Y) direction cosines.  
Beam direction 
X direction angle 
Y direction angle 
Component (large beampipe) 
Proton beam area 
Exit scorer 
Figure 4.15: Diagram of phase space scorer for the large beampipe and the various components and 
directions that are investigated. 
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A direction cosine is the cosine of the angle between particle direction vector and 
the Z direction, a X cosine of one represents the particle travelling in the positive X 
direction 90 degrees to Z direction. In a parallel beam this should be zero, i.e. a 
beam with no angular divergence. The modelled beam has some initial divergence 
modelled to match the beam outputted from the cyclotron. The positional 
information displays particle density in a cross-section of the beam, demonstrating 
the distribution of particles in the beam. 
A pure uniform beam with no divergence would appear in the results as a fixed 
radius circle throughout the length of the beampipes. Both the positional and 
angular results display particle density. Shown as a colour map with a logarithmic 
scale. Regions that have low particle density indicated in blue and regions that have 
high particle density shown in red. A flat beam with no penumbra beam would be 
shown as a sharp uniform red circle with the remainder of the cross-section in blue. 
 
Figure 4.16 displays the position (left) and angular deviation (right) of particles in 
the beam prior to entering the graphite degrader. The beam is highly parallel with 
a diameter of 3 mm. Shown as a small red spot on the position figure and small 
Gaussian spot on the cosine figure with a standard deviation of 0.0087. This is a 
very pure beam with extraordinarily small divergence and serves as a reference for 
further results. As the beam interacts with materials along the beamline it will 
degrade from this. 
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The beam then passes through the graphite degrader, which is designed to decrease 
the dose rate and broaden the beam. Figure 4.17 displays the results for the 
entrance to the large beam pipe this can be compared to the previous figure to 
demonstrate the impact the graphite degrade has on the beam. The position results 
show the 3 mm wide beam has not immediately broadened with interactions with 
the graphite degrader. It can also be observed that the entrance beam is 
significantly smaller than the total radius of the large beam pipe. The cosines have 
both increased from 0.0087 to 0.0280 an increase of more than 300%. This 
increase in the angular deviation of the particles will cause the beam to broaden 





Figure 4.16: Position and direction cosine distributions for particles on the front surface of the 





The beam then travels down the large beam pipe. Figure 4.18 shows the results 
from the beam on the exit surface of the beam pipe. The positional figure shows 
that the beam has expanded to the entire radius of the beam pipe as it has travelled 
down the beam pipe. The density of the positional figure displays the beam is 
uniform over the whole width of the beam. The beam has a mostly uniform 
distribution at this point as shown by the uniform colour. The angular distribution 
is remarkably like the distribution from the entrance surface to the large beam 
pipe, however particles with the most extreme angular deviations have been 
removed. Figure 4.18 (right) illustrates that the outer edge of the position cosine 
has a sharp change, showing no light blue. This is caused by particles impacting the 
walls of the large beam pipe. In turn, this is responsible for a slight collimation of 
the beam as it travels down the beam pipe and results in a standard deviation in 
the angular distribution of 0.209 which is slightly less than the previous result of 
0.280. 
 
Figure 4.17: Position and direction cosine distributions for particles on exit surface of the graphite 
degrader after passing through it. Colour scale represents number of particles. 
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The beam then passes into the stray beam connector, made of graphite which 
reduces the radius of the beam, shown in Figure 4.19. The primary impact of the 
beam connector is to reduce the beam from a radius of 45 mm to a radius of 15 
mm. The angular deviation is also reduced from 0.0208 to 0.0158. The large 
reduction in particles, discussed earlier, can also be observed at this point as there 
are only 10% of particles from the initial beam reaming. 
Figure 4.19: Position and direction cosine distributions for particles on exit surface of the large 
beam pipe after passing through it. Colour scale represents number of particles. 
 
Figure 4.18: Position and direction cosine distributions for particles on exit surface of the stray 






As the beam travels through the stray beam connector, the small beam pipe then 
exits through a Kapton window. The beam has very little interactions with the stray 
beam connector and small beam pipe, so only the results for the beam exiting the 
Kapton window are shown in Figure 4.20. The beam’s positional information 
shows that the radius of the beam increases from 15 mm to 17 mm as it travels the 
length of the stray beam connector and small beam pipe. The angular divergence 
appears larger as it has a full Gaussian shape after exiting the Kapton window, 
however its standard deviation has decreased to 0.0151. 
 
The beam exits the Kapton window, leaving the vacuum of the beampipe and 
travelling through air before passing through the ion chamber. Passing through the 
ion chamber has the primary effect of increasing the angular divergence of the 
beam from 0.0151 to 0.0327 as shown in Figure 4.21. 
Figure 4.20: Position and direction cosine distributions for particles on exit surface of the Kapton 
window after passing through it. Colour scale represents number of particles. 
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This is a result of passing through the many layers inside the ion chamber thereby 
losing energy via Coulomb interactions as it interacts with the material. The 
positional information for the beam shows that the radius of the beam remains 
unchanged and uniform over its radius of 17 mm. Note that although the density 
of particles appears higher, this is an artefact of it covering a smaller area in the 
figure, it does in fact have the same density of particles. 
 
  
Figure 4.21: Position and direction cosine distributions for particles on exit surface of the ion 




The beam then travels a short distance through air before passing through the 
minibeam collimator. Figure 4.22 displays the positional distribution of the beam 
as it exits the collimator. The beam is reshaped into 31 vertical slits over a 30 x 30 
mm area. As the beam is circular the corners of the beam remain curved. The 
angular distribution is also displayed showing the beam has been collimated in the 
vertical direction, making the cosine result not symmetrical. The standard 
deviation of the cosine in the x direction has decreased to 0.0301, whilst the 
standard deviation on the y direction has increased to 0.0391. The collimator has 
a “polarisation” effect on the beam. From this point the beam then impacts the dose 
target, usually a water phantom to deliver a minibeam dose. 
  
Figure 4.22: Position and direction cosine distributions for particles on exit surface of the 
minibeam collimator after passing through it. Colour scale represents number of particles. 
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4.3.4. Beamline Components Dose Contribution 
This section displays results from modelling how each component impacts the final 
dose distribution. Results are displayed as a PDD of the central axis of the beam. 
These results were processed in MATLAB plotting a column of dose along the 
central axis. A 20 by 20 voxel area around the central axis was averaged to obtain 
a mean dose at each 0.1 mm depth to produce the PDD. Each PDD is scaled relative 
to their maximum dose, which occurs at the Bragg peak. All depth results have an 
origin on the surface of the water in the water phantom, unlike standard 
measurements where the origin is the exterior surface of the Lexan on the outside 
of the water phantom. In order to determine the impact of the Lexan exterior of the 
water phantom. Figure 4.23 displays the PDD results for the various components 
in the model. 
Figure 4.23:PDDs of beam exiting each component in the beamline 
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In the following section, results are described following the path of the beam, 
adding one component at a time, starting with the beam from the cyclotron without 
any additional components. This way the effects of each component has on the PDD 
can be investigated. Starting with the PDD on the right of the figure and moving 
left. The initial Bragg peak from the cyclotron exhibits a pristine peak at a depth of 
22.5 mm with a low surface dose of 0.156 Gy. This is expected, as the beam is a 
monoenergetic 50.5 MeV proton beam. 
 
The next PDD includes the graphite degrader, reducing the depth of the Bragg peak 
depth to 20.5 mm and increases the surface dose to 0.162 Gy a 3.8% increase. This 
is due to the fact that all protons in the beam lose energy to the graphite degrader 
and produce scatter in these collisions, as discussed previously. The third PDD 
shows that adding the large beam pipe has no impact on the depth of the Bragg 
peak. Interestingly it does have a large impact on the surface dose and the shape of 
the curve leading up to the Bragg peak. The surface dose is increased by 3.6%, 
demonstrating that scatter from the large beam pipe can travel through all 
components and impact the final dose distribution. The secondary proton peaks, 
that were observed in the previous section, can be seen here as the small peaks 
before the Bragg peak. The fourth PDD shows that adding the stray beam connector 
does not impact the depth of the Bragg peak, however it does decrease the surface 
dose by 1.5%, due to it blocking scattered radiation generated from the large beam 
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Air (113.78 mm) between the small beam pipe and the water phantom is then 
added. The air only has a minor impact on the depth of the Bragg peak, decreasing 
it by 0.1 mm to 20.4 mm. Adding the exit window decreases the Bragg peak depth 
by a small amount of 0.3 mm to a depth of 20.1 mm. The surface dose was increased 
by 0.7% due to increased scatter as discussed previously. The Kapton window was 
designed to be very thin so it will only have a minor impact on the beam. Adding 
the air beam pipe has no impact on the PDD or dose distribution, as the beam does 
not interact with this component, or pass through it, so the PDD is identical to the 
previous one corresponding to the stray beam connector. 
 
The ion chamber decreases the depth of the Bragg peak from a depth of 20.1 mm 
to 18.1 mm. The large decrease in depth is primarily due to Coulomb interactions 
between the protons in the beam and the various materials in the ion chamber, 
resulting in decreasing the energy of the particles. The ion chamber increases 
surface dose slightly from 19% to 20% of the maximum dose. 
 
Adding the minibeam collimator does not shift the Bragg peak depth, as a portion 
of the beam is able to pass through the collimator without interacting with it. A 
portion of the beam will interact with the collimator and these protons are 
responsible for an increase in the surface dose from 20% to 34% of the maximum 
dose. Secondary peaks can also be observed before the Bragg peak because of 
interactions between protons and the minibeam collimator. The large increase in 
the surface dose demonstrates that most secondary dose at the surface is caused by 
beam interactions with the collimator. Results in the previous section showed these 




The final PDD is shown in red, containing all components of the beamline with a 
Bragg peak at 17 mm depth. The Bragg peak in this PDD has decreased in depth by 
1.1 mm and the secondary peaks have also been shifted by the same amount due 
to interactions with the Lexan material of the water phantom. This indicates that 
the correction factor of 1 cm of Lexan is 1.158 cm water equivalent depth that used 
in previous section agrees with the TOPAS model. The PDD has the same surface 
dose as the previous PDD without Lexan. The secondary peaks from the collimator 
and large beam pipes can be observed at depths of 14.8 mm and 12.9 mm. 
 
Overall, the Bragg peaks depth is decreased by 2 mm by both the graphite degrader 
and the ion chamber, 1.1 mm by the Lexan material and 0.3 mm by the Kapton exit 
window. The large beam pipe adds scattered lower energy protons which increase 
the surface dose by 3.6% and, add secondary peaks. A portion of these scattered 
protons are collimated by the stray beam connector. The collimator itself also adds 
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4.4. Discussion 
The discussion summarises the impact of all beamline components simulated in 
the TOPAS model. The more important beamline components are first discussed 
and how they impact the final dose distribution before moving on to discuss the 
validation and modification of the TOPAS model. 
 
4.4.1. Impact of Components in the Beam 
A novel strategy has been presented to thoroughly investigate the impact of beam 
components in the proton beamline in terms of dose and angular spread. By doing 
so, a comprehensive understanding of the relative contribution each component 
has on delivered dose has been gained. 
 
This section of the discussion steps through each major component in the beamline 
starting with the graphite degrader. The graphite degrader is shown to lower the 
mean output energy of the protons in the beam to 47.99 MeV and increases their 
spread (standard deviation) to 1.21 MeV. The divergence of the beam is greatly 
impacted, with the standard deviation of the angular cosines increasing to a 
maximum of 0.0280 from 0.0087. Secondary electrons are produced from 
interactions with the degrader, however, they do not impact the final dose 
distribution as they have large angular divergence, and, as such are absorbed by 
other components in the beamline. The purpose of the graphite degrader is to 
broaden the beam without degrading significantly. While it does broaden the beam 
by increasing the angular divergence it possibly increases the divergence by too 
much, this results in 90% of the beam’s particles being lost by the end of the 
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beamline. A reduction in the thickness of the degrader could potentially fix this 
problem and would have the added benefit of having less impact on the energy of 
the protons and the spread of energy. The simulation helps to explain what is 
happening with this component and its impact on the final dose distribution1. 
 
The large beam pipe is a critical component in the beamline as it impacts the final 
dose distribution. The increased divergence from the graphite degrader results in 
the proton beam impacting the beam pipe part way down the pipe, causing a 
decrease in energy of protons and production of low energy electrons. Only part of 
the beam impacts with the sides of the beam pipe producing multiple energy peaks 
in the proton energy distribution; a primary peak of protons that have not 
interacted with the beam pipe and multiple smaller secondary peaks at a lower 
energy. These secondary protons increase the surface dose of the beam and 
introduce additional shallower Bragg peaks. The additional Bragg peaks were not 
observed in measured results, leading to some disagreement between the model 
and the physical beamline. It is postulated that the cause of this disagreement is 
due to our model producing too much scatter in the large beam pipe, for which 
there are two possible causes. First there could be inaccuracies in the historic 
drawing of the beamline resulting in an issue with the material or dimensions of 
the large beampipe that causes increased scatter. Or second there could be an issue 




1 A thinner degrader was physically installed in July 2020 
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An analysis of this disagreement led to modifications of the Monte Carlo model, in 
particular the radius of the large beam was increased from 30 mm to 45 mm, which 
decreased the number of lower energy protons produced as the beam travels 
further before impacting the large beam pipe. 
 
The next components of the beam; the stray beam connector, the small beam pipe 
and Kapton window do not have a large impact on the beam or the final dose 
distribution, only a slight decrease in the energy of the proton beam when passing 
through the Kapton window and a decrease of the radius of the beam from the stray 
beam connector. 
 
The ion chamber in the beamline is used to measure the number of monitor units 
delivered to the target, and thus gives a running approximation of the dose 
delivered to the target. In passing through the ion chamber there is an observed 
decrease in mean energy of proton in the beam of 2.79 MeV bringing the beam 
energy down to 44.95 MeV. This decrease in energy causes the depth of the Bragg 
peak to decrease from 20.2 mm to 18.1 mm. The divergence is also increased as a 
result of interactions between the beam and the ion chamber, increasing its 
directional cosines from 0.0151 to 0.0327. Although the ion chamber has a 
significant influence on the beam characteristics, it is essential component as it 
ensures the prescribed dose is delivered and thus must remain part of the 
beamline. 
 
The collimator modifies the beam from being uniform in the x and y direction into 
30 0.3 mm wide minibeams in the x direction, with a CTC spacing of 1 mm in the 
x direction. This results in the collimator blocking approximately 70% of the 
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incoming beam. Of the portion of the beam that passes through the collimator, 
some of it will interact with the sides of the collimator as a result of the beam’s 
angular divergence and the beam broadening with depth. When protons interact 
with the collimator, they lose energy through Coulomb interactions, resulting in a 
small number of lower energy protons. These low energy protons cause an increase 
in surface dose, increasing it from 20% to 34% of the maximum dose. The low 
resolution in the x direction, which is same direction as the spatial modulation, 
results in the spatial differences between the peaks and valleys being averaged 
together. Meaning that the minibeam peak dose has a very high surface dose, the 
implication of which are discussed in Chapter five. 
 
4.4.2. Validation and Modification of TOPAS Model 
The Bragg peak was measured with the diamond detector and ion chamber to be 
17.8 ± 0.5 mm in section 4.3.1. The depth agrees with the value from our TOPAS 
model of the beamline of 18.1 ± 0.1 mm within the experimental uncertainties. In 
order for the modelled PDD curves to closely match the measured data, the model 
was modified, and the large beam pipe’s internal radius was increased from 30 mm 
to 45 mm. The change removed some scatter that the beam pipe was causing, which 
occurs when the beam broadens as it travels through the large beam pipe. After a 
certain distance, the beam will interact with the outside of the beam pipe and 
produce secondary scatter. This can be removed either by expanding the width of 
the beam pipe, shortening the length of the beam pipe, or reducing the divergence 
of the incoming beam. Each method has disadvantages and requires that we 
diverge from the current best estimates of the beamline dimensions. Expanding the 
width of the beam pipe is straight-forward to implement. Changing the length of 
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the large beam pipe was also investigated, however it was deemed to be less 
realistic. The divergence of the incoming proton beam before it impacts the 
graphite degrader was modified in some tests. This did not have a large impact on 
the dose distribution, or the secondary scatter produced from the large beam pipe. 
Since the graphite degrader is primarily responsible for the divergence in the beam 
as it enters the large beam pipe. Thickness of the graphite degrader could be 
modified to correct the spread in the large beam pipe; however, this would modify 
the output energy of the beam. The depth of the Bragg peak has been shown 
experimentally to match the TOPAS model, there was a small offset between the 
model and physical measurement that was within uncertainty a very small change 
to the degrader could resolve. However, initial work on did not demonstrate that it 
was the only factor and is an area for future work. The best option was to increase 
the diameter of the beam pipe, as this best matched the output of the model to the 
physical measurements, resulting in only a difference between the model and the 
beam pipe drawings. It is unclear if this is because some change to the beamline 
had not been documented, or an error in TOPAS is responsible for this discrepancy. 
An error in TOPAS is not considered a likely cause as it has been verified by a wide 
range of groups for use in proton therapy [73, 75, 76, 79, 80]. Disassembling the 
entire beamline would be costly and time consuming, this is not feasible. Leaving 
the only practical course to change the model to match the measured results. We 
accept this solution is not ideal but, due to practicalities, we are unable to confirm 
whether our changes fully reflect the physical beamline. However, our simulation 
now matches measurements well and assumption moving forward is that our 







Through the application of Monte Carlo methods, a simulation in TOPAS was 
developed to closely match the University of Washington preclinical proton 
research beam platform. The model was based on dimensions provided by the 
University of Washington and, whilst most information was available, no accurate 
information was available for some sections of the beamline. The model developed 
matched the measured PDD well with some minor deviations. A novel beamline 
component analysis was carried out to gain an understanding and provide insight 
into what caused some initial mismatch between model and the physical beamline. 
Possible solutions were discussed, and it was decided to change the diameter of the 
large beampipe in the model. The depth of the Bragg peak in the Monte Carlo model 
agrees within experimental uncertainty of the depth measurements. The model 
depth was measured to be 18.1 mm, corresponding to a proton beam with an 
output energy of 44.95 MeV. This depth also agrees with the reference values for 
the depth of a 44.95 MeV beam [82]. 
 
The graphite degrader at the start of the beamline has been shown to lower the 
energy of the beam and drastically increases the divergence. The large beam pipe 
and the collimator have a large impact on increasing the surface dose. The ion 
chamber and graphite degrader decrease the energy of the beam with the final 
output energy being 44.95 MeV, this is a decrease from an initial energy of 50.5 
MeV. The other components of the beam have minimal impact on the output beam. 
Further work should be carried out to identify the cause of the difference between 
the model and the beamline. Measurements could be taken with the ion chamber 
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removed to further verify the accuracy of the model. This would be difficult as 
delivering the correct dose without being able to measure the number of monitor 







Chapter 5           
Collimator Design 
This chapter performs an investigation into design considerations when 
constructing minibeam collimators. The aims are to reduce the production of 
secondary particles from interactions with the collimator and the proton beam, as 
observed in Chapter 4, and to maximise the PVDR. To achieve these aims, three 
collimator variables were investigated: the total thickness of the collimator, the 
width of the slots used to produce minibeams, and the material of the collimator. 
The chapter starts with a brief introduction into the areas of collimator design 
investigated followed by a method section describing the design of each simulation 
performed and then a results section with important results from each method 
shown. The overall outcomes and findings are discussed in the discussion section 
and an overall summary is provided in the conclusion. 
 
5.1. Introduction 
As discussed previously in Chapter 2, a minibeam dose distribution is produced 
from a uniform beam by blocking sections of it with a collimator. A collimator is 
usually a block of metal with sections removed allowing the beam to travel through. 
Either a slot configuration where the dose distribution is only modulated in one 
direction or a grid of holes configuration can be used which provides modulation 
in two directions, theoretically offering advantages. However, this has yet to be 
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shown with biological testing. As slot collimators are easier to manufacture and 
consequently less costly than hole collimators, this section of work will focus on 
slot collimators. However, the results should also be applicable to hole collimator 
designs. One of the advantages of proton minibeams is the ability to produce a 
uniform dose for treatment at depth whilst maintaining a spatially modulated dose 
near the surface, potentially sparing normal tissues. Therefore, it is important to 
design a collimator which maximises this advantage. 
 
A diagram of a collimator with the various terminology used in this section is 
shown in Figure 5.1 and the coordinate system is shown in Figure 5.2. Figure 5.1 
shows that the septa thickness, CTC spacing, and the slot width are all 
interconnected in the x direction. The CTC spacing is dependent on the lateral 
spread of proton at the Bragg peak, which is a function of the initial energy of the 
proton beam, and thus for a particular beam energy a certain spacing is required 
to produce a level of uniformity at the Bragg peak. 
CTC spacing (x) 
Slot width (x) 
Slot height (y) 
Figure 5.1: Beams eye view of collimator slots and variables used in TOPAS simulations. 
Septa thickness (x) 
Collimator thickness (z) 
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For the 50.5 MeV proton beam a 1 mm CTC spacing was used to produce a uniform 
dose distribution at the Bragg peak, which follows on from the discussion in 
Chapter 3. For higher energies, a larger CTC spacing can be used to produce a 
uniform Bragg peak. The CTC spacing also has a large impact on the spatial 
modulation close to the surface. Increasing the CTC spacing increases the distance 
between the minibeams and reduces the dose delivered to the valley, which comes 
at a cost of decreased uniformity at the Bragg peak. Reducing the uniformity of the 
dose delivered to the target to increase the PVDR could see an increase in sparing 
health tissue at the cost of local tumour control. This is not an area of research this 
section of work undertakes, as producing a uniform dose at the Bragg peak is a key 
design aspect for this thesis. This could be a potential area of research in the future. 
Leading to fixing the CTC at 1 mm distance, which results in the septa thickness 







Figure 5.2: Diagram of simulation setup and directions. Showing the proton beam in green, the 
minibeam collimator with vertical slits (fewer are shown for clarity) in grey and the water 
phantom in blue 
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The width of the minibeam exiting the collimator is determined by the width of the 
slots of the collimator. The width of this minibeam directly impacts the mini/micro 
beam sparing effect. This sparing effect has been observed for beams with widths 
between 0.02 - 0.67 mm [13, 50, 57]. Most of this research has historically been 
performed on photon beams and there is currently little research into this area for 
proton beams. Previous research by Eunsin Lee et al demonstrated that narrower 
slots and a thicker collimator does increase the PVDR at 5 mm and 10 mm depths 
[23]. This thesis aims to extend on this work and provide a more thorough 
investigation into this area, leading towards a better understanding of the 
collimator thickness and slot width for our 50.5 MeV beam. 
 
For a particular material, a proton will on average travel through a material a fixed 
range before stopping. This range is primarily determined by the proton’s initial 
energy and the attenuation properties of the material. It is important that a 
collimator is thick enough to block incoming protons that are travelling within the 
septa. A concern for minibeam collimators is the fact that they consist of many thin 
slots in the block of material. If the angle of incidence is sufficiently large, a proton 
with a large angular deviation has the potential to pass though the septa from one 
slot to another. This would result in scattered particles exiting the collimator and 
reducing the quality of the minibeams. Increasing the thickness of the collimator 
can reduce this effect but will also reduce the dose rate. Dose rate is reduced when 
the thickness of the collimator is increased removing particles with high angular 




The material of the collimator dictates the interactions between the beam and the 
collimator, and the subsequent secondary particles produced by the collimator. An 
ideal material would have a short path length of protons travelling through it, thus 
high attenuation, so protons are easily blocked. The ideal material would absorb all 
energy locally so that unwanted energy is not delivered as extra dose to valley 
regions, negatively impacting normal tissue. Although it may seem sensible that 
both the above criteria could be best met using a dense material, the type and 
energy of secondary particles produced is quite important as this can have a major 
impact on the final dose delivered. Previous research by Gustafsson on neutron 
production from collimators in proton therapy showed heavier materials produce 
more neutrons [21]. To reduce neutron production, lighter materials are preferred. 
However, as already mentioned, in order to produce clinically viable minibeams 
thicker collimators would be needed [21]. Gustafsson demonstrated that tungsten 
collimators produced a significantly higher neutron dose when compared to other 
materials e.g. Brass, Iron and Nickel, shown in Figure 5.3. Gustafsson’s research 
guided the use of stainless steel as the collimator material in previous sections. This 
work expands on aspects of Gustafsson’s research and investigates details on all 
secondary particles produced from the collimator, with a focus on how these 
materials impact proton mini/microbeams.  
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Figure 5.3: Normalised weighted neutron flux versus collimator thickness. Each element is 




This section is divided into different simulations, each of which investigates a 
specific component of collimator design. TOPAS version 3.1.3 was used for this 
section of work and default physics lists were used as these are optimised for proton 
therapy. Each simulation uses a uniform flat 50.5 MeV monoenergetic beam in a 
vacuum world. In this section a monoenergetic beam was used in preference to the 
entire beamline to allow a more direct interpretation of how the individual 
collimator parameters impact the output minibeam. This also decreases “noise” 
and uncertainties from other components in the beamline and reduces simulation 
processing time. A stainless steel collimator and water phantom were placed 
adjacent to each other in the centre of the world, with the collimator placed 
between the beam source and a 25 mm cube water phantom. The width (x) and 
height (y) of the collimator were fixed at 60 mm to ensure only those particles 
which are able to get through the collimator were measured in the phantom, i.e. no 
contamination of measurement from particles transiting around the edge of the 
collimator. The collimator has a CTC spacing of 1 mm for reasons discussed in the 
introduction. Dose is measured in the water phantom with (x, y, z) voxel dimension 
of 0.075 x 5 x 0.075 mm, respectively, as this size has been previously determined 
to be most efficient for these simulations. Note, the coarse resolution in y- 
dimension is acceptable and actually advantageous as the collimator has the slots 
running vertically, thus producing a uniform beam in the vertical direction. This 
results in the water phantom being divided into 333 x 5 x 333 voxels. A phase space 
scorer was placed at the boundary between the collimator and the water phantom 
to record energy, position, direction, and particle type for all particles that pass 
through it. This scorer was not perceived by TOPAS as a component of the 
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simulation geometry and will not affect the particles passing through or the final 
dose deposited. The phase space scorer and dose data were then categorised as 
having either interacted with or NOT interacting with the collimator. This is to 
enable examination of the impact the collimator has on the scattered particles 
produced. In order to reduce processing time and decrease disk space usage, the 
phase space scorer only collected the first one million histories, as we are primarily 
interested in the number, type, and energy of particles, not the position 
distribution of these particles. This resulted in less than 2% uncertainties for the 
data displayed in the results section. 
 
5.2.1. Impact of Collimator Thickness 
Initial setup was performed as described in section 5.2 but with the following 
additions and modifications. The proton beam was defined to have a field size of 
25 x 25 mm (x, y). The collimator had 21 vacuum filled 0.3 x 20 mm (x, y) slots 
spaced 1 mm apart, the length (z) of these slots was equal to the collimator 
thickness (z). The length (z) of the collimator thickness was varied with values of 5 
mm, 10 mm, 15 mm, 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 50 mm, and 60 mm. 
These values were chosen based on the proton range in stainless steel. Proton range 
in stainless steel is 4.24 mm, thus the lengths of 5 mm multiples were chosen to 
ensure protons should be blocked from a range of incident angles. The minibeam 
field then impinges on a water phantom. Dose and phase space data are collected 




5.2.2. Impact of Collimator Slot Width 
The simulation was modelled with the method described in 5.2, with the following 
additions and modifications. The collimators thickness was set at 25 mm for this 
experiment. The collimator had again 21 vacuum filled slots with a fixed height of 
20 mm. The width of each slot was varied between 0.1 – 0.7 mm with the septa 
width varied between 0.9 – 0.3 mm respectively, to maintain the 1 mm CTC 
spacing. This range of minibeam widths was chosen to represent a range of 
minibeam options. The minibeam sparing effect has been observed and reported 
for beams up to 0.68 mm. This gives an approximate upper limit on the width of 
the slots which we rounded to 0.7 mm [57]. Moving below 0.1 mm slot widths 
could potentially show improvements, this would however lead to technical 
difficulties building collimators with very thin slots and the differences between 
minibeams and microbeams is beyond the scope of this thesis. Dose and phase 
space data is collected for each collimator slot width with 108 histories. 
 
5.2.3. Impact of Collimator Material 
This simulation aims to determine the impact collimator material has on the 
resultant proton minibeam and subsequent dose distribution. For this a 12.5 x 12.5 
mm flat beam was generated in a vacuum. The size of the beam was reduced to 
decrease processing time. The number of slots in the collimator was reduced to 
eleven 0.3 mm slots spaced 1 mm CTC. The length of the slots was also reduced to 
10 mm reducing the minibeam field area from 20 x 20 mm to 10 x 10 mm. The 
water phantoms height and width were adjusted to 12.5 x 12.5 x 25 mm to match 
the beam size. The voxel size was kept consistent with previous sections in width 
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and depth directions resulting in 167 x 5 x 333 voxels. The collimator thickness 
was set to 100 mm to ensure that most materials regardless of density should be 
able to fully block a 50.5 MeV proton. The collimator material was varied with 
different elements from atomic number Z = 4 - 94, excluding gases. These elements 
were chosen to give a comprehensive investigation of elements that a collimator 
could potentially be built from. Dose and phase space data was collected for each 
collimator slot width with 107 histories. The number of histories was an order of 
magnitude less than previous simulations in this chapter in order to reduce 
processing time. However, this should not impact final results as the size of the 
beam and number of voxels were also reduced, resulting in a similar number of 






The term “peak” as used in this section refers to the highest dose across central axis 
(as opposed to the Bragg peak along central axis) of each minibeam and the “valley” 
is the midpoint between two parallel minibeams. When referring to the Bragg peak 
this will always be called the ‘Bragg peak’. The minibeam peak profiles were 
collected in MATLAB for all 21 minibeams beamlets. Then 19 of these were 
averaged together to produce an average minibeam depth dose curve. The two 
minibeams on the outer edge are not included as these have reduced dose at the 
Bragg peak due to reduced in-scatter. The 20 valleys between the minibeams are 
also averaged together to produce an average valley depth dose curve. The ratio 
between these two averaged dose curves is the peak to valley dose ratio, hereafter 
simply referred to as the PVDR. The phase space files were processed in MATLAB 
only including particles travelling into the water phantom, as particles that are 
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5.3.1. Collimator Thickness 
The PDDs for different collimator thicknesses are shown in Figure 5.4 and 
normalised to the Bragg peak in Figure 5.5. The entrance peak dose for the 10 – 50 
mm thick collimators was large relative large, about 70% of the Bragg peak, 
compared to that for a monoenergetic proton beam which as shown in Chapter 4 
had an entrance dose of 16% of the Bragg peak. This is a consequence of protons 
that interact with the septa lose energy through Coulomb interactions, resulting in 
the beam being contaminated with lower energy protons. Per the Bethe equation, 
they will have subsequent shorter path lengths in water. The height of the Bragg 
peak is also decreased by a lack of in-scatter equilibrium in the beam at depth, 
resulting in a relative decrease in dose at the Bragg peak compared to surface dose 
[83]. This Bragg peak dose equilibrium effect is further investigated in the results 
section on collimator slot width. A small marginal peak is also observed at a depth 
of approximately 20 mm, resulting from scattered lower energy protons from the 
collimator. 




The 5 mm and 10 mm collimator thickness results both have a high surface dose in 
the minibeam peaks and a higher valley dose between the surface and 15 mm 
depth. The PVDR for both the 5 mm and the 10 mm long collimators is notably 
lower than that of the rest of the collimators. This is due to the thickness of the 
collimator being less than 15 mm and therefore not sufficient to block all protons 
from the uniform beam. While it would be expected that a length of 4.24 mm would 
block a proton travelling in stainless steel, this only applies to protons with no 
angular divergence. Protons with sufficient angular divergence can pass 
horizontally between the minibeam slots, through the stainless steel and the gaps 
forming the minibeam slots. These protons would have an effective path length 
through the stainless steel which is less than 4.24 mm whilst travelling through the 
5 – 10 mm collimators. Resulting in a minimum length for the collimator of 15 mm 
or slightly more than three times the path length of the material. 
 
Figure 5.5: Average peak dose PDD, average valley dose PDD and averaged PVDR  for various 
collimator lengths. Peak and valley PDDs are normalised to the Bragg peak. 
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The results in Figure 5.4 show that increasing the collimator thickness decreases 
the dose at all depths therefore lowering dose rate. As the beam has some 
divergence some protons will impact the side of the slots when passing through. As 
the collimator’s thickness increases, more particles are likely to be removed by this 
effect, the benefit being the angular divergence of protons with the produced 
minibeams is decreased when using longer collimators. The PVDR results show 
that there is not clear benefit to increasing the collimator thickness as there is no 
observable increase in the PVDR going beyond 20 mm. The reason for this result 
is shown in the next set of results, the phase space results: Figure 5.6 and Figure 
5.7. 
Figure 5.6: Number of protons entering the water phantom as a result of collimator thickness. 
Showing protons scattered off the collimator and protons that passes straight through. 
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Between 98 – 89% of the particles measured in the phase space scorer were protons 
for the 10 – 60 mm collimators, respectively as shown in Figures 5.6 and 5.7. 
Figure 5.6 compares numbers of protons exiting the collimator having passed 
directly though (crosses) or having interacted with the collimator septa (dots). As 
the thickness of the collimator increases the number of protons passing directly 
through the collimator decreases linearly. This matches the previous observations 
showing a decreasing dose with collimator thickness. 
Figure 5.7: Number of particles entering the water phantom as a result of collimator thickness. Showing 
particles scattered off the collimator. 
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There are a large number of scattered protons for collimators thinner than 15 mm 
are due to these collimator’s thickness being insufficient to block protons with 
angular divergence. For collimators with thicknesses beyond 15 mm, increasing 
the thickness has little impact on the number of scattered protons. This difference 
between scattered and non-scattered protons helps to explain the differences in the 
PVDR’s previous dose results. With a range of between 15 - 20 mm for the 
collimator thickness producing a maximum in the PVDR with limited benefits 
beyond 25 mm thickness. 
 
Figure 5.7 shows the results from all particles entering the water phantom that 
have interacted with the collimator septa. Note, this figure uses a log scale on the 
y-axis to display the data more clearly. Of the particles that have interacted with 
the collimator septa most are scattered protons. When the protons interact with 
the septa a small number of photons, neutrons, and electrons are produced. Other 
particles are not shown due to insignificant numbers present in the results. The 
number of photons, electrons and neutrons reaching the water phantom is reduced 
with increased collimator thickness. This decrease follows the trend of the total 
number of protons passing through the collimator and decreases with collimator 
thickness. However, these non-proton scattered particles have limited impact on 
the dose distribution as there are far fewer of them. It should also be noted that 
neutrons are not fully blocked by the small water phantom and are able to pass 
through without interactions. Neutrons have a high biological impact and have a 
high penetrating power though many materials, making them a radio-safety hazard 




5.3.2. Collimator Slot Width 
The collimator minibeam slot width results are shown in Figure 5.8 and Figure 5.9 
unscaled and normalised to the Bragg peak, respectively. The peak results indicate 
that as the width of the minibeams decrease the relative ratio between the surface 
dose and the Bragg peak increases. In particular, the dose at the Bragg peak 
increases as shown in the Figure 5.8. The surface dose also displays a cut-off effect 
with all minibeams from 0.3 - 0.7 mm receiving the same surface dose but the 0.2 
mm and 0.1 mm to a larger degree showing a large decrease in dose. The effect 
occurs at both the Bragg peak and the surface and is a result of the lack of in-scatter 
in the beam discussed in the previous section. While this effect has a large impact 
at the Bragg peak for all beams it also has an impact for the 0.1 mm and 0.2 mm 
wide minibeams. 
 
Figure 5.8: Peak dose, valley dose and PVDR  for various collimator slot widths. 
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Interestingly, a small peak at 19.5 mm depth can be observed in Figure 5.10 in both 
the peak and valley results. This peak is again a result of protons scattering off the 
collimator and depositing their energy at shallower depths in the water phantom. 
The scatter from the collimator is more clearly shown in the normalised results 
with the ratio between scattered dose to non-scattered dose increasing in the peaks 
and valleys as the width of the beam decreases. It can also be observed in Figure 
5.10 that increasing the width of the minibeam increases the relative valley dose 
between 5 mm and 16 mm depths. This is a result of requiring a fixed CTC spacing 
between the minibeams, as discussed in Section 5.1. As the width of the minibeam 
increases the width of the septa decreases, resulting in less attenuating material for 
the wider minibeams, allowing some unwanted protons to propagate through the 
collimator. This is similar to decreasing the thickness of the overall collimator 
shown in the previous Section 5.3.1. This has a large impact on the 0.7 mm, a 
medium impact on 0.6 mm and a small impact on the 0.5 mm wide minibeams. 
Figure 5.9: Peak dose, valley dose and PVDR  for various collimator slot widths. Peak and 
valley dose are normalised to the Bragg peak. 
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The 0.2 – 0.4 mm results show no noticeable differences between the 0 and 17 mm 
depths. This is a function of the thickness of the collimator and the width of 
material between minibeams. For no impact to be observed for a 25 mm thick 
collimator a minimum septa thickness between slots of 0.6 mm is required. 
Increasing the thickness of the collimator would allow this effect to be removed for 
wider minibeams. This effect is explored further in the phase space results section 
below. Decreasing the width of the minibeam is shown to increase the PVDR for all 
results, with large increases at the surface. This has the downside of a lower 
uniform dose distribution at the Bragg peak and a high surface dose in the 
minibeams. 
 
Results from the phase space are shown in Figures 5.1 and Figure 5.11. It can be 
observed that the number of primary protons passing through the collimator 
increases linearly with slot width. This increase can be attributions to the linear 
increase in area as the slots have a fixed height. The number of scattered protons 
does increase with slot width but at a much slower rate. The narrower the slot the 
larger the PVDR. With narrower slots the ratio between un-scattered to scattered 
protons decreases, thus reducing the quality of the beam. The scattered protons 
have much lower mean energy of 36.7 MeV, resulting in a projected range in water 
of 12.5 mm, which is considerably less than the range of 22.3 mm for a 50.5 MeV 
proton. The scattered protons also increase the surface dose whilst not delivering 
dose to the Bragg peak. This produces a high PVDR at the surface, but reduces the 
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Figure 5.11 shows a breakdown of all scattered particles from the collimator. The 
number of neutrons, photons and electrons show no major trends as related to 
collimator slot width. This implies that these particles are produced by roughly the 
same number of protons impacting the sides of the collimator regardless of slot 
width. This indicates that it is a function of the internal area of the slots impacting 
the production of these particles, which remains roughly constant. 
  
Figure 5.10: Number of protons entering the water phantom as a function of collimator slot 







Figure 5.11: Number of particles entering the water phantom as a function of collimator slot 
width. Showing various particles scattered off the collimator. 
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5.3.3. Collimator Material 
The collimator material results are shown in Figure 5.12 and Figure 5.13, 
displaying the mean peak dose and valley dose as a function of density at the 
surface for various collimator elements, respectively. The results only contain a 
component of the total dose from particles that have interacted with the collimator 
and then deposit dose in the water phantom. 
 
Particles that have not interacted with the collimator have been omitted as these 
produce results which do not vary with material. It can be observed that use of 
material with increased density results in decreased scattered dose from the 
collimator. There is a negative approximate exponential relationship with density. 
It can also be observed in the surface peak data that not all elements sit on a single 
curve; some elements particularly between 5 and 15 g/cm3 density show increased 
peak dose at the surface. The valley data also follow a similar trend. However, 
elements that have densities less than 5 g/cm3 have a large spread, this is 








Figure 5.12: Impact of collimator material on scattered particles from the collimator, showing 
minibeam peak dose at the surface of the water phantom. Elements are labelled by their symbol 
Below is a zoomed in section of elements between 3 and 14 density for clarity. 
Collimator Design 134 
 
 
Figure 5.13: Impact of collimator material on scattered particles from the collimator, showing 
minibeam surface valley dose. Elements are labelled by their symbol. Above displayed with a 





Figure 5.14: Impact of collimator material on scattered particles from the collimator, showing ratio 
between minibeam peak dose and valley dose at the surface. 
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The combined result of this becomes clear when looking at the ratio between the 
peak and valley at the surface in Figure 5.14, which shows an increasing trend 
where the PVDR increases with density up to a maximum of around 300 for 
osmium, the densest naturally occurring elements. Some other interesting results 
are also observed. There is a main curve from potassium through mercury to 
osmium, with two extra ‘branches’ coming off the main curve. Elements in these 
branches have significantly higher PVDRs than expected for their given densities. 
These are period 4 and 5 transition metals. The period 4 results are of particular 
interest as these elements obtain very high PVDR’s at moderate densities 
particularly Ni, Co, Cu and Fe, with Ni producing a very high PVDR. The period 5 
elements follow a similar trend. However, they produce a lower PVDR than that of 
the period 4 elements. 
 
Figure 5.14 and Figure 5.15 show the PVDR at depths of 5 and 10 mm, respectively. 
The average PVDR decreases with depth due to proton beam divergence, producing 
a pseudo-uniform distribution at the Bragg peak. As the PVDR decreases with 
depth in the water phantom the range of differences in the PVDR caused by various 
elements decreases. At a depth of 10 mm these is a difference in PVDR of only seven 
between all elements, with most difference between elements clearly caused by the 
difference in density. This effect is less noticeable at 5 mm depth, where the 
transition metal ‘branches’ are still observable with Ni, Co, Fe and Cu producing 
excellent PVDR’s. Clearly showing that element choice has a large effect on the 










Figure 5.15: Impact of collimator material on scattered particles from the collimator, showing ratio 
between minibeam peak dose and valley dose at 5 mm depth. Elements are labelled by their symbol. 
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Figure 5.16: Impact of collimator material on scattered particles from the collimator, showing ratio 




The results from the phase space data have been sorted in to proton, electrons, 
photons, and neutrons produced by each element in order to gain some insight into 
the cause of the differences between the different materials. Figures 5.16 - 5.19 
shows the data from the total number of each particle produced by each material. 
Most elements scatter around 10 - 30 times more protons than any other particle. 
The number of protons scattered by the collimator exponentially decreases with 
density. Most elements follow this trend closely with only a small deviation for 
some of the transition metals. This trend agrees with results from the dose data in 
the previous section, showing that number of protons are the primary cause of this 
effect. 
Figure 5.17: Effect of collimator material on the number of protons scattered by the collimator. 
Elements are labelled by their symbol. 
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The scatter results for the electrons, show that materials with a density between 0 
g/cm3 and 5 g/cm3 increasing the density will decreases the number of electrons 
produced. Materials with densities higher than 5g/cm3 have are no noticeable 
differences in the number of electrons produced. This indicates there is a cut-off 
effect based on density rather than elemental properties, and results in all elements 
with densities greater than 5g/cm3 being approximately equal in electron 
production. The mean energy for all electrons for all elements is 0.84 MeV. Of all 
the particles considered in this work, secondary electrons are the particle least 
produced from the collimator. 
Figure 5.18: Effect of collimator material on the number of electrons scattered by the 
collimator. Elements are labelled by their symbol. 
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The number of photons produced by each element follows the same trend as 
scattered protons. Increasing the density of the collimator material decreases the 
number of photons produced. The photon results do have a much larger variance 
and do not lie directly on a particular curve. Elemental differences between each 
element are responsible for these differences. The number of photons produced by 
the collimator are between 3 – 16% of all secondary particles and have an energy 
range of between 1.4 – 4.9 MeV with an average energy of 1.98 MeV. 
Figure 5.19: Effect of collimator material on the number of photons scattered by the 
collimator. Elements are labelled by their symbol. 
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The neutron results show no clear trend with density, showing neutron production 
depends mostly on elemental properties. Some of the low atomic number elements 
produce the lowest number of neutrons, particularly B, Be and C. Li was not 
simulated as its very low density resulted in it not being able to fully block protons, 
even with a 100 mm thick collimator. Period 3 and 4 elements also produce a 
considerably lower neutron yield than most other elements with Ca, C, S, Si, Mg 
and Ni standing out as particularly low neutron producers. While the number of 
neutrons produced by the collimator is drastically lower than the number of 
scattered and un-scattered protons, neutrons have a relatively high biological 
impact compared to protons, which is further investigated in the next chapter. 
Figure 5.20: Effect of collimator material on the number of neutrons scattered by the 




In this section consideration for development of a proton minibeam collimator is 
discussed. As a result of several Monte Carlo based investigations, it is clear that 
several factors need to be considered. Results from the collimator thickness 
simulations demonstrate that the thickness of the collimator should be at least 20 
mm to ensure regions of low dose are clearly defined for a 50.5 MeV beam. The 
thickness of the septa between the collimator slots is also an important factor to 
consider as it is directly related to the collimator thickness. Increasing the 
thickness increases the PVDR up to a thickness of 25 mm. For thicknesses greater 
than this there is no noticeable improvement as the number of scattered protons 
from the collimator remains roughly constant and the total number of un-scattered 
protons decreases which decreases the dose rate. 
 
Decreasing the collimator slot width was shown to increase the PVDR at the 
surface. This is primarily achieved by decreasing the valley dose. As the valley dose 
is thought to be primarily responsible for providing the ability for normal tissue 
repair, decreasing the valley dose should have significant benefits. This does come 
with the drawback of reducing the uniformity of the dose at the Bragg peak, thus 
decreasing dose delivered to cancerous tissue and potentially reducing local 
tumour control. With the various collimator slot widths, the 25 mm collimator has 
difficulty fully blocking the beam when the material between slots was less than or 
equal to 0.5 mm thickness, which works out to be 2% of the length of the collimator. 
Septa thickness between slots is based on the spacing between the slots (CTC). The 
appropriate CTC spacing depends on the energy of the beam and how uniform the 
distribution at the Bragg peak is desired to be. Overall, narrower minibeams should 
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be used to avoid this problem and have the advantage that narrower minibeams 
have increased PVDRs. Decreasing the width of the slots has the difficulty of 
increasing manufacturing complexity and therefore cost. The ideal 
micro/minibeam width/separation has also not been determined biologically. 
However, previous photon experiments have shown that smaller beams do produce 
a higher normal tissue sparing effect [12, 13]. A balance between these factors is 
required and based on the data here the use of 0.3 mm slots appears a convenient 
compromise to produce minibeams from a low cost collimator whilst still achieving 
reasonable dose at the Bragg peak and producing reasonable surface PVDR’s. 
 
Density of the collimator material has a large influence on the surface PVDR. The 
overall trend showed that increasing the density increased the PVDR at various 
depths. Increasing the density of the material has a similar impact as increasing 
the collimator thickness. As denser materials are more proficient at blocking lower 
energy protons and offer an advantage over increasing the collimator thickness as 
they will not reduce the dose rate by a similar factor. It was observed that some 
transition metals Ni, Co, Cu and Fe produce significantly higher PVDR’s than other 
elements and therefore are better candidates for use in collimator manufacture. 
The differences in PVDR when using collimator of different elements decreases 
with depth, due to the divergence of protons. For example, the difference at 10 mm 
depth between an element with 9 g/cm3 that produces a PVDR of 11 – 12 and an 
element with 20 g/cm3 or more producing a PVDR of 12 – 13 is quite minimal, 




The number of scattered protons, photons and electrons all show a dependency on 
density, with most particles scattered by the collimator being protons. As expected, 
neutrons show no discernible relationship to density, with results being dictated 
by elemental properties. Elements with low atomic number on the periodic table 
produce the lowest number of neutrons, in particular Ca, C, S, Si, Mg. However, 
Nickel is an outlier producing a very low number of neutrons compared to elements 
of similar density or atomic number. Neutrons are of particular concern due to 
their potential for high biological damage and hence radiation safety concerns [88]. 
The overall results for Ni, Fe, and Cu have excellent PVDR, low neutron production, 
low photon, electron, and scattered proton production due to their density making 
them excellent candidates for collimator material. This combined with the low cost 
of working and manufacturing these materials make them ideal choices for a 
collimator. 
 
Based on these results combined, the ideal collimator thickness for a 50.5 MeV 
proton beam our setup, a stainless steel or nickel collimator with 0.3 mm 
minibeams with 1 mm CTC spacing, which is between 4.7 and 5.9 times the path 
length of the incoming protons, with the projected range of a 50.5 MeV proton in 
stainless steel being 4.24 mm. This justifies the use of the 25 mm collimator in 
previous experiments [18, 23]. However, based on the results in Chapter 4, the 
beam was discovered to be more realistically a 45 MeV proton beam. This results 
in the projected proton range of 3.5 mm, thus, a 20 mm thick collimator would also 
have been acceptable. The ideal collimator would be made out of nickel as it 
produced excellent PVDR’s at both the surface and at depth and produced a low 
number of neutrons. Nickel an easy to manufacture material with the only 
downside is it being more expensive than stainless steel. The collimator that was 
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manufactured previously at part of this thesis was produced out of stainless steel. 
This was chosen due to its low cost, easy manufacturing and contains high 
percentages of both nickel and iron. 
 
5.4.1. Manufacturing Limitations 
A primary requirement of collimator design is that it is possible to produce a 
collimator with current technology, and that it is cost effective. This sets some 
primary limitations on available collimator design. A collimator with holes has 
been shown to have some advantages over one with slots in regard to the final dose 
distribution [89]. In particular it offers an “extra” direction of mini/micro beam 
sparing. Ideally a hole collimator should be used when producing mini/micro 
beams, however, the production of this type of collimator is technological 
challenging and costly. The slot collimator also does not block as much of the beam, 
which results in a higher dose rate throughput. This is important in limiting 
treatment times to a reasonable length or when motion is important as shown in 
Chapter 3. 
 
This chapter investigated optimal collimator design from a physics point of view. 
However, practical limitations and constraints also need to be considered. Some 
materials are difficult to machine and can be very costly which rules out the use of 
them. They are still included in this section despite their limitations to provide a 





This chapter investigated optimal collimator design for proton minibeams at a 
nominal beam energy of 50.5 MeV as is available at the University of Washington 
in Seattle. The minibeam specific approach and analysis is comprehensive and 
novel and systematically examined the most relevant parameters that influence the 
beam characteristics and dose deposition for proton minibeams. It was shown that 
increasing the thickness of the collimator beyond what is necessary to fully block 
protons was undesirable, as this reduced the number of primary protons whilst 
maintaining the same number of scattered protons. This resulted in a reduction of 
beam modulation and dose, which places an upper limit on the thickness of the 
collimator. For our setup, a collimator between 20 - 25mm thick was deemed ideal. 
The ideal width for minibeam beamlets was found to be between 0.3 – 0.4 mm as 
these widths have the highest PVDR whilst maintaining a reasonable dose 
delivered to the Bragg peak. These minibeam widths also have the lowest relative 
valley dose, thus reducing potential normal tissue damage and providing the 
possibility of tissue repair into the peak regions. In terms of collimator material, 
the collimator should be constructed from should be as dense a material as possible 
as this has been shown to maximise the PVDR. However, to reduce neutron 
production, this work has also shown the material should be ideally a group 4 
transition metal. This is a novel finding that has previously not been shown before. 
Nickel is a particularly suitable candidate for collimator construction due to its low 
neutron production and remarkably high PVDR ratios at the surface and up to 10 
mm depth. 
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One of the limitations in this chapter was that treating all particles equally in the 
results is problematic as the energy and type of particle can have a large impact on 
the resulting biological damage. This will be addressed in Chapter 6. Further work 
could investigate how higher energy proton beams are impacted by these 
collimator design parameters: expanding the scale from small animal energies at 
50.5 MeV to human scale clinical energies of up to 230 MeV. This would require 
new CTC spacing to optimise dose delivered to the Bragg peak; a larger CTC spacing 
would also generate greater PVDR’s at the surface enhancing the sparing effect 
when minibeams are used in a clinical situation. This chapter explored collimator 
design parameters and provided a novel insight into considerations for minibeam 




Chapter 6             
Relative Biological Effectiveness 
Considerations for Proton 
Minibeams 
 
This chapter investigates the RBE of proton minibeams. In particular, how 
scattered particles from various collimator materials impact the biological dose 
distribution. As discussed previously in Chapter 2, protons and neutrons can 
deliver higher biological damage for the same quantity of absorbed dose. As 
physical collimators scatter protons and produce neutron, the dose from these need 
to be considered to build an overall picture of the impact collimator material has 
on proton minibeam dose distributions. This has been an area of hot debate with 
letters to the editor in the International Journal of Radiation Oncology, Biology 
and Physics by V. Sahadevan, and F. Dilmanian et al., particularly the RBE of 
neutrons produced by proton minibeam collimators [90, 91]. 
 
When protons interact with the collimator, there is a small probability that 
neutrons are produced. These neutrons produce high biological damage and can 
potentially negatively impact regions of normal tissue. In a letter to the editor by 
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Sahadevan et al. concerns were raised over the production of neutrons when 
generating proton microbeams with a 109 MeV proton beam and a tungsten-
copper alloy collimator [90]. Dilmanian et al. claimed that the RBE of these 
neutrons in their paper was 10 [91, 92]. The RBE of 1-2 MeV neutrons has been 
shown to be as high as 100, and for a typical proton therapy, a constant neutron 
RBE of 25 was also suggested by Sahadevan et al. In Dilmanian et al.’s reply they 
state that “Newhauser et al. found mean neutron weighting factors in the range of 
6.7 to 9.2” and this was the basis for the RBE of 10 [91]. They also state that since 
the neutron dose was only 1% of the peak proton dose, it is insignificant. They did 
accept that further work on collimator material was required in order to minimise 
the biological neutron dose. Therefore, this chapter investigates in depth the 
biological damage caused by various collimator materials. With an emphasis on 
how each particle is produced by the collimator and how these particles affect the 
relative biological dose. 
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6.1. Introduction 
RBE is the ratio of bio between two doses to reach the same level of effect, or 
endpoint, between various different types of ionising radiation and that of typically 
photons. RBE is the ratio of the biological effectiveness between two types of 
ionising radiation for the same amount of absorbed energy for a given biological 
endpoint. The reference radiation  is generally an X-ray beam with 250 keV 
photons or cobalt-60 gamma rays. The primary interest of this chapter is in the 
RBE double-strand break endpoint. An equal dose of radiation from protons and 
photons has shown to have different resulting biological outcomes when delivered 
to a volume of cells. For example, a proton beam will cause more biological damage 
than a Co-60 source [93]. Traditionally for clinical use, RBE for cell survival for 
protons has been assigned a value of 1.1 [37]. However, RBE has been shown by 
Paganetti et al. to vary with e.g. depth, energy, and delivered dose, making this an 
approximation of the average of all these values [93]. A 50 MeV proton beam has 
been demonstrated to have a variable RBE DSB of between 1.05 at the surface and 
1.4 post Bragg peak [18]. This can result in under- or overestimating the dose 
delivered to regions, creating unforeseen complications. The difference at the distal 
end of the Bragg peak is important, because there is variation in the range of an 
individual protons [94]. The problem is further exacerbated by an increase in RBE 
of the beam at this point [95]. This leads to the beam potentially overdosing 
unintended regions and can be particularly problematic when the beam stops just 
before critical structures. The RBE variability is greater for lower energy proton 
beams, for example the 50.5 MeV proton beam at the University of Washington. 
An accurate measurement of RBE can be determined with cell experiments 
measuring cell kill as a function of dose. By modelling various cell death endpoints 
153 
 
from the delivered dose, an estimation of RBE can be simulated in Monte Carlo. 
For this work we are using a double-strand break model by Stewart et al. [96]. This 
model works off the idea that DSBs and multiple damage sites, where DNA is 
damaged or broken in multiple places in close proximity, have been linked to be 
primary causes of radiation cell death [97]. Therefore, an estimation of the cell kill 
can be calculated by modelling the number of DSBs that occur. The model 
randomly distributes damage in a section of DNA based on the delivered dose in 
Gy. Then it checks if the distance between damage segments is below a threshold 
to determine if a double-strand break occurs. This data was then used to produce 
an RBE estimate for all light-ions up to Fe, based on the number of DSBs relative 
to 60Co. This data was then fitted to an analytical formula for cells irradiated under 
anoxic and nonmonic conditions. This analytical formula is what is used in the 
model used in TOPAS. While this model aims to produce a reliable estimate of 
RBE, research by Rorvik et al. has demonstrated that not all RBE models produce 
the same results [98]. This work consisted of a single model being utilised to 
provide a quantifiable result. Due to the variation between the different 
approaches, the modelling results should always be verified, by cell experiments in 
the future. The LET, which is a physical parameter is also included in this chapter 
as a reference as some RBE models are based off LET [35]. 
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6.2. Methods 
The first simulation presented in this chapter is of a simplified setup consisting of 
a near monoenergetic beam in a vacuum, passing through a minibeam collimator 
and delivering dose into a water phantom. The use of this setup was to highlight 
the impact the collimator has on the beam, and to remove influence from other 
beamline components from the simulation. The first simulation used a 
monoenergetic 50.5 MeV proton beam, that was a flat 12.5 mm square source with 
a small angular spread of 0.0026 rad. The angular spread matches what was used 
in Chapter 5. The collimator was a 60 x 60 x 100 mm metal block with eleven 
vertical minibeam slots cut into it. The slots were 0.3 mm x 10 mm and spaced 1 
mm apart to cover a 10 x 10 mm square field. This was the same collimator design 
as used in Chapter 5. The collimator was modelled with four materials: brass, 
nickel, stainless steel, and tungsten. These materials represent a wide range of 
materials presently used and have a low neutron production as discussed in 
Chapter 5. 
 
After the beam exits the collimator, all particles were collected by a phase space 
scorer. Data collected by the phase space scorer were grouped based on particle 
types, protons, beta particles, photons, and neutrons. The protons were further 
categorised by whether they had interacted with the collimator. The grouping of 
these particles enables the evaluation of how each individual component impacted 





A second scorer was also placed along the internal left-hand side of the collimator’s 
central slot, shown in Figure 6.3. This scorer allowed the collection of information 
on: 1) where in the collimator particles were produced, 2) what types of particles 
were produced, 3) the energy of these particles, and 4) the direction of these 
particles. From this information a detailed analysis was performed on how 
collimator geometry impacts the minibeam dose. 
 
A second analysis was performed simulating how each group of particles from the 
phase space scorer deposited dose in a water phantom. LET was simulated in each 
voxel as a total average of energy given to the voxel using the TOPAS LET scorer 
[99]. RBE was also scored using dose with the double-strand break model 
developed by Stewart et al. [96]. RBE was based on V79 cells from Chinese 
hamsters and was based on a prescribed dose of two Gy [100]. 
  
Figure 6.1: Diagram of phase space scorer location used in TOPAS simulations from a beams eye 
view. 
Second scorer 
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An initial problem encountered was that the simulated dose from neutrons was 
low, even with more than a billion initial proton histories approximately 1% of 
particles exiting the collimator were neutrons. This resulted in poor dose statistics 
from neutrons, and consequently no useable data for neutron LET and RBE. The 
statistics could be improved by either running the phase space file multiple times 
or using variance reduction, however this would produce biased results. The 
solution decided upon was to first acquire the neutron spectrum for neutrons 
exiting the collimator made out of different materials by means of Monte Carlo 
simulations and then produce a neutron beam that was randomly sampled from 
this spectrum. The neutron beam could then be used to simulate dose to a water 
phantom. The spread of the beam was measured from the phase space file and used 
in the TOPAS simulation. The data from the phase space scorer is shown in Figure 
6.2. 
Figure 6.2(a): Neutron Flux from a Brass collimator showing the horizontal spread of neutrons 




Figure 6.2(a) shows the positional spread of neutrons exiting a brass collimator. It 
is interesting to note that the spread of neutrons shows no spatial correlation to the 
collimator minibeam slots and instead appears continuous. A fit was applied to this 
spread that could be used to produce the neutron beam within TOPAS for further 
simulations. The fit that most closely matched the collimator spread shown in 
Figure 6.2 (a) was a combination of two Gaussians. The same model fit approach 
was applied for each collimator material, details of the fit parameters are shown in  
 Table 6.1. This shows the weighting of the Gaussian (height), the positional spread 
 (standard deviation) and the angular spread angular deviation. 
 
Figure 6.2(b) shows the energy spectra for neutrons generated by each collimator 
material. The neutron spectra have a peak at 0.5 MeV for tungsten and 0.7 MeV for 
brass, nickel, and stainless steel. The entire spectra were used in the TOPAS model 
to ensure the neutron beam matched the collimator output.  
  
Table 6.1: Neutron beam fit data 
 Brass Nickel Stainless Steel Tungsten 
1 
Weighting Gaussian  75% 76% 72% 96% 
Position Spread  0.498 cm 0.505 cm 0.491 cm 0.450 cm 
Angular Spread  1.108 rad 1.110 rad 1.117 rad 1.071 rad 
2 
Weighting Gaussian  25% 24% 28% 4% 
Position Spread  1.826 cm 1.851 cm 1.844 cm 1.989 cm 
Angular Spread  1.108 rad 1.110 rad 1.117 rad 1.071 rad 
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Using the positional spread and neutron spectra, data each simulation was set up 
to produce a beam matching these characteristics. The output dose values were 
normalised to match the number of input neutrons to enable a fair comparison of 
neutron results with results of other particles. 
 
A further simulation was performed to compare the difference between the 
monoenergetic beam described previously in this chapter, to that of a more detailed 
simulation, in this case the simulation of the whole small animal proton beamline 
at the University of Washington Medical Centre. This comparison allowed an 
investigation of the difference in RBE, caused by an idealised monoenergetic beam 
and a realistic poly-energetic beam, and how this impacts the overall dose delivered 
to the water phantom. The simulations parameters can be found in the Chapter 4 









An analysis of the different types of particles exiting the collimator are presented 
first. Dose results from these particles are then investigated and an analysis on the 
LET and RBE results is performed. Finally, a comparison between a monoenergetic 
and a realistic proton minibeam is performed comparing RWD. 
 
6.3.1.  Particle Energy and Distribution Results 
For the monoenergetic beam, particles exiting the collimator were grouped into 
particle and interaction with the collimator. Using MATLAB, a histogram of all 
particles and energies was produced, shown in Figure 6.3. Note any particles that 
did not interact with the collimator are not shown. 
Figure 6.3: Energy distribution of particles that interacted with the collimator before exiting the 
collimator. 
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The neutron results, Figure 6.3 (a) match the findings recorded in Chapter 5 where 
the tungsten collimator produced a large number of neutrons, and nickel produced 
the least. Tungsten had peak number of counts approximately 2.67 times the other 
materials, with an energy peak of 0.46 MeV. Nickel, brass, and stainless steel 
energy had peaks of 0.46, 0.68, 0.68, and 0.74 MeV, respectively. The 
corresponding densities of tungsten, nickel, brass, and stainless steel energy are 
19.3 g/cm3, 8.91 g/cm3, 8.55 g/cm3, 7.99 g/cm3, respectively. Reconfirming the 
results from Chapter 5 that material density is not the primary factor in neutron 
production. The differences in the total number of neutrons produced by a material 
is likely to be dependent on the nuclear cross-section between protons and a 
material’s nucleus. 
 
The beta particle results Figure 6.3 (b) include both positrons and electrons. It can 
be observed that the collimators only produce a relatively small number of beta 
particles and therefore, they will only have a minor impact on the final dose 
distribution. It is interesting to note that the results for tungsten were considerably 
different from the results of the other materials, with a higher peak of 250 counts 
at 110 KeV. Brass, nickel, and stainless steel peak at 130, 90 and 140, counts 
respectively, with a peak energy of 300, 400, and 380 KeV, respectively. These 
results demonstrate that tungsten produced the highest number of beta particles, 





Results for the scattered protons are shown in Figure 6.3 (c), displaying protons 
exiting the collimator having interacted with the collimator at some point. The 
interactions cause the protons to lose energy. It can be observed there are three 
main peaks for all materials, with smaller peaks at regular intervals. These results 
are shown in Table 6.2. 
 
The average energy loss between each peak is also shown starting with the 
difference between the 50.5 MeV protons, then each subsequent peak. Brass, 
nickel, and stainless steel have an average energy drop of 6.6% between peaks, 
whilst tungsten has an average energy loss of 7.2%. Protons primarily interact via 
Coulomb interactions and, as a consequence, energy is lost. The differences in 
energy loss between materials, correlates with each material’s density and number 
of electrons. The systematic differences between the peaks indicates that the 
particles are undergoing multiple scatter events and each peak represents a 
subsequent scatter. Each peak is not a sharp peak, indicating variability in the 
energy lost in each collision, resulting in energy spread of the resulting particles. 
Table 6.2: Scattered proton energy peaks 
 
Material Peak Energy (MeV) Average 
Energy Loss 
Between Peaks 
1 2 3 4 
Brass 47.2 44.0 41.1 38.4 6.6% 
Nickel 47.1 44.0 41.1 38.4 6.6% 
Stainless Steel 47.2 44.1 41.2 38.4 6.6% 
Tungsten 46.9 43.5 40.4 37.4 7.2% 
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The photon results in Figure 6.3 (d) show that, amongst the materials simulated, 
tungsten produces the lowest number of photons, whilst the other three materials 
all produce a similar number of photons. The photons for brass, nickel, and 
stainless steel all peak at approximately 250 KeV. This does not include 
characteristic peaks, with a height of 5.3, 3.5 and 4.4 times that of tungsten, 
respectively. Tungsten peaks with an energy of 650 KeV. Minor secondary peaks in 
the photon’s distribution are caused by characteristic photons. For example, the Ni 
58 1454.3 KeV photon peak can be observed and a strong peak at 511 KeV from 
electron positron annihilation [101, 102]. These photons only make up a small 
component of the particles leaving the collimator and thus have a minimal impact 
on the dose delivered by the beam. 
 
Overall, of the particles produced by interactions with the collimator, 85 – 89% are 
scattered protons. Tungsten has a smaller number of these scattered protons 
compared to the other materials which all show comparable results. The next 
largest group by number of particles is neutrons, between 3 – 12% and then 
photons between 3 – 9%. Out of all the materials tungsten has the highest number 
of neutrons and the fewest photons. The number of beta particles is negligible 
compared to the other particles producing less than 0.1% of the total number of 
particles for all materials. 
 
The phase space scorer results are displayed in the next section. This scorer was 
placed on the internal septa of the collimator and collected all particles exiting the 
septa’s internal surface. All these particles have either interacted with the 
collimator or have been produced in the septa. As each surface is geometrically 
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symmetrical, it can be assumed that the number of particles exiting one side of the 
internal septa of the collimator should be similar to the number exiting any other 
septa. The positional and energy information is of interest as this allows us to build 
an understanding of what is occurring in specific locations as the beam passes 
through the collimator. 
 
The first set of these results is the combination of position and energy results for 
the four main particle types: neutron, beta, proton, and photons. This data was 
processed in MATLAB and plotted using a 3D histogram where the counts in each 
bin are indicated by colour. A logarithmic scale was used for the colour spectrum, 
enabling the large difference between particle flux to be observed. The phase space 
scorer lies along a central septum, making the scorer a plane with height (y) and 
length (z). This section of research is primary interested in the depth within the 
septa at which the particles are found. The height position is assumed to be less 
important as the beam should be homogenous in this direction, therefore it can be 
averaged, reducing noise. Data is grouped into 10,000 energy bins and position 
bins. 
 
Figure 6.4 shows the results for all particles. The neutron graphic shows that most 
neutrons are generated near the entrance of the collimator, between 0 – 1.5 cm 
depth in the collimator. These neutrons peak at a depth of 0.05 - 0.35 cm with a 
range of energy between 0.7- 1.3 MeV. A small number of higher energy neutrons 
are also generated at this depth. These neutrons have energies up to 20 MeV and 
are produced when protons interact with the collimator from the uniform 50.5 
MeV beam. For depths between 1.5 – 10 cm, neutrons of 0.1 – 3.0 MeV energy are 
produced throughout the thickness of the collimator. 
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These neutrons have an energy peak at 0.65 MeV. It can also be observed that the 
number of neutrons decreases with depth. This is a likely to be a function of the 
number of particles in the minibeam reducing with depth as the beam is collimated, 
thus absorbing primary protons. 
 
  
Figure 6.4: Position and energy distribution of particles exiting the surface of a septa in a Brass 
collimator. Colour scale represents number of particles. 
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Only a small number of beta particles are produced near the surface of the 
collimator at a depth between 0 – 1.5 cm with energy between 0 – 2.0 MeV. These 
particles are generated from proton interactions in the collimator as a result of the 
collimator stopping the main beam in the septa. Most of these beta particles do not 
exit the collimator and are absorbed back into the collimator material. 
 
The results for protons can be divided into two sections: vertical curves and 
horizontal lines. The first section of results show a red near vertical curve starting 
at the surface at 50 MeV and decreasing energy with depth, until a depth of 0.43 
cm. Corresponding to the projected range of a proton in brass and matches the 
calculated value from SRIM [82] and demonstrates that these protons are from the 
collimator blocking 50.5 MeV protons from the uniform beam. Showing the 
minimum thickness of a brass collimator required to fully block the main beam. 
 
A second vertical band is also present at a depth of 0.6 – 1.2 cm. Starting with an 
energy of zero MeV and peaking at 34 MeV. The band results from scatter 
generated by the adjacent collimator septa. Protons from the initial red vertical 
curve on the opposite septa impact with these septa and some of the protons are 
reflected into the gap. Protons reflected form this ‘shadow’ of the initial curve. Most 
of these protons in the vertical curve and reflected ‘shadow’ have a large angular 
deviation from the main beam and therefore impact with the collimator septa, 
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The second section of the proton results shows horizontal lines that can be 
observed running along the entire length of the collimator. The vertical lines begin 
at the same depth as the vertical curve. These lines reveal that protons are being 
scattered throughout the length of the collimator. The number of protons in each 
vertical line decreases as the energy level decreases. Each line represents a higher 
order scatter event in decreasing energy. The majority of the particles travelling 
down the collimator are 50.5 MeV protons. Therefore, it is most probable that the 
scatter that reduces the 50.5 MeV protons to 47.2 MeV. Each order scatter event 
after the first is less probable. The scatter events do not occur with discrete angles 
or energy. There is a range of energy lost in each collision and the peak is used as a 
comparison. As the number of protons travelling down the collimator decreases 
due to collimation, the number of scatted protons also decrease with depth. With 
the log scale this is difficult to observe but is present in the data. The protons that 
are scattered off the sides throughout the length of the collimator have low angular 
divergence from the beam, demonstrating that the protons only skim the surface 
of the collimator slot and exit the collimator into the water phantom. These results 
help explain the previous data from Chapter 4 in Section 4.3.2 where the proton 
energy peaks at uniform energy intervals. 
 
The photon results can be split into two sections as previously described with the 
proton results. Firstly, a large peak of photons at the surface and second horizontal 
lines throughout the depth of the collimator. The greatest number of photons are 
generated near the surface, between 0 – 1.5 cm, with energy between 0 – 10 MeV. 
Of these photons the majority are between 0 – 2.0 MeV and at a depth between 0 
– 0.46 cm. These photons are produced by stopping of the main beam. Many of 
these photons are absorbed by the collimator and do not contribute to the final 
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particle stream exiting the collimator. The horizontal lines throughout the depth of 
the collimator are caused by interaction of protons bouncing off the side of the 
collimator septa. These are at fixed energy intervals and are a function of the initial 
proton energy and the material properties. These photons have energies between 
0 – 2.0 MeV. Most of these photons exit the collimator and contribute to the final 
dose. 
6.3.2. Dose Contribution from Scattered Particles 
In this subsection the magnitude of the dose resulting from scattered particles for 
different collimator materials is evaluated. The results are split into particle type 
showing the dose from neutrons, beta particles, scattered protons, and photons. All 
results are scaled based on the total number of particles exiting the collimator, 
allowing the simulations to be compared. The neutrons, beta particles, and photons 
show little, to no, spatial dose differences between the valley and peak regions. This 
observation indicates that the dose from neutrons, beta particles, and photons 
produce a uniform dose over the width of the phantom. An important note is the 
uniformity of these particles could have a larger impact in the valley regions. The 
lack of spatial variation is a result of two factors; first, the particle’s ability to pass 
though the collimators septa without being fully absorbed and secondly, the high 
angular deviation of these particles exiting the collimator. 
 
Figure 6.5 shows the depth dose for neutrons (a), beta (b), scattered protons(c), 
and photons (d), for different collimator materials. Dose was normalised to the 
Bragg peak, for protons that did not interact with the collimator. Starting with the 
neutron dose results, they all follow similar trends, starting low at the surface then 
peaking within the first 5 mm and decreasing with depth after the dose peak. 
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Tungsten starts at 56 nGy and peaks at 81 nGy at a depth of 1.1 mm, which 
corresponds to 5.6x10-6% and 8.1x10-6% of the total dose in at the Bragg peak. 
Brass and stainless steel have a similar initial dose relative to the Bragg peak dose 
at 3.8x10-6% and 3.5x10-6% nGy, respectively, and both peak at a depth of 2.6 mm 
with a peak dose of 6.4x10-6% and 6.0x10-6%, respectively. Nickel has the lowest 
dose with a surface dose relative to the Bragg peak dose of 2.1x10-6%, a peak of 
3.8x-6% at 2.9 mm depth. These results concur with Chapter 5 where tungsten had 
Figure 6.5: Dose of various particles that have interacted with or are produced by various 




the highest neutron output and thus, the highest neutron dose, which is 30% higher 
than the dose for brass and stainless steel. The relative scattered dose from nickel 
is low, 60% the dose from either brass or stainless steel. Agreeing with the results 
from Chapter 5 that nickel produces less neutrons and thus produces a low neutron 
dose. 
 
The beta dose (b) has a general trend of a high surface dose which decreases with 
depth for all materials. Stainless steel has the highest surface dose of 3.6 µGy. This 
dose rapidly decreases with depth and by 0.15 mm, stainless steel has less dose 
than the other materials. Tungsten, nickel, and brass have a similar surface dose 
relative to the Bragg peak dose of 1.8x10-4%, 1.7x10-4% and 1.8x10-4%, 
respectively. Tungsten has the highest dose beyond 0.15 mm depth, followed by 
nickel, brass, and then stainless steel with the lowest dose. 
 
Results for the scattered protons (c) can be split into the peak results and valley 
results. The peak dose results have a high surface dose which decreases with depth 
before peaking with multiple Bragg peaks. The surface dose relative to the Bragg 
peak dose for stainless steel, nickel, brass, and tungsten is 13.7%, 13.1%, 12.9%, 
and 8.0%, respectively. The main peak at 19.7 mm depth, has a height of 8.2%, 
7.9% and 7.8% Gy for nickel, brass, and stainless steel, respectively. This peak 
corresponds to the 47.2 MeV scattered protons. The main peak for tungsten is at 
19.5 mm depth with a dose of 5.1% Gy and this peak is a result of the 46.9 MeV 
first order scattered protons. A second peak can be observed at a depth of 17.3/16.9 
mm and this corresponds to the 44.2/43.5 MeV second order scattered protons. A 
third peak is also present from the third order scattered protons. Further peaks are 
not visible above the dose curve. The large surface dose results from the lower 
Relative Biological Effectiveness Considerations for Proton Minibeams 170 
 
energy protons originating from the initial conversion of the uniform beam into 
minibeams. The dose from proton scattered off the tungsten collimator is 40% 
lower than that of the other materials due to tungsten’s greater density, increasing 
the collimation of the beam, thus decreasing the number of particles exiting from 
the collimator. Stainless steel has the highest dose from scattered protons due to 
having the lowest density of the materials evaluated. 
 
The valley dose results for the scattered protons (c) show a general trend where the 
dose increases with depth before peaking with multiple Bragg peaks. The surface 
dose for stainless steel, nickel, brass, and tungsten is 0.07%, 0.28%, 0.4%, and 
0.26% mGy, respectively. The valley dose at the Bragg peak is 7.6%, 7.3%, 7.2%, 
and 4.7%, respectively. Stainless steel and nickel have similar high surface dose. 
While, nickel and tungsten have low surface dose. This impacts the ratio between 
the peaks and valley resulting in nickel producing the best peak to valley ratio of 
45.4 at the surface, followed by stainless steel with a value of 35.6, brass and 
tungsten have similar values of 30.6 and 29.3, respectively. 
 
Photon dose (d) is shown to peak near the surface and then decrease with depth for 
all materials. The peak occurs at a depth of approximately 1.7 mm for all materials 
apart from stainless steel which peaks at 1.1 mm. Brass has a peak of 1.01x10-4%, 
followed by tungsten at 0.86x10-4% which is 15% less. Nickel is next with a peak of 
0.78x10-4%, and stainless steel has the lowest photon dose with a peak of 0.52x10-
4%. This demonstrates the material of the collimator can reduce the photon dose 
by 50% depending on material used. Hence, stainless steel has a major advantage 




Comparing the total scattered dose from all particles signifies that scattered 
protons are the primary contributor of scattered dose, delivering more than 105 
times that of any other particle. The neutron dose is extremely low being a factor 
of ten times less than both beta and photons. This is more clearly shown in Figure 
6.6 which summarises the dose contribution for all secondary particles exiting a 
stainless steel collimator, including the primary protons that did not interact with 
the collimator for a comparison.  
Figure 6.6: Depth dose curves of all particles exiting a stainless steel collimator. Peak dose is 
shown as a solid line, valley dose is a dashed line. 
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Stainless steel is shown for clarity and it should be noted that the graph uses a 
logarithmic scale for the y-axis to display the dose from all particles clearly. This 
data is mostly repeated from the previous results but aims to highlight the relative 
differences in greater detail. The dose from primary is also included for reference 
to give a more complete picture of the overall dose delivered to the water phantom. 
 
The peak dose region for protons that have not interacted with the collimator has 
the highest dose at all depths. This dose peaks at the Bragg peak with a peak of 0.98 
Gy before rapidly decreasing. The second highest dose is produced by the peak 
regions of protons that interacted with the collimator, from a depth of 0 – 13.5 mm, 
after which the valley dose of protons that did not interacted becomes the second 
highest source of dose. The valley dose for proton that not interacted is less than 
ones that that did interact. The difference between the two is a factor of ten at the 
surface which then decreases until a depth of 11.7 mm. The valley region for 
protons not interacted has a higher dose than protons that did interact with the 
collimator. All other particles contribute negligible dose at all depths. 
 
These results show that approximately 80% of the peak dose is a result of un-
scattered protons, and 20% of the peak dose is from scattered protons, with less 
than 0.001% of the dose from other particles. The valley dose is comprised of 
approximately 91% scattered protons and 9% un-scattered protons with less than 
0.1% of the dose is from other particles. The decrease in the PVDR is therefore 
caused by these scattered protons as they dominate the valley dose. The peak dose 
is also increased by 25% due to the scattered protons at the surface, this percentage 
decreases with depth. It is important to note that the RBE of each particle has not 
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been considered in these results and does need to be before a final conclusion can 
be drawn. This analysis will be performed in following sections of this chapter. 
 
6.3.3. LET Distribution 
Using the TOPAS LET scorer, LET was measured for the protons and neutrons 
exiting brass, nickel, stainless steel and tungsten collimators. LET in TOPAS is 
measured per voxel and therefore is a measure of the total LET delivered to that 
voxel, rather than on a per track basis. Results were processed in MATLAB. For the 
neutron results, LET was averaged around the central axis in both the width (x) 
and height (y) directions in order to reduce noise. This is possibly due to the 
neutron distribution being semi-uniform. The proton LET results combine all 
peaks, except the two on the edge, to form an average. Voxels can also be averaged 
in the height direction around the central axis as there is no spatial variation in this 
direction. 
 
Results from the neutron LET simulations are shown in Figure 6.7. The LET 
distribution of neutrons with depth generated by the tungsten collimator is higher 
than that from the other materials considered here. All materials have a high 
surface LET which decreases slightly with depth. Tungsten’s LET peaks at 46 
MeV/mm/g/cm3, whilst all other materials peak at 42 MeV/mm/g/cm3. 
Tungsten’s high LET indicates that the dose from neutrons will be more 
biologically damaging especially at the surface. The neutron dose is semi-uniform 
over the width of the phantom and leads to a higher apparent impact in the 
minibeam valleys, decreasing the PVDR.  
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Thus, reducing the normal tissue sparing from the micro/minibeam effect. Nickel 
produces the least neutrons, however this does not have a large impact on the LET, 
resulting in nickel’s neutrons still having the same LET as brass and stainless steel. 
Results for the peak and valley LET of protons are shown in Figure 6.8. Starting 
with the peak dose it can be observed that all materials have an LET of 2.3 
MeV/mm/(g/cm3) for protons that interact with the collimator. For protons that 
did not interact with the collimator the LET in the peak regions is only 1.3 
MeV/mm/(g/cm3), which is 43% less.  This will increase the surface dose in the 
peak region by a larger factor than would be expected compared to that of a 
monoenergetic beam. 
Figure 6.7: LET of neutrons from minibeam collimators of various materials. 
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LET for the peak dose region slowly increases with depth and peak and valley LET 
become equal from a depth of 15 mm. This depth was shown in the previous dose 
results section as the point where the dose merges into a semi-uniform dose. 
The valley regions have a high LET at the surface, which decreases with depth. The 
LET at the surface is particularly high at 11.0 MeV/mm/(g/cm3) for the protons 
that did not interact with the collimator. Tungsten has the next highest LET at 9.9 
MeV/mm/(g/cm3), followed by nickel at 9.3 MeV/mm/(g/cm3). Leaving brass and 
stainless steel with the lowest surface LET of 9.1 MeV/mm/(g/cm3). A high surface 
LET is caused in part by a biasing effect where the valley region is a low dose region. 
Figure 6.8: LET of Protons from various collimator materials. Peak dose is shown as a solid line, 
valley dose is a dashed line. 
Relative Biological Effectiveness Considerations for Proton Minibeams 176 
 
The few particles that do deliver dose have a higher LET on average as they have 
already been through interactions enabling the deposition of dose in this region. 
The relationship between the dose and LET is inversely proportional in this region. 
As dose increases with depth, the LET decreases until the dose is semi-uniform at 
a depth of 15 mm. 
 
Three peaks can be observed in the LET at depths from 15 to 25 mm. The results 
for brass, nickel, and stainless steel are all very similar with peaks of 22.7 
MeV/mm/(g/cm3), 25.7 MeV/mm/(g/cm3) and 8.0 MeV/mm/(g/cm3) at 22.4 
mm, 20.7 mm, and 17.7 mm depths respectively. These correspond to the dose 
peaks from 50.5 MeV, 47.2 MeV, and 44.0 MeV protons. It should be noted that 
the dose peaks occur at a depth of 22.5 mm, 19.7 mm, and 17.3 mm. The peak that 
corresponds to the 50.5 MeV protons in these three materials only contain a few 
protons that have lost a small amount of energy and therefore is not a complete 
peak and dose not match the results for the un-scattered protons. The two other 
LET scattered peaks occur 1.0 mm and 0.4 mm deeper than the dose peaks. For 
protons that did not interact with the collimator, they peak at 32.8 
MeV/mm/(g/cm3) at a depth of 23.8 mm, 1.3 mm deeper than the dose peak. This 
large peak both increases the effective dose at the Bragg peak and on the distal edge 
of the Bragg peak. The large LET on the distal edge of the Bragg peak is a major 
concern as it increases the dose uncertainty of the Bragg peak depth, limiting the 
ability for placement near critical structures. The results for tungsten is shifted as 
this material produces different scattered proton energy peaks tungsten has the 
following peaks 26.2 MeV/mm/(g/cm3) at depth of 23.1 mm, 22.3 
MeV/mm/(g/cm3) at a depth of 20.3 mm, and 7.5 MeV/mm/(g/cm3) at a depth of 
17.3 mm. The two scattered peaks are 0.8 mm and 0.4 mm deeper than the dose 
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peaks. As dose past these peaks drops to near zero LET past the end of the peaks 
becomes influenced by individual particles with high LET producing noise past the 
main LET peaks. 
 
6.3.4. RBE Distribution 
RBE was scored with the RBE DSB scorer in TOPAS, modelling the DSB biological 
damage [96]. RBE was measured for protons and neutrons exiting brass, nickel, 
stainless steel, and tungsten collimators. RBE is measured per voxel and gives an 
average of RBE in each voxel based on all particles that have deposited dose in the 
water phantom. Results were processed in MATLAB with the same with described 
in Section 6.3.3. 
 
Figure 6.9 illustrates the neutron RBE results, showing a similar trend to the 
results from LET. Demonstrating the close relationship between RBE for DSB and 
LET used in this model. The RBE for tungsten starts at 3.00 at the surface and 
decreases to 2.65 with depth. The three other materials have an RBE of 2.85 at the 
surface which decreases to 2.25 with depth. These results highlight the larger 
amount of biological damage that neutrons cause at the surface and throughout the 
phantom. The tungsten collimator has a higher neutron output, and this results in 
a higher LET and thus a higher RBE.  
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The high RBE of the neutrons increases the neutron dose to at least 2.25 at all 
depths. This is of particular importance in the valleys and post Bragg peak where 
the dose from protons drops, as the neutron dose can have a larger relative effect. 
The proton RBE results, shown in Figure 6.10 for RBE DSB follow similar trends 
to the LET results in the previous section. A high surface RBE can be observed for 
the valleys of 1.52, 1.42, 1.40, 1.39, and 1.38 for protons interacted, tungsten, 
nickel, stainless steel, and brass, respectively. 
  
Figure 6.9: Neutron DSB RBE from various collimator materials 
179 
 
The RBE in the peak regions at the surface is 1.03 for protons that have not 
interacted with the collimator, and 1.06 for protons that have interacted with 
collimators regardless of material. At a depth of 15 mm the RBE for peaks and 
valleys merge at 1.07 for protons not interacted and 1.16 for protons that did 
interact. Protons that did not interact with the collimator increase RBE until a peak 
of 3.15 at 23.8 mm depth. This peak is past the dose peak as discussed previously. 
There are three peaks for the brass, nickel, and stainless steel collimators. These 
peaks occur at 22.6 – 22.8 mm, 20.7 mm and 17.7 mm depths and have an RBE of 
2.22 – 2.59, 2.43, and 1.25, respectively. 
 
Figure 6.10: Proton DSB RBE from various collimator materials. Peak dose is shown as a solid line, 
valley dose is a dashed line. 
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The differences in the 22.6 – 22.8 mm peak is caused by a low number of protons 
being present in this peak. Resulting in protons that do influence this peak having 
a larger impact on the average RBE making the peaks noisier. Tungsten has the 
following RBE peaks 2.81 at 23.1 mm depth, 1.99 at 20.5 mm depth, and 1.24 at 
17.3 m depth. It is noted that RBE is significantly higher than that of a normal 
clinical beam due to two factors. Firstly, this model uses an idealistic 
monoenergetic beam, resulting in a large number of protons stopping at the same 
point which increases the RBE at this point. Secondly, lower energy protons have 
a higher LET and consequently RBE. 
 
To gain an overall picture of the impact RBE has on the biological dose, both RBE 
and dose can be combined to the RBE weighted dose, RWD. RWD is simply the 
product of RBE and the physical dose. The RWD was calculated in MATLAB by 
multiplying corresponding voxels from the previous simulations. Figure 6.11 
shows this combination with the stainless steel collimator for protons that have 
interacted with the collimator. Only stainless steel is shown here for clarity as this 
is the material a collimator was manufactured from for the University of 
Washington based on the results from this thesis. Figure 6.11 demonstrates the 
increased RWD over the whole dose curve, with a factor of 1.4 at the Bragg peak. 
While this is a large increase it is less the RBE maximum of 2.6. This is caused by 
the RBE peak not coinciding with the dose peak, but instead peaking after the dose 
peak. This increases the dose on the distal edge of the Bragg peak by a 47% and 




The overall comparison between RWD and physical dose results shown in Figure 
6.12 demonstrate that the increase in effective dose the neutrons and protons have 
in comparison to all components of the minibeam exiting the stainless steel 
collimator. Note, a log scale is used so a comparison between all particle 
contributions can be performed. An increase in the peak dose of the protons is quite 
visible at the Bragg peak and at the surface for the valley regions. The neutron dose 
has increased by a large amount, however, it does not contribute a large amount to 
the overall dose received by the water phantom and the overall dose is still 
dominated by protons. The peak regions are dominated by protons which have not 
Figure 6.11: RBE weighted dose compared to dose for protons scattered off a stainless steel 
collimator, differences is shown in grey. Peak dose is shown as a solid line, valley dose is a dashed 
line. 
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interacted with the collimator and the valley regions are dominated by protons that 
have interacted with the collimator. 
 
  
Figure 6.12: Comparison between dose and RBE weighted dose for all particles exiting a stainless 
steel collimator. Peak dose is shown as a solid line, valley dose is a dashed line and RBE weighted dose 




6.3.5. Comparison Between Simplified Model and PPRP 
The next section of results gives the difference between a simplified monoenergetic 
and a realistic beamline with a collimator. The realistic beamline uses the PPRP 
model as discussed previously in Chapter 4. The monoenergetic setup uses a nickel 
collimator as this represents an ideal material for producing minibeams with a 
collimator. Which has been shown in previous sections produces the least neutrons 
and delivering remarkably high PVDRs compared to other materials. Dose was 
normalised to the Bragg peak of the peak regions for both the peak and valley data, 
allowing a comparison between the two sets of results. 
 
Figure 6.13 (a) illustrates the dose and RBE for the monoenergetic setup with a 
nickel collimator. Figure 6.13 (b) shows the dose and RBE for the whole beamline 
with a stainless steel collimator. The monoenergetic beam has a Bragg peak depth 
of 22.5 mm and the whole beam has a Bragg peak depth of 17.0 mm. The surface 
dose for the pure beam is 0.67 Gy for the peak regions and 0.003 Gy for the valley 
regions. The surface dose for the realistic beam is 1.45 Gy for peak regions and 
0.020 Gy for the valley regions. Both beams have the secondary peak before the 
main Bragg peak in both the peak and valley dose, caused by scattered protons from 
the collimator. 
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There is a factor of two in the peak and 6.7 in the valley difference in dose between 
monoenergetic and realistic beams at the surface. This difference in surface dose 
between peak and valley results in a PVDR of 214 for the monoenergetic beam and 
73 for the realistic beamline. These differences are caused by the number of scatter 
particles in the realistic beam produced by interaction with components upstream 
Figure 6.13: Comparison between and ideal (a) beam and realistic beam (b) for dose and RBE
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of the water phantom. Many of these scattered particles are lower energy protons 
depositing energy at the surface, particularly in the valley regions. This also 
impacts the depth of the Bragg peak as protons in the realistic beam must pass 
through multiple components of the beamline resulting in energy loss and thus a 
lower energy beam than the monoenergetic beam. This observation has been 
shown in the previous chapter where the entire beamline was modelled. 
 
The RBE for the monoenergetic beam starts at 1.03 and has a slight increase to 
1.12 until it peaks at a depth of 23.7 mm with a peak of 3.39, 1.2 mm deeper than 
the dose Bragg peak. A small peak in RBE is also observed in the monoenergetic 
beam at a depth of 20.0 mm with a peak of 1.17, caused by scatter from the 
collimator. The dose past the Bragg peak falls to a near zero value, when this occurs 
the RBE becomes dominated by a few particles resulting in poor statistics. This is 
shown as the noise distal to the RBE peak at a depth of 23.7 mm. The RBE for 
realistic beamline starts at 1.06 and increases with depth to 1.15 before the main 
peak. The main peak is located at a depth of 18.1 mm with a peak of 2.94 and is 1.1 
mm deeper than the dose peak. A small peak caused by collimator scatter at a depth 
of 14.9 mm with a peak height of 1.2 before the main peak. The higher dose of the 
whole beamline increases the surface dose and the respective RBE at the surface. 
This is primarily caused by scattered particles depositing dose in these regions. 
These particles are primarily low energy protons, which have a high LET at the end 
of their tracks. 
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The valley RBE is higher than that of the peak RBE at the surface and starts at 1.40 
and 1.41 for the monoenergetic and realistic beam, respectively. RBE decreases 
with depth until at 15.0 mm depth it is equal to the peak RBE. This shows that even 
though the valley dose for the whole beam is 2.8 times higher than that of the 
monoenergetic beam the RBE in the valley dose is remarkably similar. The RBE is 
high at the surface possibly due to a biasing effect, where low energy protons more 
likely to be the particles that deposit dose in the valley at the surface, and these low 
energy protons have higher LET and RBE. As depth increases, most of these lower 
energy protons have already deposited all their dose, so the remaining protons will 
deposit dose in either the primary or secondary Bragg peaks, decreasing the LET 
and RBE at these peaks. 
 




In this section the various particles produced from minibeam collimators and their 
biological impact was discussed. The Monte Carlo modelling revealed that the first 
15 mm of the collimator is particularly important in converting the beam from a 
uniform beam into a collimated beam. This starting region is also responsible for 
the generation of most of the neutrons and photons that exit the collimator. From 
15 mm depth to the end of the collimator, protons are scattered which contributes 
to the lower energy Bragg peaks previously observed in the dose distribution. This 
is caused by protons impacting the side of the collimator and being scattered with 
a small angular deviation from the main beam. It is possible that the number of 
these scattered protons would increase with a beam of higher angular divergence 
than the near monoenergetic beam simulated. 
 
The issue concerning the impact of neutrons generated by the collimator has been 
raised as an important consideration when generating proton minibeams with a 
collimator. This dose is uniform and therefore is of greatest concern in the valley 
dose regions any treated volume. However, the dose delivered to the water 
phantom by neutrons is exceedingly small compared to that of the dose delivered 
by protons. This results in the valley region dose being mainly dominated by 
scattered protons. Even when the high RBE of these neutrons is included they still 
deliver an exceedingly small dose, resulting in only minor impacts on final RWD. 
The only situation where it could be a concern if a collimator were made out of a 
material with a high neutron output and these neutrons had significantly higher 
RBE. A large number of neutrons with a high RBE may impact the valley dose, 
especially if the dose from protons is also exceptionally low. Therefore, it is 
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recommended that a tungsten collimator, or a high-density material with a high 
neutron production, is not used. The difference between nickel, brass and stainless 
steel is minimal for most results, however nickel does continue to show some 
benefits over the other materials. The choice of using stainless steel for a minibeam 
collimator remains justified in part due to low cost and ease of manufacture. In any 
future development, stainless steel material could be optimised further by using an 
alloy that has a higher nickel content. 
 
Photons produced by the collimator deliver very little dose to the water phantom 
even though there is a large quantity, indicating that photon scatter should not be 
a major design constraint, as limiting this avenue of secondary dose will not have 
a major impact on the output of the collimator. 
 
The majority of the dose delivered to the water phantom in the peak regions is from 
protons that have not interacted with the collimator. With a minor component 
particularly at the surface from protons that have interacted with the collimator 
and lost energy. The inverse of this is true for the valley regions with scattered 
protons dominating the dose. The RBE of protons has also been shown to be higher 
in the valley’s regions than in the peak regions. Decreasing the PVDR of the overall 
minibeams and reduces the normal tissue sparing of the minibeams. Minimising 
dose to the valley regions is critical to reduce damage to normal tissue. These high 
RBE protons in the valleys and uniform dose from neutrons mean that collimator 





The RBE was also shown to be high post Bragg peak. This is a major concern for 
the 50.5 MeV beam as this effect increases the effective depth of the beam, thereby 
increasing the effective dose past which the normal dose Bragg peak occurs. This 
result has been shown in previous research by Cuaron et al. where the RBE 
increases post Bragg peak increasing biological damage at the distal edge [95]. The 
relative dose when the RBE peaks is exceptionally low so it over all has a minor 
impact. This effect also occurs with the scattered proton Bragg peaks at shallower 
depths, increasing the impact the scatter has on the dose distribution. Compared 
to clinical proton beam for which an average RBE of 1.1 has been deemed 
sufficient, for the low energy PPRP it is highly recommended to include a variable 
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6.5. Conclusion 
A comprehensive and novel analysis of the physical and biological dose 
contributions for different minibeam collimator materials has been presented. 
New insights were obtained into the different components that contribute 
scattered dose to the various regions and this was investigated for different 
collimator materials that were identified in Chapter 5. Neutrons generated from a 
minibeam collimator, whilst having a high LET and RBE only have a minor impact 
on the final dose distribution as the majority of the dose in the peak regions is from 
protons that have not interacted with the collimator, and the majority of dose in 
the valley regions is from protons that have interacted with the collimator. The RBE 
of protons in the valley regions is extremely high, up to 1.5 at the surface. This 
reduced the PVDR and decreased the potential normal tissue sparing of the 
treatment and should be considered in designing future treatments with proton 
minibeams. This RBE is for a 50.5 MeV proton beam and raises questions on the 
RBE in the valley for higher energy proton beams. This RBE data is based off a 
double-strand break model and future work should perform biological experiments 
to verify the accuracy of these RBE values. 
 
This chapter also demonstrated that the region of the collimator that blocks the 
uniform beam is critical in generation of secondary particles. Future work may 
involve designing a multi-material collimator that would be designed to reduce 
neutron production from this region and reduce scattered protons from remainder 
of the collimator, which would reduce the dose in the valley regions. This would 
help to increase the PVDR of the minibeam dose distribution and increase the 




Chapter 7              
Concluding Remarks and Future 
Work 
This chapter provides a summary of the work presented and the key findings of this 
thesis. A discussion on future work as an outcome off from this work then follows. 
 
7.1. Summary 
The overarching aim of this thesis was to characterise proton minibeams for use in 
radiation therapy via the Monte Carlo method. The first area investigated was to 
address the concern that spatially modulated dose distributions are susceptible to 
target motion. Work by Manchado de Sola et al. demonstrated that motion was a 
concern for X-ray microbeams even with high dose rate synchrotrons [19]. The 
work on motion presented in Chapter 3 of this thesis investigated and characterised 
the effects on the dose distribution for various proton minibeam collimator 
designs, providing insight into how the effect of motion can be reduced for proton 
minibeam therapy, enabling it to be used preclinically to treat small animals and 
potentially humans in the future. This work is novel and covers a wide range of 
motion relevant for small animal irradiation, however it also extends to clinical 
beams and as such is easily translatable to a range of proton minibeam geometries. 
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Results from using Monte Carlo and MATLAB modelling presented in this thesis 
demonstrated that motion has a detrimental impact on all proton minibeam dose 
distributions. Motions with a small amplitude such as cardiovascular brain 
pulsations, which are of the order of 60 µm and 300 µm for mice and humans, 
respectively, have only a minor impact on the peak dose and minibeam width, and 
no observable impact on the valley dose. For motions that are less than the width 
of the minibeam the peak dose maximum height remains roughly constant. 
Internal motion in humans is often much larger than the width of the proton 
minibeams and will decrease the peak dose and spread dose into the valleys. 
However, the valley dose was shown to depend on the spacing between the 
minibeams and the magnitude of motion. Proton energies typically used for human 
treatment allows for a larger CTC spacing; this helps to mitigate dose delivered to 
valley regions and indicating the potential of proton minibeams in treating cancers 
in regions of small motion i.e. brain. 
 
The second research area of this thesis was to simulate and characterise the 
University of Washington’s 50.5 MeV PPRP beamline. This characterisation is 
important for future proton minibeam biological experiments, and was published 
in part in Physics in Medicine & Biology [18]. A difference between simulations 
and measurement was initially observed in the shape of the PDD curve requiring a 
detailed analysis to gain an understanding of what was causing the differences. The 
depth of the Bragg peak in the Monte Carlo model agreed (within experimental 
uncertainty) with the depth measurements. The model depth was measured to be 
18.1 mm. This is shallower than expected for a 50.5 MeV proton beam and actually 
corresponds to a proton beam with an output energy of 44.95 MeV. This depth also 
agrees with the reference values for a 44.95 MeV beam [82]. The decrease in energy 
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from 50.5 to 44.95 MeV was determined to be a result of interactions with the 
graphite degrader, Kapton exit window, and the ion chamber. 
 
Uncertainties in the exact physical dimensions of some beam pipe components 
were identified, resulting in differences between the measurements and model in 
the shape of the PDD. An analysis of the scattering characteristic of the protons 
along the beam transport system revealed that by iteratively increasing the 
diameter of the large beam pipe the shape of the PDD curve could be matched. A 
small number of scattered protons were produced by the large beam pipe and this 
was also shown to lead to an increase in the surface dose within the water phantom. 
Other components were found to have a minimal impact on the proton beam. 
 
The remaining sections of the thesis considered an optimal collimator design for 
proton minibeams at a nominal beam energy of 50.5 MeV as it is available at the 
University of Washington in Seattle. The minibeam specific approach is 
comprehensive and novel, and systematically examined the most relevant 
parameters influencing the beam characteristics and dose deposition. Results 
showed that increasing the thickness of the collimator beyond what is necessary to 
fully attenuate protons reduced the number of primary protons whilst maintaining 
the same number of scattered protons. This resulted in a reduction in beam 
modulation and dose and placed an upper limit on the thickness of the collimator. 
For our setup, a stainless steel collimator between 20 – 25 mm thick was deemed 
ideal. The first 5 mm, the proton range in a material, of the collimator was shown 
to be critical in converting the uniform beam into spatially modulated beams. This 
region is also where most neutrons, electrons, and photons that exit the collimator 
are generated. The ideal width for minibeam beamlets was found to be between 0.3 
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– 0.4 mm as these widths have the highest PVDR whilst maintaining reasonable 
dose delivery to the Bragg peak depth. These minibeam widths also have the lowest 
relative valley dose, thus reducing potential normal tissue damage and providing 
the possibility of tissue repair into the peak regions. In terms of collimator material, 
the collimator should be constructed from as dense a material as possible, as this 
has been shown to maximise the PVDR. However, to reduce neutron production, 
this work has also shown that the material should be ideally a group 4 transition 
metal. This is a novel finding that has previously not been shown before. Nickel is 
a particularly suitable candidate for collimator construction due to its low neutron 
production and remarkably high PVDR ratios from the surface to 10 mm depth. 
 
The last area of research in this thesis was to explore any effect different collimator 
materials have on the RBE of particles exiting the collimator. This has been an area 
of debate and results presented in this work provided novel insight into this area. 
Results from Monte Carlo modelling showed that the LET and RBE of neutrons 
generated from various collimators was higher than previously understood. 
However, the overall RWD from neutrons was only a minor component of the dose 
distribution. In the valley regions where the neutron dose is relatively high, it is 
still only a minor component and should have minimal, if any, impact on the overall 
treatment. The LET and RBE results from protons did show RBE values of up to 
1.5 in the valley regions increasing damage to normal tissue and reducing the 
PVDR of the dose distribution at the surface. At the distal end of the Bragg peak 
the simulated RBE values were up to three for the 50.5 MeV minibeam. This 
increases the effective depth of the Bragg peak somewhat and adds uncertainty to 
the depth at which maximum dose is delivered. This can be problematic when 
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placing the distal edge of the Bragg peak near critical structures and until better 
understood should be avoided with this low energy proton beam. 
 
7.2. Limitations and Future Work 
Modelling the impact of motion on dose distributions assumed that translational 
motion only occurred in a single direction (parallel to the direction of spatial 
modulation), and that this motion was regular and repeatable. For motions in any 
generic directions the component of the motion, which is parallel to the direction 
of modulation, could be used for an estimation on the results. However, this was 
beyond the scope of this work and a full analysis should be performed to verify this 
prediction. Ideally treatment planning should consider the impact of patient 
motion when utilising mini/microbeams. Research into the advancement of 
treatment planning systems would need to consider that microbeams require very 
high spatial resolution with a very fast acquisition time, which is not feasible in 
most clinical environments. Therefore, it is likely that a spread factor will be 
needed to estimate the reduction in spatial modulation of the minibeams. 
 
Throughout this thesis the maximum dose in the centre of the peak and minimum 
dose in the centre of valley have been used to produce the PVDR. While this has 
been shown to vary with depth, there is no investigation of how dose varies within 
each peak and valley region. The variation of dose laterally in these regions 
potentially could have an impact on the biological damage delivered to the normal 
tissue, particularly at the peak/valley boundaries and particularly when motion is 
considered. 
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Output from simulations of the PPRP beamline modelled from supplied drawings 
disagree with measurement and hence adjustments to the simulation beamline 
were made. This limits somewhat the results from the model produced by this 
work. However, a large portion of this work used a monoenergetic beam to aid in 
understanding the physical processes and interactions, making the results more 
transferable to other beamlines and to overcome this limitation. Future work that 
uses this model should take this into account and, if possible, correctly identify or 
validate the reason suggested herein for the source of disagreement. This was 
considered beyond the requirements for this thesis due to likely the requirement 
of having to dismantle the current beamline. 
 
While the main focus of this work has been on low energy (50.5 MeV) proton 
beams, the simulations, and results where generalised were appropriate to 
consider higher proton energies. Future work should verify that the collimator 
results are applicable to these higher energies necessary for human treatments. 
True understanding of tissue damage cannot yet be realised with models. The 
future of this work needs to involve collaboration with biologists who are able to 
do studies of actual tissue damage having been exposed to these proton beams. As 
proton minibeams diverge with depth, the width of the minibeam also increases. 
Which raises questions over how this increased width of the minibeam will impact 
normal tissue. Ideally future tissue studies should be performed to confirm the 
effect proton minibeam width has in normal tissue. Normal tissue sparing of 
photon microbeams has been shown to depend on the width of the beam [11]. It is 
therefore critical to determine if there is a maximum beamlet width where the 
sparing effect is no longer applicable. If this is the case, then proton minibeams will 
only maintain the sparing effect at the surface regions in treatments. This work 
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primarily uses monoenergetic, or a realistic near monoenergetic proton beam 
which only covers a limited volume with their Bragg peak. Future work could 
investigate how to produce a spread out Bragg peak, in depth, with proton 
minibeams and what implications this has for the conclusions found in this thesis. 
 
The collimator geometry used in this thesis only uses slot collimators, which are 
spatially modulated in a single direction. Hole collimators can be spatially 
modulated in two orthogonal directions, potentially offering advantages. While 
this work should be applicable to hole collimators, future work should investigate 
the differences between them, as hole collimators have a larger internal surface 
area so possibly will produce a larger number of scattered particles. This thesis also 
aimed to deliver dose uniformity at the Bragg peak, with the minimum dose no less 
than 85% of the maximum dose. This level of uniformity was somewhat arbitrary, 
and was used to fix the CTC spacing between the minibeams. It is therefore 
important that that impact of level uniformity versus increased spacing for 
minibeams is investigated with tissue based studies to identify a requirement level 
of uniformity for successful tumour control. 
 
This thesis also investigated single element materials for use in collimator 
construction to provide a better understanding of the influence material has on 
dose deposition for future work. In this thesis  multi-material collimators were not 
considered, however there could be advantages in using such designs and this 
should be investigated. The first 15 mm of a minibeam collimator material was 
shown to be responsible for producing the majority of neutrons that exit the 
collimator. Changing this material to one more suitable at reducing the number of 
neutrons, could be beneficial. The remainder of the collimator could then be 
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designed to reduce proton scatter and maximise the PVDR. These collimators 
should be produced from a higher content nickel alloy for further improvements. 
A concern that was beyond the scope of this thesis, was the activation of certain 
materials from a proton beamline. It is possible that when a proton beam interacts 
with a material some of the protons can be absorbed by the materials nucleus 
creating unstable nuclei, which can pose a radio-safety concern. Care needs to be 
taken when using a material to ensure that people are not exposed unknowingly to 
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